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Résumé 
La sclérose latérale amyotrophique (SLA) est la maladie des neurones moteurs la 
plus fréquente, affectant 4-6 individus par 100,000 habitants à l’échelle mondiale. La 
maladie se caractérise par une faiblesse et une atrophie musculaire suite à la 
dégénérescence des neurones du cortex moteur, tronc cérébral et moelle épinière. Les 
personnes atteintes développent les premiers symptômes à l’âge adulte et la maladie 
progresse sur une période de trois à cinq ans. Il a été répertorié qu’environ 10% des patients 
ont une histoire familiale de SLA; 90% des gens affectés le sont donc de façon sporadique. 
La découverte il y a 19 ans de mutations dans le gène zinc/copper superoxide dismutase 
(SOD1), présentes dans 15-20% des cas familiaux de SLA et environ 2% du total des 
individus affectés, a été l’événement déclencheur pour la découverte de variations 
génétiques responsables de la maladie. La recherche sur la génétique de la SLA a connu 
une progression rapide ces quatre dernières années avec l’identification de mutations dans 
de nouveaux gènes. Toutefois, même si certains de ces gènes ont été démontrés comme 
réellement liés à la maladie, la contribution d’autres gènes demeure incertaine puisque les 
résultats publiés de ceux-ci n’ont pas, à ce jour, été répliqués. Une portion substantielle de 
cas reste cependant à être génétiquement expliquée, et aucun traitement à ce jour n’a été 
démontré comme étant efficace pour remédier, atténuer ou prévenir la maladie. 
 
Le but du projet de recherche de doctorat était d’identifier de nouveaux gènes mutés 
dans la SLA, tout en évaluant la contribution de gènes nouvellement identifiés chez une 
importante cohorte multiethnique de cas familiaux et sporadiques. Les résultats présentés 
sont organisés en trois sections différentes. Dans un premier temps, la contribution de 
mutations présentes dans le gène FUS est évaluée chez les patients familiaux, sporadiques 
et juvéniles de SLA. Précisément, de nouvelles mutations sont rapportées et la proportion 
de mutations retrouvées chez les cas familiaux et sporadiques de SLA est évaluée. De plus, 
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une nouvelle mutation est rapportée dans un cas juvénile de SLA; cette étude de cas est 
discutée. Dans un deuxième temps, de nouvelles avenues génétiques sont explorées 
concernant le gène SOD1. En effet, une nouvelle mutation complexe est rapportée chez une 
famille française de SLA. De plus, la possibilité qu’une mutation présente dans un autre 
gène impliqué dans la SLA ait un impact sur l’épissage du gène SOD1 est évaluée. 
Finalement, la dernière section explique la contribution de nouveaux gènes candidats chez 
les patients atteints de SLA. Spécifiquement, le rôle des gènes OPTN, SIGMAR1 et SORT1 
dans le phénotype de SLA est évalué. 
 
Il est souhaité que nos résultats combinés avec les récents développements en 
génétique et biologie moléculaire permettent une meilleure compréhension du mécanisme 
pathologique responsable de cette terrible maladie tout en guidant le déploiement de 
thérapies suite à l’identification des cibles appropriées.  
 
Mots-clés : Sclérose latérale amyotrophique, maladie des neurones moteurs, dégénération 
neuronale, génétique humaine, mutations rares, séquençage de gènes candidats, SOD1, 
TARDBP, FUS, OPTN, SIGMAR1, SORT1. 
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Abstract 
Amyotrophic lateral sclerosis (ALS) is the most common of motor neuron diseases, 
affecting 4-6 individuals per 100,000 individuals worldwide. ALS is characterized by 
muscle weakness and atrophy caused by the degeneration of neurons located in the motor 
cortex, brain stem and spinal cord. This fatal disease generally has an adult onset and 
progresses over a three to five year period. While 10% of patients affected have a family 
history of the disease, 90% of cases do not and are considered sporadic. The finding of 
mutations in the zinc/copper superoxide dismutase gene (SOD1) gene 19 years ago in about 
15-20% of familial ALS (FALS) patients and approximately 2% of overall cases developed 
the interest of identifying rare genetics variants causing the disease. The ALS research field 
experienced a rapid progression during the last four years as mutations in new genes have 
been identified. While mutations in some of those new genes have been clearly linked to 
ALS, the role of others is still questionable and so far has not been positively replicated in 
other populations. Importantly, a significant portion of cases still need to be genetically 
explained and, unfortunately, there is still no effective treatment to cure, attenuate or 
prevent the disease. 
 
The aim of this Ph.D research project was to identify new ALS mutated genes while 
analysing the causative role of other newly identified genes in a large familial and sporadic 
ALS cohort of different origins. The results presented here are categorized into three 
different sections. First, the contribution of FUS mutations to familial, sporadic and 
juvenile ALS is analysed. Specifically, new FUS mutations are reported in ALS cases and 
the proportions of variants present in the tested familial and sporadic ALS cohorts are 
assessed. In addition, a new mutation is reported in a juvenile ALS patient, and this 
interesting case is discussed. Second, new genetic avenues are explored for the SOD1 gene. 
Precisely, a new and complex SOD1 mutation is reported in a French ALS family. 
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Moreover, the possibility that other ALS mutated genes influence SOD1 splicing events is 
evaluated. Third, the contribution of new candidate genes is evaluated. Precisely, the 
contribution of OPTN, SIGMAR1 and SORT1 genes to the ALS phenotype is assessed. 
 
Hopefully, our different findings combined with recent developments in genetics 
and molecular biology will permit a better understanding of the pathological mechanisms 
involved in the disease and will lead to the identification of the right targets in order to 
develop appropriate therapeutics for ALS patients. 
 
Keywords : Amyotrophic lateral sclerosis, motor neuron disease, neurodegeneration, 
human genetics, rare mutations, candidate genes sequencing, SOD1, TARDBP, FUS, 
OPTN, SIGMAR1 et SORT1. 
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Chapter 1 : Introduction 
1.1 Physiology, clinical manifestations, and epidemiology of 
amyotrophic lateral sclerosis 
1.1.1 Physiology 
Amyotrophic lateral sclerosis, commonly named Lou Gehrig’s disease or Charcot’s 
disease is also called motor neuron disease (MND) in the United States, which actually 
refers to a larger spectrum of heterogeneous diseases affecting the motor neurons. 
Specifically, motor neuron diseases include classic amyotrophic lateral sclerosis (ALS), 
progressive bulbar palsy (PBP), spinal bulbar muscular atrophy (SBMA), progressive 
muscular atrophy (PMA), spinal muscular atrophy (SMA), hereditary spastic paraplegia 
(HSP) and primary lateral sclerosis (PLS). These seven disorders are all characterized by a 
progressive degeneration of motor neurons but differ in terms of where the neuronal death 
takes place. PBP, SMA, SBMA, and PMA result from the death of lower motor neurons 
(LMN) while HSP and PLS are explained predominantly by the degeneration of upper 
motor neurons (UMN). ALS affects both the UMN and LMN of the corticospinal tract 
located in the motor cortex, brainstem and anterior horn of the spinal cord. Specifically, 
neuronal degeneration in the cortex deprived the LMN located in the brain stem and spinal 
cord to receive executive command from the brain, while neuronal death in the anterior 
horn of the spinal cord causes denervation of skeletal muscles. The term amyotrophy in 
ALS actually refers to the atrophy of the denervated muscles. As the motor neurons located 
in the anterior and lateral corticospinal tract degenerate in patients, they are replaced by 
gliosis. The terms lateral sclerosis refer to the hardening of this region because of gliosis.1  
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The first symptoms of motor neuron degeneration in ALS patients are usually 
experienced during mid-adulthood and progresses very rapidly, usually on a 3 to 5 years 
period. Affected individuals finally deceased following the denervation of respiratory 
muscles. 
 
The cause of neuronal death in ALS is currently unknown, and no effective 
treatment to prevent, slow down or stop neurodegeneration exists to date. Riluzole is the 
only treatment that brings a small beneficial effect, slightly extending the life of patients of 
two to three months.2 Significant efforts have been deployed for decades worldwide to 
better understand the pathological mechanisms involved in ALS and eventually develop 
therapeutics. Noteworthy, findings about the pathology of other neurodegenerative diseases 
contributed to the identification of common molecular events between different but 
somehow related neuronal diseases. Specifically, various neurodegenerative disorders have 
been associated to the pathological accumulation of misfolded proteins in neurons and glial 
cells, specific aggregation protein components being a characteristic of different 
neurological conditions. Importantly, aggregations of TDP-43, FUS or SOD1 proteins are 
detected immunohistochemically in neurons of ALS patients. Aggregations containing one 
of these proteins are found exclusively without the presence of the other two, dividing the 
molecular pathology of ALS into three distinctive groups.3-10 A common view is that 
misfolded endogenous proteins form inclusions then aggregates, this way initiating the 
disease and contributing to its progression by the acquisition of a toxic gain of function. 
Specifically, these new acquired properties include increasing hydrophobicity and/or 
sequestration of important cellular components into the aggregates, inhibiting proteasomes, 
generating oxidative species, and/or influencing other pathways.11 Another possibility is 
that the functional non-misfolded portion of the protein is not sufficient to efficiently 
perform its role in the neuronal cell, the misfolded protein not being able to perform its 
function. This loss of function also prevents other proteins to perform their roles after being 
recruited into the aggregates. One last possibility is that toxicity of aggregates do not 
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initiate the disease per say but is actually a defensive response from the cell to protect itself 
following another unknown toxic event.12  
 
1.1.2 Clinical manifestations 
Patients experiencing UMN degeneration develop muscle weakness and spasticity, 
hyperreflexia and pseudobulbar palsy, while LMN death is characterized by muscle 
weakness and atrophy, cramps, hyporeflexia and fasciculations.13 A progressive spreading 
of symptoms must be observed within the same and/or other regions of the body, and the 
ALS diagnosis is made only after the certitude that the UMN are involved along with 
LMN. However, early diagnosis could be difficult since patients often have symptoms 
overlapping with other MND at the first stages of the disease.14 Also, in some patients, 
either UMN or LMN are predominantly involved throughout the disease progression, 
making the diagnosis even more difficult. Patients are usually classified into four different 
categories using the El Escorial criteria: suspected, possible, probable, or definite ALS.15 
 
ALS diagnosis is usually made by excluding all other neurological disorders after 
obtaining evidence from electrophysiological, imaging, cerebrospinal fluid, or serological 
studies16. Specifically, patients undergo complete neurological, motor, cranial nerves, 
sensory and cerebellar examinations, cervical and spinal magnetic resonance imaging 
(MRI), electromyography (EMG), lumbar puncture, and toxicology/biochemical blood 
screenings. Indeed, cortical morphology analyses revealed specific cortical thinning in the 
precentral gyrus of ALS patients in addition to relative thinning in the temporal regions of 
individuals experiencing a rapid progression of the disease.17 Consistent white matter 
reduction is also recorded in the corpus callosum while grey matter reduction is specifically 
observed in primary and supplementary motor areas, as well as in the anterior cingulate and 
temporal lobe regions of ALS patients.18 Electrophysiologic studies evaluate muscles 
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denervation and motor nerve conduction using compound muscle action potential (CMAP) 
and sensory conduction velocities using sensory nerve action potential (SNAP). ALS 
patients show muscles denervation while their sensory functions are mainly intact. A 
complete physical examination is needed to evaluate the atrophy, spasticity and weakness 
of muscles in limbs asymmetrically/unilaterally or symmetrically/bilaterally. Precisely, 
muscle weakness is first experienced in the lower or upper limbs in about 70-75% of 
affected individuals, making spinal onset the most common form of ALS onset. About 20-
25% of cases develop the first symptoms in the bulbar region, while approximately 3% of 
patients experience a respiratory onset. Presence of hyperreflexes is also investigated, as 
well as the existence of fasciculations, clonus and Babinski signs, and absence of Hoffman 
signs. Considering that up to 50% of ALS cases have some cognitive deficits,19 the 
cognitive functions of patients are also assessed by an extended neuropsychological 
examination. The progression of symptoms is regularly evaluated by clinicians, monitoring 
drastic weight loss because of muscular atrophy, and difficulty eating after the development 
of dysphagia and dysarthria.  
 
Detailed information is collected concerning the health status of family members 
constituting previous, current and following generations. It is estimated that 90% of ALS 
patients do not report any previous familial history of motor neuron symptoms, the disease 
mainly affecting people in a sporadic way. The remaining 10% of patients do have 
additional family members with similar symptoms or with other related neurodegenerative 
diseases. While ALS is an adult-onset disease, some ALS families have been reported with 
other affected members developing the disease before 25 years of age, which is considered 
a juvenile form of amyotrophic lateral sclerosis (JALS).20 Also, other families were 
reported with members affected with dementia such as Alzheimer’s disease (AD) or 
frontotemporal dementia (FTD),21 or members developing Parkinsonism or Parkinson’s 
diseases (PD)22. While some studies reported that neurodegenerative disease aggregates 
within ALS kindred,22, 23 it was recently demonstrated after a large prospective population-
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based study in the Netherlands that familial aggregation of ALS, dementia and PD is 
significantly lower than previously assumed.24 
 
Familial and sporadic ALS patients are almost undistinguishable based on clinical 
manifestations.25 The only two variations that exist concern the age of onset and the sex 
distribution. Familial amyotrophic lateral sclerosis (FALS) tends to develop ten years 
earlier than sporadic amyotrophic lateral sclerosis (SALS), with a mean age of onset around 
45 years. Also, sporadically affected males tend to be slightly more predominant, with a 
ratio of 1.3-1.6:1 female,25 while males and females are equally affected in ALS families. 
 
1.1.3 Epidemiology 
ALS is the most common of MND worldwide. It newly affects about 1-2 
individuals per 100,000 inhabitants each year, approximating its prevalence to 4-6 cases per 
100,000 individuals.26, 27 While it is perceived that the incidence of ALS tend to increase 
and major fluctuations have been reported both in men and women, no consistent trend was 
reported through a decade.28 In addition, it was demonstrated that the apparent incidence 
increase is explained by growing ascertainment cases because of better ALS diagnosis.29, 30 
Change in the reported incidence could also be explained by the increasing age of the 
general population because of longer lifespan expectation, this way increasing the mortality 
frequency from ALS, especially in women.31, 32 While the mean age of onset is 45 years of 
age for the familial cases and 55 years of age for the sporadic cases, a study using a large 
sample of affected individuals confirmed an increased incidence in the 60 to 69 year age 
group.30 Precisely, ALS is uncommon in individuals under 30 years old, but significantly 
more common among people in their 50s, with a sharp increase until the seventh decade. 
Considering that the mean age of onset peaks in mid-adulthood but very young or very old 
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onsets have been reported, it cannot be concluded that ALS is an age or aging related 
disorder. 
 
The struggle to diagnose ALS was explained in the previous section, raising the 
difficulty to accurately estimate incidence, specifically in certain age group. It is 
particularly true for the elderly developing motor neuron symptoms, considering the 
difficulty to differentiate ALS from other various comorbidities affecting muscle strength, 
motion and cognitive functions often seen in this age group. Indeed, musculoskeletal pain 
and fatigue are the most frequently reported symptoms by older adults,33 and ALS tends to 
be more frequently misdiagnosed among patients over 60 years old, especially those living 
in large cities.34 Importantly, elderly are also less likely to encounter neurological services, 
and delivery of routine medical services is not optimal for this age group.35 
 
Another changing issue is the male to female ratio of affected individuals. Past 
reports estimated the ratio to be 2.6:1 in the 60s and 70s but recently decreased to 1.1:1 in 
the 90s.30, 36, 37 This can be explained by the higher incidence of women seeking medical 
advice and receiving diagnosis38 or by the higher lifespan expectancy of women, which 
increases their probability to eventually develop the disease. Another possibility is the 
changing lifestyle of women because of the socioeconomic modifications of the last 
century, which has become more comparable to men’s lifestyle. Women are increasingly 
exposed to occupational and environmental risk factors, which may explain the decrease in 
the male to female ratio. Another interesting report described an increased risk for ALS 
among smokers,39 especially females,40 underlying another important contributing factor. 
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While it is commonly stated that the mean disease duration range between three to 
five years, precisely 70-80% of cases decease within five years.41 The remaining 20-30% 
experiences an extremely fast or an unusually slow progression of symptoms. A marked 
variation in terms of disease progression during the first three years after onset has been 
reported, suggesting a wider progression spectrum of the disease. Again, problems with the 
differential diagnosis between ALS and other motor neuron disorders might in part explain 
this variation. An important contributing factor is the site of onset of the first symptoms, 
with bulbar and respiratory onsets usually ending in shorter disease duration since 
respiratory muscles are affected more quickly. Another explanation is the contribution of 
modifier genes, influencing the resulting phenotype in each patient by accelerating or 
reducing its progression rate. Finally, certain essential motifs in a given protein known to 
cause ALS might be prone to accelerate neuronal degeneration when mutated if the genetic 
change is translated into a non-functional protein. It is also possible that other mutations 
located in the same gene might only partially deprive the cell of the protein function, 
resulting in a slower disease progression. The only variables that have been clearly shown 
to independently predict ALS outcome are age at the onset,29, 42-46 site of onset,42, 45-49 and 
speed of symptoms progression.47, 50 In summary, increased survival was predicted by a 
younger age of onset, a spinal onset, less severe symptoms at the time of the first visit, and 
a body mass index loss lower than 5%.46 Another study predicted a longer survival for 
patients with the predominant involvement of upper motor neuron.51 
 
1.2 Etiology of amyotrophic lateral sclerosis 
1.2.1 Genetic component to ALS: familial versus sporadic ALS 
Familial cases of ALS represent 10% of overall cases. 25 This estimation is based on 
the analysis of a few large pedigrees with a Mendelian autosomal dominant inheritance and 
a complete penetrance. The remaining portion of patients is considered to be affected 
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sporadically, with no previous reports of motor neuron symptoms in other family members. 
This classification is indeed made by default, and some proposed to name sporadic ALS 
isolated ALS. In fact, it could be difficult to obtain accurate or complete information about 
other kindred who are sometimes affected with another neurodegenerative disorder which 
is often seen in ALS families. Apparent sporadic onset can be found in very small ALS 
families, the number of chances to develop the disease for other members is this way 
reduced by the family size. Also sometimes a patient has lost contact with some family 
members and is not aware of the health status of those members. Also, some siblings of 
apparent sporadic cases are reluctant to report symptoms, are sometimes misdiagnosed, or 
deceased before developing the first ALS signs, the sporadic patient actually being part of a 
familial syndrome. Adoption or illegitimacy could also shuffle the cards. Recessive form of 
the disease, ALS onset in children before the onset of symptoms in one of their parent who 
is a mutation carrier, or incomplete penetrance in families can also lead to a sporadic 
categorization of cases.52  
 
This being said, the active investigation of genealogies actually evaluated the 
prevalence of FALS to 17-23%.53-56 Considering that FALS cases actually represent about 
20% of overall cases, that the clinical manifestation of SALS and FALS is almost 
undistinguishable, and that mutations identified in FALS have also been found in SALS 
cases this way confirming the contribution of genetics to sporadic ALS, it is clear that the 
identification of FALS genes would extend our understanding of the ALS pathology 
affecting both sporadic and familial cases. Moreover, recently, one group assessed the 
relative risk for ALS in families counting more than 6,000 Swedish individuals who have 
been first classified as sporadic ALS patients. They also evaluated the concurrence of ALS 
in more than 86,000 Swedish twin pairs. They reported a significant higher risk for siblings 
or children of ALS patients to develop the disease, and concluded that a major genetic role 
contributes to familial ALS.57 Based on these assumptions, it is reasonable to claim that 
most, if not all ALS cases can be explained by genetic predispositions. Consequently, 
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significant progress in the genetics of ALS has been made during the last two decades. 
Precisely, mutations in 13 different ALS genes have been identified among 15 different 
ALS loci, and two different ALS-FTD genes have been identified among three different 
ALS-FTD loci (see table I). These are described thoroughly in the next section. 
 
1.2.2 Genetic component to ALS: loci and genes identified 
1.2.2.1 ALS1: SOD1 
Section of the editorial entitled: SOD1 mutations : more to learn. To be published in 
the Canadian Journal of Neurological Sciences, March 2012,39 :2. 
 
In 1989, genetic analysis using 150 families with classical ALS helped identify two 
regions of possible linkage on chromosomes 11 and 21.58 Further evidence of linkage on 
chromosome 21q22.1-q22.2 was published in 1991, this way identifying the first ALS locus 
currently known as ALS1.59 In 1993, an international consortium reported 11 different 
SOD1 missense mutations in 13 out of 18 dominantly inherited ALS families.60 Since then, 
about 168 disease-causing mutations (Human Gene Mutation Database: 
http://www.hgmd.org),61 87% of which are nucleotide substitutions, have been identified 
among the 153 amino acids of this five-exon gene. The remaining 13% of mutations are 
deletions, nonsense or splicing mutations which affect the length of the protein. 61-64 Even if 
most SOD1 mutations are transmitted in an autosomal dominant manner, a few families 
have been reported with a reduced penetrance or a recessive transmission among 
members.65 Moreover, compound heterozygotes have also been reported, with two different 
heterozygote SOD1 mutations in the same patient.66 An intriguing report recently described 
a patient affected with both familial ALS and cerebellar ataxia and an SOD1 mutation.67 
Rare SOD1 mutated cases with frontotemporal dementia (FTD), cognitive impairment, and 
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autonomic dysfunction have also been reported.68-70 Interestingly, some substitutions 
affecting particular SOD1 amino acids are associated with a slow disease progression, 
while other amino acid substitutions sometimes located in the same region of the gene, are 
found in patients with a very fast progression.64, 71, 72 The effect on rate of progression is 
thought to be related to the fact that some mutants lead to a stable protein while others are 
highly unstable.55, 64, 73-75 Approximately 42 mutations have been reported in SALS cases, 
representing 25% of the total SOD1 variation and about 1% of SALS cases. Precisely, 15-
20% of familial cases result from SOD1 mutations, hence variations in this gene explain 
approximately 1-2% of overall cases.60  
 
The superoxide dismutase 1 (SOD1) protein is ubiquitously expressed and is mainly 
located in the cytosol of cells, catalyzing the reduction of the superoxide anion to O2 and 
H2O. Most mutations reduce dismutation,76 but some have normal or only slightly reduced 
dismutase activity.73, 74 Based on the dominant inheritance and the fact that SOD1 knockout 
mice have no motor neuron phenotype while overexpression of mutant SOD1 does,77, 78 it is 
agreed that mutant SOD1 acquires a novel cytotoxic function which promotes 
neurodegeneration. This toxic gain-of-function has been proposed to involve different 
mechanisms including protein aggregation and misfolding, oxidative stress, mitochondrial 
dysfunction, microglia activation, glutamate excitotoxicity, and defects in axonal 
transport.79 Specifically, the presence of protein misfolding and aggregation is a recurrent 
observation in cells of ALS patients, which may inactivate or impair normal processes such 
as proteasomal degradation or chaperone function.80 Some observations also suggested that 
SOD1 might be involved in RNA processing after the finding that mutant SOD1 impaired 
the post-transcriptional processing of VEGF mRNA, which encodes an important 
neuroprotective factor, this way provoking a significant decline in VEGF expression.81 In 
addition, SOD1 toxicity has been found to modify wild type (wt) SOD1 by inducing it to 
misfold.82 Moreover, it was demonstrated that proximity to mutant SOD1 in non-neuronal 
cells such as microglia and astrocytes is necessary for the toxicity of neighboring motor 
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neurons.83 Though extensive research has been conducted to understand the specific 
pathways involved, it is still unclear how mutant SOD1 leads to the ALS phenotype. 
 
1.2.2.2 ALS2: ALSIN 
In 1994, a locus on chromosome 2q33-q35 was reported after a linkage analysis 
using a large ALS family from Tunisia.84 In 2001, two different homozygous deletions in 
the ALS2 gene causing a loss-of-function of its encoded protein were identified in one 
amyotrophic lateral sclerosis and two primary lateral sclerosis autosomal recessive families 
with members experiencing a juvenile onset of the diseases with a slow progression.85, 86 
While no ALS2 mutations were reported in adult-onset typical ALS, variants were observed 
in infantile–onset ascending spastic paralysis (IAHSP).87 The 34-exon ALS2 gene encodes 
the GTPase regulator alsin, which plays a role in intracellular endosomal trafficking. 88 
 
1.2.2.3 ALS3: chromosome 18q21 
A locus on chromosome 18q21 was identified in 2002 after performing a genome 
scan using a large European family with 20 members affected with classical ALS.89 The 
disease was transmitted in an autosomal dominant fashion, and all affected members 
developed typical ALS. While a maximum lod score of 4.5 was obtained, no causative 
mutations in the ALS3 region have been identified to date. 
 
1.2.2.4 ALS4: SETX 
A locus on chromosome 9q34 was identified in 1998 and was named ALS4.90 After 
testing 19 genes in the region, SETX autosomal dominant mutations have been identified in 
juvenile FALS and SALS patients experiencing a slow progression of the disease without 
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the involvement of bulbar and respiratory muscles.91 Interestingly, autosomal recessive 
mutations have also been identified in patients with spinocerebellar ataxia, specifically with 
ataxia-ocular apraxia 2 (AOA2), ataxia with elevated levels of alpha-fetoprotein, distal 
amyotrophy, and peripheral neuropathy.92, 93 In fact, it is believed that this mutated type of 
recessive ALS is an intermediate form of motor neuron disease, standing between ALS and 
spastic paraplegia, while involving lower limbs and excluding the bulbar region. No 
mutations were reported in adult-onset ALS. The SETX gene encodes for the senataxin 
protein that contains a DNA/RNA helicase domain in its c-terminal, suggesting a role in 
DNA repair and RNA processing.91 It was also suggested that the gene play a role in the 
coordination of transcriptional events.94 
 
1.2.2.5 ALS5: SPG11 
Mapping of the ALS5 locus to chromosome 15q15.1-q21.1 was obtained in 1998 
using five families from Europe and North Africa with affected members developing 
typical ALS at an earlier age of onset. This form of juvenile ALS was believed to be the 
most prevalent form of recessive ALS.95 SPG11 (spatacsin) mutations were first identified 
in 2010 in juvenile ALS patients characterized by a long-term survival.96 Compound 
heterozygous deletions were recently identified by our group after the whole exome 
sequencing of two affected family members with a recessively inherited juvenile motor 
neuron disease.73 Spatacsin is a transmembrane protein ubiquitously expressed in the 
nervous system which is phosphorylated upon DNA damage. While mutations in the 
SPG11 gene were previously involved in spastic paraplegia,97 it is interesting to note that, 
in this study, one affected family member displayed atypical juvenile ALS and the other 
developed classical hereditary spastic paraplegia (HSP), this intra-familial phenotypic 
heterogeneity reinforcing the idea that motor neuron diseases are part of a continuum. 
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1.2.2.6 ALS6: FUS 
In 2003, three ALS families linked to chromosome 16q12 were published by three 
different groups. 98-100 The discovery of mutations in a DNA/RNA binding protein in 
2008101, 102 prompted geneticists to look for mutations in genes encoding proteins having 
similar functions. Consequently in 2009, two groups reported mutations in the FUS gene 
located on chromosome 16p11.2 which encodes another DNA/RNA binding protein, this 
way elucidating the ALS6 locus.6, 103 This discovery was made after the identification of a 
family of Cape Verdean origin with a possible recessive inheritance pattern. A cluster was 
identified on chromosome 16, and sequencing revealed a homozygous missense mutation 
(H517Q) in exon 15 of the FUS gene in all affected members of this family. Additional 
screening identified 13 other dominant mutations in 24 different families. No FUS 
mutations were found in sporadic ALS cases, but later reports established the frequency of 
FUS mutations to be present in about 4% of familial cases, 1% of sporadic patients, and 
less than 5% of overall cases.62, 104 More than 52 different mutations have been identified so 
far in this 15 exons gene (Human Gene Mutation Database: http://www.hgmd.org).61 
Interestingly, almost all mutations are clustered in the c-terminal of the protein, mostly 
lying in the final 17 amino acids of FUS. While the associated phenotype is typical ALS, 
mutations in juvenile ALS patients as well as in FTD and essential tremor cases have been 
reported.64, 71, 104, 105 ALS patients with FUS mutations seem to develop the first symptoms 
earlier, have a higher rate of bulbar onset, and experience a more rapid progression when 
compared to patients with SOD1 mutations.71 
 
The fused in sarcoma (FUS) protein is ubiquitously expressed and is predominantly 
located in the nucleus of cells. However, FUS immunoreactive inclusions have been 
detected in the neuronal and glial nuclei and cytoplasms of patients affected not only with 
ALS, but also with FTLD as well as Huntington’s, Alzheimer’s, and Parkinson’s disease,106 
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this observation defining a new proteinopathy in neurodegeneration. The spectrum of FUS 
RNA targets still has to be defined in order to establish the normal function of the protein. 
 
1.2.2.7 ALS7: chromosome 20p13 
Linkage to chromosome 20 was established in 2003 using one typical ALS family 
with a dominant mode of inheritance from the Boston area.100 The best LOD score was 
obtained using markers on the distal short arm of the chromosome. However, the linkage 
was not reproduced with any other ALS families, and was obtained after genotyping only 
two affected individuals of the same generation. The ALS7 locus was claimed to be 
probable but less secure at the time of publication, and the gene have not yet been 
identified. 
 
1.2.2.8 ALS8: VAPB 
A locus on chromosome 20q13, now known as ALS8, was identified using eight 
different families from Brazil.75 Founder studies demonstrated a common Portuguese 
ancestor to all families. The dominant P56S missense mutation in the VAPB gene was 
identified in all affected members,76 which has been demonstrated to induce the formation 
of insoluble cytoplasmic aggregates of the mutant protein. Interestingly, the same mutation 
gave rise not only to ALS, but also alternate phenotypes including late-onset spinal 
muscular atrophy, progressive bulbar palsy, and progressive muscular atrophy. 76 The same 
mutation has also been identified in other ALS patients of different origins including 
German, Japanese and American, but surprisingly has not been found in Portuguese.62, 79, 
107, 108 Only one other mutation in the gene has been reported to date to cause ALS. 78 The 
VAMP-associated protein type B participates in intracellular transport and is mainly 
located in the endoplasmic reticulum.  
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1.2.2.9 ALS9: ANG 
Linkage analysis using Scottish and Irish families permitted the identification of a 
region on chromosome 14q11.2, making this locus the ninth to be discovered in ALS.83, 109 
The finding that mutant SOD1 binds to VEGF and alters its expression prompted the 
screening of candidate genes located in the ALS9 locus sharing the same metabolic 
pathway. Indeed, to date, about 21 variants have been identified in the ANG gene (Human 
Gene Mutation Database: http://www.hgmd.org).61 However, only one dominant variant 
was actually shown to cosegregate with the disease in a unique Dutch family with one 
member affected not exclusively with ALS, but also with Parkinsonism and FTD.81 The 
same variant was identified in French, North American, Irish, Scottish and Swedish patients 
affected with classical ALS,62, 94, 110, 111 making it the most common ANG mutation reported 
to date. Functional expression studies demonstrated a loss of angiogenic function of the 
mutant protein.110 
 
1.2.2.10 ALS10: TARDBP 
Mutations in the TARDBP gene101, 102 were first reported after the discovery that its 
encoded protein TDP-43 is the principal constituent of neuronal cytoplasmic inclusions in 
ALS and FTD patients,112 this way identifying the ALS10 locus on chromosome 1p36.22. 
More than 49 dominant mutations have been identified so far in adult onset ALS (Human 
Gene Mutation Database: http://www.hgmd.org),61 mostly lying in the c-terminal portion of 
the protein. Mutations have been reported in about 5% of familial ALS cases, 0.5-2% of 
sporadic patients, and approximately 5% of overall cases.101, 102, 113, 114 While most 
TARDBP mutated patients are affected with typical ALS, some develop alternate phenotype 
including FTD, progressive supranuclear palsy, Parkinson’s disease and chorea.67, 93 
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The tar DNA-binding protein (TARDBP) gene encodes a nucleic DNA/RNA binding 
protein that is redistributed to the cytoplasm of neurons and glial cells when mutated. TDP-
43 is involved in DNA/RNA processing, a common function that later guided the screening 
of the FUS gene located in the ALS6 locus. 68-70 TDP-43 immunoreactive inclusions have 
been observed both in the nucleus and cytoplasm of neurons and glial cells, defining a 
unique proteinopathy, distinct from the one observed in patients with FUS inclusions.115 
Postranslational alterations of TDP-43 such as hyperphosphorylation, ubiquitination and 
cleavage have been reported to modify its interaction with other proteins involved in RNA 
metabolism,96, 106 hence influencing pre-mRNA splicing, RNA stability and axonal 
transport.116 Some of these interactions were found to dependent on TDP-43 RNA-binding, 
whereas others are RNA-independent. 117 Specifically, some TDP-43 interacting proteins 
cluster into two different interaction networks: a nuclear or splicing cluster and a 
cytoplasmic or translation cluster.117 This suggests that TDP-43 assumes different roles in 
RNA metabolism, and acts in the nucleus as well as the cytoplasm. Additional TDP-43 
RNA targets need to be identified in order to better understand the pathway in which they 
are involved, as well as to determine their precise role in neurodegeneration. 
 
1.2.2.11 ALS11: FIG4 
Mutations in the FIG4 gene located on chromosome 6q21 have been first identified 
in 2007 in severe cases of Charcot-Marie-Tooth disease characterized by an early onset and 
involving both sensory and motor neurons.118 The finding of mutations in patients affected 
with a disease involving the motor neurons prompted the screening of FIG4 in ALS and 
PLS patients. Nonsynonymous variants were found in nine patients out of 473, mutations 
being present in about 2% of the tested cohort. Among them, seven patients were diagnosed 
with classical ALS and two had PLS. Six of the dominant variants identified were shown to 
be deleterious.119 No other FIG4 mutations reports have been published since then and 
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further screening in other populations is needed to properly establish the genetic 
contribution of FIG4 to the ALS pathogenesis. FIG4 is a phosphatidylinositol 3,5-
bisphosphate (PtdIns(3,5)P2) that might play a role in autophagy in the nervous system, 
while mutations have been proposed to contribute to inclusion body diseases.120 
 
1.2.2.12 ALS12: OPTN 
Homozygosity mapping using six ALS patients from Japanese consanguineous 
families helped define in 2010 the ALS12 locus on chromosome 10p13. After sequencing 
17 candidate genes in the region, variants were identified in OPTN,121 a gene in which 
mutations were previously associated with primary open-angle glaucoma (POAG).122 
Additional mutations were identified by the same group in familial and sporadic classical 
ALS cases causing both recessive and dominant traits. Subsequent screening of OPTN in 
patients of European origin did not confirm the genetic implication of optineurin in ALS, at 
least for this specific population,123, 124 and more reports are needed. Mutated OPTN 
cytoplasmic distribution has been however demonstrated to differ from wt OPTN, and 
OPTN-immunoreactive cytoplasmic inclusions have been observed. OPTN have also been 
demonstrated to be recruited in TDP-43 or SOD1 inclusions.121  
 
1.2.2.13 ALS13: ATXN2 
An extended (CAG)n repeat in ATXN2 was first reported in 1996 in patients 
affected with spinocerebellar ataxia-2.125 While normal chromosomes contain 14 to 31 
repeats interrupted by one to three CAA repeats, chromosomes of patients contain a pure 
stretch of 34 to 57 CAG repeats. The CAG is highly unstable during transmission, and its 
size is negatively correlated with the age of symptoms onset in 50% of cases.125 The ALS13 
locus on chromosome 12q24.12 was attributed to the ATXN2 gene in 2010 when it was 
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discovered that an intermediate repeat length ranging from 27 to 33 glutamines was 
significantly associated with ALS.126 Additional reports confirmed the same association, 
and it was also shown that intermediate repeats were CAA interrupted.127-130 It was also 
demonstrated that polyQ expansions in ATXN2 enhance its interaction with TDP-43, and 
that both ATXN2 and TDP-43 relocalize to stress granules after oxidative stress. 126 Ataxin-
2 is primarily located in the Golgi apparatus. While expression of full-length extended 
ataxin-2 disrupted the normal morphology of the Golgi complex,131 it is still unclear how 
intermediate repeat length influences the risk to develop ALS. 
 
1.2.2.14 ALS14: VCP 
In 2004, missense mutations were found in the VCP gene located on chromosome 
9p13.3 in patients affected with FTD or inclusion body myopathy with Paget disease of 
bone (IBMPFD).132 The valosin-containing protein (VCP) is associated with a spectrum of 
essential cell protein pathways including cell cycle, homotypic membrane fusion, nuclear 
envelope reconstruction, postmitotic Golgi reassembly, DNA damage response, 
suppression of apoptosis, and ubiquitin-dependent protein degradation.132 In 2010, exome 
sequencing revealed a heterozygous mutation as a cause of adult-onset ALS with or without 
FTD in an Italian family,133 this way identifying the 14th locus for the disease. While a few 
additional mutations were reported in FALS and SALS cases,133-136 none were found in the 
Australian ALS population.137 It can be concluded that mutations in VCP is not a common 
cause of ALS. 
 
1.2.2.15 ALS15: UBQLN2 
Linkage analysis using a large ALS family composed of 19 affected members with 
either a juvenile or an adult disease onset permitted the identification of the ALS15 locus 
  
 
19
on chromosome Xp11.21.20 The disease was transmitted in a dominant fashion among the 
family members, with a reduced penetrance in females and no evidence of male-to-male 
transmission. Therefore, 41 candidate genes out of 191 coding genes in the region were 
sequenced, and a single cosegregating mutation was identified in the UBQLN2 gene. 
Additional FALS or FALS-FTD cases were screened for mutation in this intronless gene, 
and four novel mutations were identified. The five missenses found by this group all 
affected proline residues located in a single PXX repeat region. Ubiquilin-2 was shown to 
be present not only in inclusions located in the hippocampus and pyramidal neurons, but 
also to be involved in inclusion formation in X-linked ALS.20 These observations are 
critical, considering that protein inclusions are a persistent landmark in neurodegenerative 
diseases, and especially in ALS and FTD. Further mutation reports are however needed.  
 
1.2.2.16 ALS-FTD: CHMP2B 
Linkage to chromosome 3p11.2 was established using a large Danish family with 
autosomal dominant FTD.138, 139 In 2005, the mutation responsible for the disease in this 
family was reported to be located in the CHMP2B gene. The chromatin modifying protein 
2B (CHMP2B) is part of an endosomal secretory complex which is believe to participate in 
endosomal trafficking.140 Another variant in the same gene was additionally found in an 
unrelated individual with unspecific dementia.141 While two different groups did not find 
any CHMP2B causative mutations in their tested FTD cohort,142, 143 two other groups found 
one truncated mutation in one autosomal dominant FTD patient and one missense mutation 
in an ALS patient.144, 145 Mutations in the CHMP2B gene are found rarely in ALS or FTD 
patients, and its causative role in neurodegeneration is questionable. 
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1.2.2.17 ALS-FTD: chromosome 9q21-q22 
Genomic screening was first conducted using 16 families from the Boston data set 
with members affected with either dominant ALS or ALS-FTD, which permitted the 
identification of a locus on chromosome 9q21-22. Subsequent analysis was performed to 
independently confirm the region involved by genotyping four other families from the 
Chicago data set with members affected with ALS and/or FTD.146 The mutated gene 
causing the two phenotypes in these families still needs to be identified. 
 
1.2.2.18 ALS-FTD: C9ORF72 
Three different groups contributed to the identification of a major locus on 
chromosome 9 by reporting three overlapping loci after conducting linkage analysis using 
different autosomal dominant families with members affected with ALS and/or FTD along 
with TDP-43 proteinopathy.21, 147, 148 Additional reports helped refine the minimum linkage 
region to 3.7 Mb, containing only five known genes.149-153 The common coding and non-
coding region was extensively sequenced by many for several years, but no causative 
mutations were identified. Several association studies conducted in the ALS and FTD 
sporadic population confirmed the implication of the chromosome 9p locus in both 
diseases.154-157 Rigorous efforts finally permitted the identification of important 
heterozygote hexanucleotide repeat expansions in the chromosome 9 open reading frame 72 
(C9ORF72) gene in three of the reported families linked to the chromosome 9p.21 locus. 
158, 159 The gene has three identified transcripts and the expansions are either located in the 
first intron or the promoter region of the gene. Specifically, the maximum size of the 
hexanucleotide repeat in control participants was 23 units, while it ranged approximately 
between 700 and 1600 in patients. The same noncoding but highly conserved GGGGCC 
expansions were further found in a significant proportion of familial and sporadic ALS 
and/or FTD cases. Precisely, 11.7% of familial FTD and 23.5% of familial ALS patients 
were found with the repeat, making this variant the most common genetic abnormality 
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identified to date for those two familial forms of diseases.158 In addition, repeat expansions 
were present in almost one-half of Finnish familial ALS cases and in about one-third of 
familial ALS cases of European descent.159 While the C9ORF72 protein is uncharacterized 
and its domains are unknown, it is expressed in a variety of tissues and is mainly a 
cytoplasmic and synaptic protein in neurons.159 Using lymphoblastoid cell lines, it was 
demonstrated that the hexanucleotide repeat expansions in C9ORF72 are associated with a 
decreased expression of C9ORF72 mRNA.158 The same group observed RNA foci in 
neuronal tissues of ALS and FTD patients. It is suggested that these expansions interfere 
with the normal expression of the protein, causing the loss of one alternatively spliced 
C9ORF72 transcript and the formation of nuclear RNA foci. It is also suggested that 
variations in the repeat length influence the resulting expressed phenotype, 158 explaining 
the development of ALS and FTD in some familial cases, while other family members 
develop either ALS or FTD. Finally, anticipation might be present in C9ORF72 extended 
FALS patients, considering that younger members of Finnish ALS-FTD families 
experienced a very early age of onset. More reports are needed to establish more precisely 
the proportion of C9ORF72 extended patients. 
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Table I Summary of ALS associated loci 
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1.2.3 Association studies in ALS 
Whole genome association studies (GWAS) have been proven to be a powerful tool 
in genetics after the results obtained from research on different complex diseases. In 
GWAS, thousands of single nucleotide polymorphisms (SNPs) are genotyped across the 
genome in a large number of samples without any preconceived assumption about diseases. 
Many association studies have been conducted in different populations worldwide using 
sporadic cases of ALS, but not all have been conclusive. The first report failed to 
significantly identify hits but contributed to future studies by making the SNP data freely 
available on the internet. 160 Those data were used as a replication set in a follow-up study 
identifying FGGY as a candidate gene for ALS.160 Another GWAS was conducted by a 
group from the Netherlands, reporting an association with the ITPR2 gene.161 This study 
also combined the results obtained with the data available on the internet after the first 
GWAS, and failed to re-associate the ITPR2 gene with sporadic ALS. A novel association 
with the DPP6 gene was however identified,162 this way replicating an already published 
Irish study.163 However, the Nertherlands and Irish groups included data from the same 
cohorts, which explains the replicated association of the DPP6 gene. One subsequent study 
replicated this association in an Italian cohort,164 while data obtained using samples from 
Poland, France and Canada did not.165, 166 Another study attempted to replicate the 
associations with hits obtained from previous GWAS, but was unable to confirm any 
conclusive association.167 Association of the gene ELP3 to ALS was also reported after 
performing a GWAS using three different populations.168 Two susceptibility loci were also 
identified without replicating previous associated genes or SNPs, including one within the 
boundaries of the UNC13A gene and another on chromosome 9p21.2.157 The identification 
of the susceptibility region on chromosome 9p21.2 was the first conclusive data obtained 
from a GWAS in ALS research, considering that a major ALS-FTD locus was known to 
exist in the same region after several linkage studies. Subsequently, two additional groups 
reported an association between sporadic ALS and a region on chromosome 9p21 in the 
Finnish and British populations.154, 155 
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Unfortunately, GWAS findings in one population are rarely replicated in others, and 
no genes have been concretely associated to ALS. Intriguingly, genes identified using 
candidate-based approaches have not been the top hits in GWAS. Indeed, the published 
associations to chromosome 9p were the only replicated and conclusive GWAS in ALS 
research. The availability of several thousand cases with definite diagnosis is a key element 
for GWAS to identify genetic factors responsible for a disease. The high degree of allelic 
and non-allelic heterogeneity in SALS cases is a limiting factor for the identification of 
causative genes, considering that different disease-causing alleles may exist within the 
same gene. Moreover, the identification of rare highly penetrant mutations in genes such as 
TARDBP or FUS in SALS patients is problematic given that GWAS can only detect 
common low penetrant variants. The whole genome or exome sequencing approaches seem 
to be more suitable for the identification of such novel rare causative variants in ALS, and 
the results that will be obtained from such approaches in the next few years will hopefully 
highlight unknown genetic contributions to familial and sporadic ALS. 
 
1.2.4 Environmental component to ALS 
The first association of an environmental factor contributing to the emergence of 
ALS was with the Chamorro indigenous people of Guam, who presented an extremely high 
incidence of the disease, who consumed a lot of flying fox and consequently accumulated 
cycad neurotoxins in their organism including beta-N-methylamino-L-alanine (BMAA) 
shown to be produced across the cyanobacterial order.169, 170 Later, a report of an ALS 
cluster near Lake Mascoma associated the increased disease incidence to the presence of 
cyanobacteria in the surrounding water area.171 Many in vivo studies using mice, rats, 
monkeys and chicks demonstrated that exposure to BMAA induce neurodegenerative 
symptoms.170 Results obtained from zebrafish also demonstrated a disruption in neuronal 
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development resulting from BMAA exposure. In vitro studies using rodents also concluded 
that BMAA predominantly acts on motor neurons by increasing the generation of reactive 
oxygen species (ROS) and Ca(2+) influx along with disrupting mitochondrial activity. 
Consequently, neuronal death is believed to result from excitotoxic mechanisms.170 No 
other robust association have been reported since then, and the search for other causative 
evidence connecting environmental risk factors or neurotoxic chemicals to sporadic ALS 
has not been fruitful. Nevertheless, some epidemiologic trends suggested that several 
environmental influences might be linked to the ALS etiology. Several environmental toxic 
exposures are believed to induce the liberation of free radicals, which might lead to 
oxidative stress. Precisely, free radicals are ROS produced normally in biological systems. 
Human cells have developed a complex system of defence mechanisms to eliminate 
excessive ROS accumulation which otherwise has the ability to damage lipids, proteins, 
and DNA. When cellular antioxidant defences are unable to keep the ROS levels below a 
toxic threshold because they are overwhelmed with free radicals or they are encoded in 
insufficient amount, cells experience oxidative stress.172 A few environmental factors have 
been proven to increase ROS levels and hence the risk to develop ALS. These include lead, 
mercury, and selenium exposure, contact with pesticides and insecticides, intense physical 
activities, head injuries, electromagnetic fields (EMF) exposure and tobacco smoking.173 
These studies are briefly explored in the next section. 
 
1.2.4.1 Toxicity and ALS 
Since most ALS cases are sporadic, many studies have been devoted in the last 
decades to the possible contribution of neurotoxic chemicals to ALS phenotype. 
Accumulated evidence confirmed the potency of metals to induce toxicity to cells and 
consequently cause a number of pathologies. Precisely, many metals are able to catalyse the 
formation of ROS and indeed damage key proteins, leading to protein denaturation and 
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aggregation as well as to the inability of the ubiquitin/proteasome system to eliminate 
dysfunctional proteins.174 
 
The role of lead among other metals in the ALS pathology is the most studied in the 
field.175 Lead is not normally present in the human body and is a known neurotoxicant, not 
a neuroprotectant.176 Interestingly, low exposure has been shown to liberate free radicals, to 
induce oxidative damage to essential biomolecules and to affect antioxidant defence 
systems of cells.177 Paradoxically, higher exposure to lead has been associated with an 
increased survival in humans.178-180 Further studies are however needed to establish the 
possible neuroprotective role of lead in ALS. 
 
 Neurotoxicity after mercury exposure is also well documented,181 yet its 
contribution to ALS has not been clearly demonstrated. Case studies with patients affected 
with ALS symptoms along with inorganic mercury intoxication have been reported,182, 183 
while retrospective case–control studies failed to report an association between mercury or 
other heavy metals in the pathogenesis of the disease.184, 185 Interestingly, G93A-SOD1 
mice experienced an early onset of hind limb weakness after a chronic exposure to 
methylmercury, suggesting that an exposure to a toxic metal could hasten the onset of 
symptoms in individuals carrying a genetic polymorphism for ALS.186 Deposition of 
mercury in motor neurons of the spinal cord, brainstem and cerebral cortex were observed 
in rodents after being exposed to mercury.187, 188 Of interest, a cluster of affected cases was 
reported in a region of Lake Michigan, where residents consumed lots of fish species in 
which a high level of mercury has been found.189 These reports propose that mercury 
exposure might contribute to the etiology of ALS. 
 
  
 
27
Another metalloid associated with ALS is selenium (Se), a trace element having 
both toxic and nutritional properties in humans. Selenium safe range of exposure based on 
its biological reactivity is controversial, depending on its organic/inorganic state and 
oxidation level. However, it seems that its safe range is significantly lower than previously 
believed.190 While organic Se is found in food and is believed to be harmless,191 inorganic 
Se found in groundwaters is fifty times more toxic.192 Two independent studies suggested a 
causative relationship between Se exposure and ALS. Precisely, one group from the US 
reported a cluster of four individuals (out of 4,000 inhabitant) who developed ALS along 
with Se intoxicated farm animals in a region affected by naturally occurring selenosis.193 
Another group from Italy also reported four individuals affected with ALS (out of 5,182) in 
a region where the municipal tap water was taken from two wells high in selenium. A 
causative relationship was suggested since no other life-style or occupational factors 
correlated with the disease.194, 195 One study also documented a correlation between Se 
contaminated areas in China and the appearance of neurological symptoms in the 
population, among other consequences.196 Laboratory models as well as experimental 
studies demonstrated that the nervous system and more specifically motor functions, are 
influenced by Se levels.190 Precisely, it was shown that the toxicity of inorganic Se affects 
selectively the motor neurons in pigs and cows.192, 197, 198 An increased level of iron and 
selenium was also observed in the brain of patients affected with Parkinson’s disease.173  
 
While associations between elevated ALS risk and lead, mercury and Se toxicity 
have been suggested in the literature, no clear causative evidence has been published so far. 
This can be explained by the fact that exposure to certain metals is not sufficient to develop 
the disease, and individual's genetic makeup is required to induce epigenetic changes that 
will eventually cause ALS.199 It is well known that the main unifying mechanisms of action 
of metals are the interference with cellular reduction/oxidation (redox) regulation and the 
subsequent induction of oxidative stress.200 These mechanisms are known to be perturbed 
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in ALS. However, the clear causative contribution of metalloids to the disease still needs to 
be demonstrated. 
 
The organophosphate (OP) class of pesticides is extensively used in agricultural and 
household settings and its role have been investigated as a potential risk factor for ALS,201 
considering that pesticides have been previously associated to other neurodegenerative 
diseases.202 It was suggested that SALS patients have an impaired ability to detoxify these 
pesticides, which could be explained by changes in genes part of the metallothionein or 
paraoxonase families.201, 203 While inconsistencies related to OP exposure and mutations in 
one of the paraoxonase gene have been reported,204 many studies using human and rodent 
subjects support this theory.205-209 An Australian case-control study associated sporadic 
ALS to solvent and chemical exposure in addition to industrial and overall herbicide or 
pesticide exposure, showing a dose-response effect.210 A systematic review of the literature 
on environmental exposure to chemicals and metals permitted the identification of two 
well-designed studies reporting a significant association between pesticides exposure and 
increased ALS risk.211 However, another large study conducted in the USA did not observe 
any conclusive association. Nonetheless, this group found a substantially increased risk of 
the disease in individuals exposed to formaldehyde, and they demonstrated a dose-response 
relationship with increasing years of exposure.212 
 
Another risk factor that has been associated to ALS is cigarette smoking. One study 
concluded that individuals who have already smoked have a twofold risk to develop the 
disease, while current smokers have a threefold increased risk. The risk level was positively 
correlated with smoking duration. While it is possible that the formation of free radicals 
during the metabolism of one or several of the 3,800 compounds present in cigarettes can 
induce oxidative stress on neurons, it is also probable that pesticides in tobacco is 
responsible for this toxicity.213 
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1.2.4.2 Environmental interactions, genes and epigenetics 
ALS has been re-named in the USA after the American Major League baseball 
player Lou Gehrig died from this MND. A substantial increase in disease frequency among 
soccer and football players has been curiously observed since then.214, 215 The possible 
association between physical activity and ALS risk was evaluated, but no significant 
difference was found among cases and controls. However, patients reported having 
participated more frequently in organized sports in high school.216 It was recently 
demonstrated that anabolic/androgenic steroids (AAS), drugs known to enhance muscle 
mass that are frequently illegally abused by athletes to increase their performances actually 
increase the risk for ALS. Precisely, a group used mice overexpressing human mutant 
SOD1 at different stages of the disease and after monitoring gastrocnemius muscles, they 
found that the expression of certain genes associated to muscle atrophy was up-regulated 
before the symptoms onset. It was concluded that AAS may intensify some of the 
alterations induced by SOD1.217 In the same line, it was demonstrated that the combination 
of intense exercise with other factors such as drugs or ischemia caused by head injuries 
actually increase the production of ROS.28 It was also reported that victims of head injuries 
have an increased risk of developing a neurodegenerative disease such as AD and PD.218, 219 
Considering that head injuries are frequent in soccer and football players, it can explain 
their increased risk to develop ALS. While some studies suggested such association,220, 221 
another demonstrated that head injury is not a significant associated factor.222  
 
War veterans can also be victims of head injuries, which could explain the twofold 
increased risk of developing ALS for Persian Gulf War USA Army and Air Force 
personnel. 223, 224 Veterans are also known to smoke cigarettes more than the control 
population, a practice also known to increase the chances to develop the disease.213 Of 
interest, a study demonstrated that head injuries alone were associated to an increased risk 
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to develop ALS in veterans and not smoking.225 Noteworthy, the veterans affected with 
ALS developed the first symptoms at a significantly earlier age than expected. 226, 227 Some 
studies suggested an association between the increased number of affected individuals and 
exposure to organophosphates, describing ALS veterans with significantly lower serum 
concentrations of PON1, 228, 229 a member of the paraoxonase family in which changes are 
known to impair the ability to detoxify this pesticide.204 Another group proposed that Gulf 
War veterans have been extensively exposed to cyanobacteria by inhaling cyanotoxins that 
are carried by dust at specific time of the year during the war.230 These reports suggest that 
neurological symptoms in those veterans possibly result from environmental chemical 
exposures during the war. 
 
The emergent relationship between environmental-induced oxidative stress and 
epigenetic modifications influencing critical genes is currently at the center of many 
studies. In fact, it has been well established that epigenetic changes occur due to 
environmental factors, this way altering genes without any previous DNA sequence 
variation.231-233 Specifically, gene expression depends on epigenetic regulations, which are 
influenced by mechanisms such as chromatin condensation, several histone modifications, 
and covalent alterations of DNA by methylation.174 Precisely, the epigenome works as an 
interface between the inherited genome and the changing environment. While metal 
exposure can damage neuronal cells through both oxidative and non-oxidative mechanisms 
such as the formation of DNA adducts, metals can also result in substantial changes in 
DNA methylation and histone modifications. These changes can lead to epigenetic 
silencing, modification or reactivation of gene expression.234 A Swedish study using a large 
cohort of workers from the engineering industry with a large proportion of resistance 
welders who were regularly exposed to extremely low frequency magnetic fields (ELF-MF) 
reported an increased risk for Alzheimer’s disease and ALS.235 However, it has been 
underlined that further studies are needed, which should consider investigating the separate 
effect of EMF exposure and electrical shocks to make more accurate interpretations.236 In 
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fact, it is possible that exposure to electromagnetic fields modifies DNA methylation and 
histone structure. More interest has been given to epigenetics in the last decade, and its role 
in neurodegeneration still has to be clearly defined. 
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Chapter 2 : Contribution of FUS mutations to ALS 
 
2.1. Mutations in FUS cause FALS and SALS in French and French Canadian populations. 
Published in Neurology. October 2009;73(15):1176-9. 
 
2.2. Identification of novel FUS mutations in sporadic cases of amyotrophic lateral 
sclerosis. Published in Amyotrophic Lateral Sclerosis. March 2011;12(2):113-7. 
 
2.3. Identification of a FUS splicing mutation in a large family with amyotrophic lateral 
sclerosis. Published in Journal of Human Genetics. March 2011;56(3);247-9. 
 
2.4. Novel FUS deletion in a patient with juvenile amyotrophic lateral sclerosis. Published 
in Archives of Neurology on January 16, 2012. 
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2.1 Mutations in FUS cause FALS and SALS in French and 
French Canadian populations 
 
Véronique V. Belzil, M.Sc.1†, Paul N. Valdmanis, Ph.D.1†, Patrick A. Dion, Ph.D.1, Hussein 
Daoud, Ph.D. 1,  Edor Kabashi, Ph.D. 1, Anne Noreau, M.Sc. 1,  Julie Gauthier, Ph.D.1 for 
the S2D team, Pascale Hince, B.Sc. 1, Anne Desjarlais, B.Sc. 1, Jean-Pierre Bouchard, 
M.D.2, Lucette Lacomblez3, François Salachas, M.D.3, Pierre-François Pradat, M.D.3, 
William Camu, MD4, Vincent Meininger, MD3, Nicolas Dupré, MD FRCP(C)2, and Guy A. 
Rouleau, M.D. Ph.D.1 
† These authors contributed equally to this work 
1 Centre for Excellence in Neuromics, University of Montreal, the Centre Hospitalier de 
l’Université de Montréal (CHUM) and Ste-Justine Hospital, Montreal H2L 2W5 Canada  2. 
Faculty of Medicine, Laval University, Centre Hospitalier Affilié Universitaire de Québec, 
Enfant-Jésus Hospital, Quebec G1J 1Z4, Canada.  3 Fédération des maladies du système 
nerveux, Division Paul Castaigne, Hôpital de la Salpêtrière, Paris 75651, France. 4 Unité de 
Neurologie Comportementale et Dégénérative, Institute of Biology, Montpellier 34967, 
France. 
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2.1.1 Rationale 
In 2003, three different groups conducted linkage analysis using ALS families from 
the United Kingdom (UK) and the United States (US), and identified the ALS6 locus on 
chromosome 16q12.98-100 The US group later localized a family of Cape Verdean origin 
with four members affected with ALS. They were informed that the maternal grandparents 
of the proband were first cousins, which raised the possibility of a recessive inheritance of 
the disease. They conducted a loss-of-heterozygosity (LOH) mapping and identified a 
major cluster on the same ALS6 locus, spanning 4Mb and containing 56 genes. They 
finally found a mutation in exon 15 of FUS, the last exon of the gene. Affected individuals 
were homozygous for the mutation, while unaffected members were heterozygous. 
Additional screenings of FALS samples helped identify twelve additional dominant FUS 
mutations in 16 different families. Interestingly, the mutations were almost all located in 
the c-terminal of the protein. However, no mutations were found in 293 sporadic patients.6 
One group from the UK tested their own FALS British samples and identified three 
different mutations in eight ALS families. The mutations were again localized in the c-
terminal of the protein.103 Overall, the two groups estimated that mutations in FUS cause 
about 5% of familial ALS, while the proportion of sporadic ALS cases mutated in FUS still 
has to be determined. 
 
The main interest in the FUS gene was about its molecular functions. In fact, the 
prominent resemblance between FUS and TARDBP was demonstrated in a 2009 review.237 
Both have been implicated in various steps of gene expression regulation such as 
transcription, RNA splicing, RNA transport, and translation.238, 239 Also, both contain RNA-
binding motifs, structurally resemble a family of heterogeneous ribonucleoproteins 
(hnRNPs), directly bind to RNA in addition to single- and double-stranded DNA, and are 
implicated in RNA maturation and splicing.237  
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Because of these three publications, we decided to screen for FUS mutations a sub-
group of our own familial and sporadic ALS cohort. We wanted first to evaluate the 
proportion of FUS mutations in our FALS patients of European origin in order to see if the 
published results could be replicated in a more heterogeneous population, and second to see 
if mutations can be found in sporadic patients. Moreover, we noticed that our lab had 
already screened autistic and schizophrenic patients for FUS mutations in the past. We re-
analysed these sequences and used them as an unrelated disease-control group for 
comparison with the ALS group. 
 
2.1.2 Contribution of authors 
Belzil & Valdmanis : Study design, data generation and analysis, statistical analysis, 
manuscript writing. 
Daoud & Kabashi : Manuscript revision. 
Noreau, Gauthier & Hince : Technical support, manuscript revision. 
Desjarlais : Clinical information organization, manuscript revision. 
Bouchard, Lacomblez, Salachas, Pradat, Camu, Meininger & Dupré : Clinical evaluation, 
sample collection, manuscript revision. 
Dion & Rouleau : Sample collection, experiment supervision, manuscript revision. 
 
2.1.3 Abstract 
Background: The identification of mutations in TARDBP and more recently the 
identification of mutations in the FUS gene as the cause of amyotrophic lateral sclerosis 
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(ALS) is providing the field with new insight about the mechanisms involved in this severe 
neurodegenerative disease.  Methods: To extend these recent genetic reports, we screened 
the entire gene in a cohort of 200 ALS patients.  An additional 285 patients with sporadic 
ALS were screened for variants in exon 15 for which mutations were previously reported.  
Results: In total, three different mutations were identified in four different patients, 
including one three bp deletion in exon 3 of a SALS patient, and two missense mutations in 
exon 15 of one FALS and two SALS patients.  Conclusions: Our study identified sporadic 
patients with mutations in the FUS gene.  The accumulation and description of different 
genes and mutations definitely helps develop a more comprehensive picture of the genetic 
events underlying ALS. 
 
2.1.4 Introduction 
The profile of genes mutated in amyotrophic lateral sclerosis (ALS) has expanded 
considerably since 2006.  The primary causative gene remains the zinc copper superoxide 
dismutase gene (SOD1) as mutations in SOD1 explain ~15-20 percent of familial ALS 
(FALS) cases, which altogether represents ~two percent of the combined sporadic (SALS) 
and FALS cases.60  However, several mutations were recently reported in the TAR-DNA 
binding protein (TARDBP) gene encoding the TDP-43 protein at the ALS10 locus.240 The 
TARDBP mutation search was initiated following the discovery that TDP-43 is a major 
constituent of aggregates found in patients with ALS or frontotemporal dementia (FTD).112 
Mutations are almost exclusively situated at the glycine-rich C-terminal portion of 
TARDBP in its sixth and last exon. The identification of mutations in TARDBP helped 
convince researchers studying the ALS6 locus on chromosome 16 that the FUS gene was a 
good candidate for harboring mutations in patients with ALS. 
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The presence of a homozygous mutation in a recessive family with ALS from Cape 
Verde combined with heterozygous changes in dominant ALS pedigrees that helped map 
the ALS6 locus led to the conclusion that FUS was the causative gene in that region.6, 103  
The product encoded by the FUS gene (FUS) has a function similar to that of the TDP-43 
protein.  It is an RNA-binding protein with hnRNP properties and it has a prior history of 
involvement in the nervous system:  mouse glutamate receptors help regulate the 
localization of FUS to dendritic spines.241  Moreover, FUS helps in actin organization of 
dendritic spines via mRNA transport of the actin-stabilizing protein Nd1-L.242  Initially, 
FUS/TLS (fusion/translated in liposarcomas) was identified as a t(12;16) translocation 
product which combines its N-terminal portion with the C-terminal portion of the CHOP 
gene leading to round cell liposarcomas.243  FUS knockout mice have been generated and 
no neurological defects were reported.244, 245 
 
We sought to validate the results recently obtained on chromosome 16 by 
sequencing the FUS gene in a panel of FALS and SALS cases.  This led to the 
identification of two mutations that were previously reported4 and one novel mutation. 
 
2.1.5 Materials and Methods 
2.1.5.1 Standard Protocol Approvals, Registrations, and Patient Consents 
Protocols were approved by the ethics committee on human experimentation of the 
Centre Hospitalier de l’Université de Montréal and the Comite d’Ethique de la Salpetriere.  
All patients gave written informed consent after which patient information and blood were 
collected.  
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2.1.5.2 Subjects 
Patients were collected from the province of Quebec, Canada (n = 100) and from 
France (n = 100) between 2004 and 2009.  DNA was extracted from peripheral blood using 
standard protocols.  A total of 80 FALS and 120 SALS patients were screened for the 15 
coding exons of the FUS gene as well as 190 ethnically matched controls and 285 patients 
with schizophrenia or autism as part of an unrelated project.  An additional cohort of 285 
SALS patients were screened for variants in exon 15, considering that most of the 
mutations already identified are located in the c-terminus of the protein.4 
 
2.1.5.3 Gene Screening 
Primers were designed using the ExonPrimer software from the UCSC human 
genome browser website (www.genome.ucsc.edu).  Twelve sets of primers were sufficient 
to cover the 15 exons in FUS (NM_004960.2).  Primer sequences and amplification 
conditions are listed in supplementary material table III.  PCR products were sequenced at 
the Genome Quebec Innovation Center.  Variants were tested in patients and controls using 
the same procedure of direct sequencing. 
 
2.1.5.4 Protein sequence alignment 
Cluster analysis was performed using the Clustal W method.  The closest 
homologue in several species was retrieved by use of NCBI’s BLAST program 
(supplementary material figure 2). 
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2.1.5.5 Phosphorylation sites prediction 
The phosphorylation site prediction scores corresponding to the deletion p.S57 were 
obtained using the NetPhos neural network-based method (supplementary material table 
IV).   
 
2.1.6 Results 
The complete sequencing of the FUS gene in 200 patients with ALS and the 
sequencing of exon 15 for an additional 285 SALS cases led to the identification of two 
missense mutations and one three bp deletion in three SALS and one FALS patients (table 
II).  These mutations were not found neither in 285 patients with schizophrenia or autism 
which were used as a non-ALS disease cohort, nor in 190 controls matched for age and 
ethnicity.  A three bp heterozygous deletion (c.169_171delTCT, p.S57del) was identified in 
a patient with sporadic ALS.  This TCT deletion results in the loss of the serine-57 residue 
and an overall decreased phosphorylation score (supplementary material table IV).  Two 
mutations were present at amino acid 521: an arginine to cysteine (c.1561 C>T, p.R521C) 
in one SALS patient, and an arginine to a histidine (c. 1562 G>A, p.R521H) in one SALS 
and one FALS case (figure 1).  Notably, these two missense mutations are the same as 
reported by Kwiatkowski et al. (2009).6  We were unable to test for segregation in the 
FALS patient as no additional family members were available.  All the patients with 
mutations had a typical ALS profile.  No documented history of FTD or cognitive 
impairment was present in these patients. 
 
A rare missense variant (c.188A>G, p.N63S) was detected in a SALS case; 
however, it was also present in eight of 190 controls suggesting that it is a benign 
polymorphism.  This particular base pair change is not well conserved across species and 
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the serine residue is present in the rhesus monkey.  Additionally, a nine bp deletion 
(c.676_684delGGCGGCGGC) was detected in exon 6 which results in the loss of three 
glycine residues (p.G226_G228del).  This variant was detected in a patient with ALS as 
well as one in 190 controls (supplementary material table V). 
 
The entire FUS gene was sequenced in 285 patients with schizophrenia and autism, 
and only one coding variant was detected, a GGC insertion in exon 6, resulting in the 
introduction of a glycine residue (c.684_685insGGC, p.G228_G229insG).  This is at the 
same location where a nine base pair deletion was detected in a patient with ALS and a 
control individual suggesting that this particular glycine stretch is prone to 
expansion/contractions.  Thus, the frequency of FUS variants is not particularly high in a 
population of non-ALS patients (supplementary material table V). 
 
2.1.7 Discussion 
Our study identified three SALS cases with mutations in the FUS gene.  These 
patients were labelled sporadic considering that the cases were isolated and that the family 
history was negative. 
 
Two mutations which were previously described by Kwiatkowski et al. (2009)6 
were also identified in this study, the p.R521H and p.R521C mutations. One new deletion 
was also identified in a SALS individual. The overall percentage of mutations identified in 
this study was one of 80 FALS or 1.25%, and three of 405 SALS or 0.74%.  This is less 
than the original reports.  Also, our study only detected heterozygous changes while the 
other reports described homozygous and heterozygous changes.6, 103 
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Future identification of more sporadic cases with missense and deletion mutations in FUS 
will definitely provide a more comprehensive picture of the proportion of mutations 
involved in ALS pathology.  The accumulation and description of different mutations in 
ALS cases and future detection of mutations in more SALS patients will help understand 
the genetic mechanisms involved in this neurodegenerative disease.  The identification of 
new genes represent a highly informative event for the selection of candidate genes to be 
investigated in the future, considering that the genetic factors underlying a substantial 
proportion of ALS cases remains unknown.  Further investigation of the function of those 
genes will progressively stimulate the development of drug treatment and therapy for the 
disease. 
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2.1.9 Tables and Figures 
Table II Clinical and genetic profile of ALS patients with mutations in the FUS gene 
Variant 
Amino 
Acid 
change 
Nucleotide 
change Exon
 
Chr16 
Position* Origin
Family 
history Sex 
 
Age of 
onset 
(years)
Duration 
(months)
Site of 
onset 
1 p.S57del c.169_171 del TCT 3 31,101,465France SALS M 80 10 Spinal 
2 p.R521C c.1561 C>T 15 31,110,240France SALS M 26 27 Spinal 
3 p.R521H c. 1562 G>A 15 31,110,241Quebec
 
FALS 
(affected 
father) 
M 54 30 Spinal 
4 p.R521H c. 1562 G>A 15 31,110,241France SALS F 32 72 Spinal 
* human genome build 36.1 
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Figure 1 Sequence traces and position of mutations in FUS 
 
(A) Sequence trace for the wildtype allele is presented over top of the sequence of the 
mutated allele.  The amino acid that is changed is listed below.  (B) Schematic (not to 
scale) of the FUS gene.  Dots represent the exons in which mutations were identified.  In 
the lower panel, the amino acid position of the mutations is indicated by the arrows.  The 
position of the RNA-recognition motif (RRM) is also highlighted in green. 
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2.1.10 Supplementary material 
Table III Primers and conditions for FUS 
Exon(s) Forward Primer Reverse Primer 
1 CTGCTCAGTCCTCCAGGC TCCCACTGAAAACGAAAAGC 
2+3 CAGTGCTTGAGTTAAGGAATTTAGC AGGACCAGACTCCGTCTCC 
4 CTGAGAGGCTGGCTTTATGAG ACTGCTCCTACTGCTGGTCC 
5 GGACTCCACTAAAAGTGAAAGG AGCCTCAGCAACAGAGACAG 
6 TCATTGCCTGGCACTTGTC GGCTTCAGGGAGATTCATGC 
7 CTACCCATGTTTGGGGAATG AAGACATCTGCAAATGAACAATC 
8 CCTGTTGACTAACGGCTCATC AGTTTCAAAGAACATCCAGGC 
9 TTGCTTGATGGATACTAGGTGC TGCTGGCAACCATTAAAGAC 
10+11 TTTGGGAATTATAAACCTCATGTTC CCATGCAAGCCTTTACCATC 
12 GCTTGCATGGAATGGGTTAG TACTTCTTTGGAAAACACGCAC 
13+14 TCCTCACTGTATCTCTAAAGTCACC TCTCAACAAAACCCTGTTATCC 
15 AGGTAGGAGGGGCAGATAGG GGAAGGTTACAAAATAACGAGGG 
 
PCR was performed using 50ng DNA, 20 pmol of each primer, 10X buffer, 0.25 nM 
dNTPs and 0.15 ul of Taq (Qiagen).  For each exon, a denaturation step of 5 minutes was 
first performed at 94°C.  Then a touchdown protocol was used which consisted of an initial 
cycle of 30 seconds denaturation at 94°C, 30 seconds annealing at 59°C and 45 seconds 
elongation at 72°C.  This was followed by nine cycles in which the annealing temperature 
was decreased each time by 0.5°C.  Then 25 cycles of 30 seconds denaturation at 94°C, 30 
seconds annealing at 59°C and 45 seconds elongation at 72°C were run.  A final extension 
at 72°C was performed for 7 minutes.  For exons 6, 9, and 12,  1x Q solution (Qiagen) was 
incorporated in the PCR mix. 
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Table IV Phosphorylation site prediction scores of deletion in FUS 
 
 
Amino 
acid 
change 
Putative effects Putative site of 
phosphorylation
Context Wildtype 
score 
Variant 
score 
 
 
p.S57del 
 
Probable 
decreased 
phosphorylation
S54 
S56 
S57 
Y58 
Y61 
YGQSSYSSY
QSSYSSYGQ
SSYSSYGQS 
GQSSYSSYG
SYSSYGQSQ
0.451 
0.974 
0.788 
0.554 
0.521 
0.203 
0.924 
0.00 
0.105 
0.575 
*Reference:  Blom, N,  Gammeltoft, S, Brunak, S. Sequence- and structure-based 
prediction of eukaryotic protein phosphorylation sites. J Mol Biol 1999; 294: 1351-1362.  
 
Phosphorylation scores range from 0.00 (minimal probability) to 1.00 (high probability). 246 
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Table V FUS variants found in controls and aut/schizo patients 
 
Gene Exon Nucleotide 
change 
Amino acid 
change 
dbSNP ALS 
x/200 
Control 
x/190 
Aut/Schizo 
x/285 
FUS 3 c.62C>A 
 
p.P21H 
 
n/a 
 
0 1 0 
FUS 3 c.147C>A 
 
p.G49G 
 
rs741810 
 
0 81 146 
FUS 3 c.153C>T 
 
p.G51G 
 
rs61733962
 
0 2 0 
FUS 3 c.188A>G 
 
p.N63S 
 
n/a 
 
1 8 0 
FUS 6 c.676_684 
delGGCGGCGC
 
p.G226_G228del 
 
n/a 
 
1 1 0 
FUS 6 c.684_685 
insGGC 
 
p.G228_G229insG 
 
n/a 
 
0 0 1 
FUS 15 c.-4G>C 
 
5'UTR 
 
n/a 
 
0 1 0 
FUS 15 c.-2A>C 
 
5'UTR 
 
n/a 
 
0 1 0 
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Figure 2 Protein sequence alignment of FUS in different species 
 
 
 
 
The proteins used for comparison and their accession numbers include: Homo sapiens 
(NP_004951.1), Bos taurus (Q28009), Equus caballus (XP_001500625), Gallus gallus 
(XP_001235919), Monodelphis domestica (XP_001364792), Mus musculus (AAH58247), 
Pan troglodytes (XP_001158561), Rattus norvegicus (XP_001060226) and Xenopus laevis 
(NP_001080383).  The ClustalW method was used for sequence alignment. 
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2.2.1 Rationale 
When conducting the first FUS mutation screening, we used only a sub-group of our 
ALS cohort. Nevertheless, we were the first lab to report FUS mutations in sporadic ALS 
cases. More importantly, two sporadic patients were found with two different substitutions 
at amino acid 521 located in the last exon of the FUS gene, and those same mutations were 
previously reported in familial ALS cases. Interestingly, the two sporadic mutated patients 
started to develop the first ALS symptoms at an unusually young age (26 and 32 years of 
age), and this definitely retained our attention. Considering that our sporadic ALS cohort is 
mostly of French and French-Canadian origin, that the three different sporadic mutations 
identified in the previous paper were in patients from France, and that the first two reports 
mostly tested Anglo-Saxon samples, we believed that we might find additional mutations 
by screening more sporadic cases. This way, our study would contribute to better evaluate 
the contribution of FUS mutations in apparently sporadic ALS patients. Furthermore, 
finding new mutations would help characterize the role of the FUS protein in the ALS 
pathology and better understand the neurodegeneration mechanism involved in this motor 
neuron disease. 
 
It is however difficult to evaluate if a specific mutation found in a sporadic patient 
actually cause the disease, since no segregation analysis can be conducted. The variant can 
only be confirmed to be absent in the patient’s parents if their DNA is available but still, no 
conclusion can be made in regards to the variant role in the disease unless it has been 
previously reported in familial cases. Bioinformatics softwares are available to predict the 
effect of genomic variants,247, 248 whether damaging or benign, but these are only 
predictions and no firm conclusions can be made. Because of this, we decided to screen for 
FUS mutations two groups of 475 participants each: one SALS group and one control 
group. Our aim was to compare the number and type of mutations identified in the two 
groups, and evaluate if variations were more common in the disease affected group than the 
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control group. This way, we would be more confident that variants found in sporadic cases 
actually cause the disease. 
 
2.2.2 Contribution of authors 
Belzil : Study design, data generation and analysis, statistical analysis, manuscript writing. 
Daoud : Manuscript revision. 
St-Onge : Data generation and analysis, manuscript revision. 
Anne Desjarlais : Clinical information organization, manuscript revision. 
Bouchard, Dupré, Lacomblez, Salachas, Pradat, Meininger, Camu : Clinical evaluation, 
sample collection, manuscript revision. 
Dion & Rouleau : Sample collection, experiment supervision, manuscript revision. 
 
2.2.3 Abstract 
Objective: Mutations in the FUS gene have been recently associated with amyotrophic 
lateral sclerosis. While most of the variants have been identified in patients with a family 
history of the disease, a few mutations were also found in sporadic patients.  Considering 
this, we wanted to evaluate the frequency of mutations in the coding region of the FUS 
gene in a sporadic ALS cohort compared to a control population. Methods: We tested 475 
SALS cases of European origin and 475 matched controls for coding variations in the 15 
exons of the FUS gene. Results: Rare novel variants were identified in a total of five SALS 
patients: one missense, one deletion, one frameshift, and one nonsense substitution. Two of 
the four variants are located in the carboxy terminal of the protein where the previously 
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reported variants were mostly clustered. Conclusion: FUS gene mutations are rare in SALS, 
with four new FUS variants identified in five different SALS cases. These findings will 
help evaluate the proportion of FUS variations in the SALS population, and to better 
understand its contributing role to ALS pathology. 
 
2.2.4 Introduction 
Amyotrophic lateral sclerosis (ALS) is the most common of the motor neuron 
diseases. It is an adult onset disease characterized by neuronal death in the motor cortex, 
brain stem and spinal cord, and patients usually die from respiratory failure three to five 
years after the appearance of the first symptoms. Ninety percent of affected individuals do 
not have a family history for the disease, and are considered sporadic cases (SALS)249. In 
1993 mutations in the SOD1 gene were found to be responsible for 15 to 20% of the ten 
percent of patients with a family history of ALS (FALS), while coding variations in SOD1 
is believed to account for 2-7% of SALS cases65. Mutations in the TARDBP gene was 
identified in 2008 as being responsible of 1 to 3% of all ALS cases101, after its protein 
TDP-43 was found to be an important constituent of aggregates in the neurons of ALS and 
frontotemporal dementia (FTD) patients112. In 2009, mutations in the FUS gene were 
reported to cause approximately 4% of FALS cases6, 103 and less than 1% of sporadic 
cases250. Considering that the proportion of SALS cases with mutations in the FUS gene 
has not been precisely established, we wanted to assess whether variations in the FUS gene 
may be responsible for a fraction of sporadic cases of ALS. We found four new variants 
that were exclusively present in five different sporadic ALS samples, while only one new 
missense was present in one control, suggesting that variations in the FUS gene are 
apparently a rare cause of SALS.  
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2.2.5 Materials and Methods 
2.2.5.1 Standard Protocol Approvals, Registrations, and Patient Consents 
The procedures followed were in accordance with the ethical standards of the 
responsible committee on human experimentation and with the Helsinki Declaration of 
1975, as revised in 1983. Protocols were approved by the ethics committees and the 
institutional review boards of the relevant institutions. All patients gave written informed 
consent after which patient information and blood were collected.  
 
2.2.5.2 Subjects 
Patients were collected from France and Quebec (n = 475) between 2004 and 2009 
and did not have a known history of ALS in their family. DNA was extracted from 
peripheral blood using standard protocols. All 475 SALS patients were screened for the 15 
exons of the FUS gene. All 15 exons were also sequenced for 475 ethnically matched 
controls. 
 
2.2.5.3 Gene Screening 
Primers were designed using the ExonPrimer software from the UCSC human 
genome browser website ((http://genome.ucsc.edu/cgi-bin/hgGateway) and have been 
previously published250. Twelve sets of primers were sufficient to amplify and sequence the 
15 coding exons of TLS/FUS (NM_004960.3). The amplified intronic region flanking each 
exon included at least 50 bp. The amplification was conducted by polymerase chain 
reactions (PCRs) using the AmpliTaq Gold DNA Polymerase (Applied Biosystems, Foster 
City, California, USA) as per manufacturer’s instructions. PCR products were amplified 
with the same procedure of direct sequencing in patients and controls, and were sequenced 
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at the Genome Quebec Innovation Center (Montréal, Québec, Canada) using a 3730XL 
DNA analyzer. Mutation surveyor software (version 3.10) was used for mutation detection 
analyses (SoftGenetics, Pennsylvania, USA). 
 
2.2.5.4 Protein sequence alignment 
Cluster analysis was performed using the Clustal W method. The closest homologue 
in several species was retrieved by use of NCBI’s BLAST program (figure 3B-C-D, figure 
4B-D). The proteins used for comparison and their accession numbers include: Homo 
sapiens (NP_004951.1), Pan troglodytes (XP_001158561), Equus caballus 
(XP_001500625), Bos taurus (Q28009), Gallus gallus (XP_001235919), Rattus norvegicus 
(XP_001060226), Mus musculus (AAH58247), Monodelphis domestica (XP_001364792) 
and Xenopus laevis (NP_001080383). 
 
2.2.6 Results 
The entire coding region of the FUS gene was amplified and sequenced from the 
DNA of 475 SALS patients and 475 control participants. 21 SALS as well as 25 control 
samples were removed from the total considering that more than 50% of their sequence 
amplification failed. Thus, a total of 454 SALS and 450 control samples were used for the 
analysis. Overall, more than 96% of the twelve amplicons tested for each sample were 
successfully sequenced and analyzed (supplementary table VI). In total, twelve coding 
variants and thirteen synonymous substitutions were identified (table VI). A novel 
heterozygous missense mutation (p.P18S; c.52C>T) was of particular interest since it was 
found in two unrelated French cases: one SALS patient with a classical ALS phenotype and 
one patient with an ALS phenotype characterized predominantly by lower motor neurons 
degeneration. The substituted proline was highly conserved across nine species (figure 3B) 
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and was absent from 450 control participants. In addition, a heterozygous deletion of 
eighteen nucleotides (c.430_447delGGACAGCAGCAAAGCTAT) leading to an in frame 
deletion of six amino acids (p.G144_Y149del) was identified in one French SALS patient 
(figure 4A). Those six amino acids (GQQQSY) are all well conserved across nine different 
species, except for G144 that is not conserved in the chicken and the Q147 that is not 
conserved in the chicken and the horse. Considering that the wild type protein has a total of 
526 amino acids, this deletion would results in a protein with 520 amino acids. A 
heterozygous adenine duplication (c.1506dupA ) was also observed in one Canadian SALS 
individuals, resulting in a shifting of the reading frame (figure 4C) which is predicted to 
cause a stop codon at position 516.  The end product has a total of 515 amino acids since 
the last well conserved 25 amino acids of the wild type protein are replaced by fourteen 
new amino acids (EQRWLWPWQDGFQG; figure 4D). A known polymorphism (rs10684) 
at nucleotide c.1509 (G>A) was present in this individual. This explains why only an 
adenine is seen in the chromatogram at this position (figure 4C). Moreover, a heterozygous 
nonsense substitution (c.1555C>T) was identified in one SALS sample of French-Canadian 
origin at amino acid 519, when a glutamine is replaced by a stop codon (Q519X). The last 
eight amino acids of the protein, which are very well conserved across the nine species, are 
deleted from the end product, resulting in a truncated protein of 518 amino acids (figure 
3D). The SALS patient having the mutation displayed a very early age of onset and 
experienced a relatively rapid disease progression (supplementary material table VII). All 
the mutations previously mentioned were unknown and absent from 475 control sequences. 
The clinical profile of SALS patients with novel coding variations in the FUS gene is 
available in supplementary material table VIII. 
 
One patient was found to have the p.G226S variant that was previously identified by 
Corrado et al. (2010)251 in one control. No control participant of our cohort had the 
mutation, but the glycine is not very well conserved across the nine species (figure 3C). In 
contrast, the mutation p.R216C (c.646C>T) found in one sporadic case by Corrado et al. 
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(2010)251 was present in one of our controls. The novel variant p.R383C (c.1147C>T) was 
the only mutation uniquely identified in a control participant. 
 
Variations in the stretch of the ten glycines in exon 6 were found in both our SALS 
and control populations. Two SALS patients had one glycine insertion (p.G222_G223insG) 
while three control participants had one glycine deletion (p.G223del). Variations in this 
repeat stretch have previously been found (rs72550890). It still needs to be determined if 
variations in this glycine stretch may predispose or be associated to ALS.  
 
A two-tailed Fisher exact test was conducted to evaluate the statistical significance 
of the frequencies of coding variations found in SALS versus the control participants. 
Considering that a total of 454 SALS patients were tested and 25 samples did have a coding 
variant (which represents 0.06% of our tested cohort), and that 450 control participants 
were tested and 18 samples did have a coding variant (which represents 0.04% of the 
control tested), the p-value is 0.29, and thus not significant. 
 
2.2.7 Discussion 
Four new variants were exclusively identified in five different SALS samples: one 
missense (p.P18S) in two individuals, one in frame deletion of six amino acids 
(p.G144_Y149del) in one person, one duplication causing a frameshift in one patient, and 
one nonsense substitution in one person. Only one novel missense was identified in a 
control participant. The six amino acids deletion, the frameshift mutation, and the nonsense 
substitution are all strong mutations which might predispose to ALS as no such mutation 
was identified in ours, or any other reported controls. Unfortunately no conclusions can be 
made with respect to the possible role of the p.P18S missense in SALS. Even if the p-value 
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is not statistically conclusive, three of the four variants found in SALS are predicted to have 
important effects on the protein. However, these data suggest that FUS mutations may be a 
rare cause of SALS. Parents were not available for any of these individuals, so we were not 
able to determine paternity or if the mutations were de novo. 
 
SALS patients with a mutation in the C-terminal of FUS seem to have an earlier age 
of onset, as previously reported by Blair et al.3 In contrast, patients with mutations in the 
first half of the protein had the typical age of onset for ALS. The number of mutated 
patients in our study is however too small to arrive at any conclusion, though the age of 
onset of our patients with the stronger mutations are consistent with this previous work, 
providing some support their having a role in disease.  
 
The identification of new mutations will help to better understand the proportion of 
sporadic ALS cases with FUS mutations as well as to provide new variants that can be 
studied to better understand the pathological mechanism underlying this neurodegenerative 
condition. 
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2.2.9 Tables and Figures 
Table VI Description of coding genetic variations in FUS found in SALS patients and/or 
control participants 
# Localization 
 
Coding DNA variant 
 
Non-synonymous 
Variant 
 
SALS 
(n=454) 
Controls 
(n=450) 
Status 
 
       
1 x3 c.52C>T p.P18S 2 0 new 
2 
 
 
3 
x3 
 
 
x5 
c.188A>G 
 
 
c.430_447delGGA 
CAGCAGCAAAGCTAT 
p.N63S 
 
 
p.G144_Y149del 
3 
 
 
1 
 8* 
 
 
0 
reported in 
SALS and 
controls 
new 
4 
5 
 
 
6 
x5 
x5 
 
 
x6 
c.475 A>T 
c.491_495+1delGAGGTg 
 
 
c.646C>T 
p.N159Y 
p.G174_G175del 
 
 
p.R216C 
11 
3 
 
 
0 
3 
2 
 
 
1 
new 
reported in 
patients and 
controls 
reported in 
one SALS 
7 
8 
9 
x6 
x6 
x6 
c.666_667insGGC 
c.667_669delGGC 
c.676G>A 
p.G222_G223insG 
p.G223del 
p.G226S 
2 
0 
1 
0 
3 
0 
rs72550890 
rs72550890 
reported in 
one control 
10 x11 c.1147C>T p.R383C 0 1 new 
11 x14 c.1506dupA p.R502fsX15 1 0 new 
12 x15 c.1555C>T p.Q519X 1 0 new 
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# Localization 
 
Coding DNA variant 
 
Synonymous Variant SALS 
(n=454) 
Controls 
(n=450) 
Status 
 
       
1 x1 c.6C>T p.A2A 2 0 new 
2 
3 
4 
x3 
x3 
x4 
c.147C>A 
c.153 C>T 
c.222A>G 
p.G49G 
p.G51G 
p.G74G 
188 
5 
0 
153 
3 
2 
rs741810 
rs61733962 
new 
5 
6 
7 
8 
9 
x4 
x4 
x5 
x5 
x6 
c.269C>T 
c.287C>T 
c.504A>T 
c.510A>T 
c.684C>T 
p.Y91Y 
p.Y97Y 
p.G168G 
p.G170G 
p.G228G 
1 
371 
23 
10 
1 
0 
351 
10 
11 
0 
rs73530286 
rs1052352 
new 
new 
new 
10 
11 
x11 
x12 
c.1156C>A 
c.1173C>A 
p.R386R 
p.P391P 
1 
1 
0 
0 
rs61733965 
new 
12 x14 c.1464C>T p.G488G 1 0 Reported in 
controls and 
patients 
13 x15 c.1566G>A p.R522R 0 2 Reported in 
controls and 
patients 
 
*Same control participants with N63S variant reported in Belzil et al., Neurology 2009.250 
When numbering the mRNA, +1 represents the A of the ATG. The start methionine is amino 
acid number 1. 
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Figure 3. Position of the P18S, G226S and Q519X mutations in FUS gene, sequence traces 
and across species conservation 
 
(A) Schematic (not to scale) representation of the coding region of the FUS gene and motifs 
of the FUS protein with the localization of the coding mutations found exclusively in SALS 
cases. (B-C-D) Sequence traces for the non-synonymous variants found exclusively in 
SALS cases; patients are shown below wild type sequences. Amino acids conservation 
across nine species at specific substituted site is also shown using the Clustal W method. 
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Figure 4 Sequence trace and protein sequence of the G144_Y149del and R502fs mutations 
in FUS 
 
(A) Chromatograms for the c.430_447delGGACAGCAGCAAAGCTAT variant. The wild 
type sequence is on top of the mutant sequence. The change in the protein sequence is also 
illustrated. (B) Complete protein sequence of the wild type 526 amino acids in FUS on top, 
followed by the mutant sequence below. The six amino acids deleted in frame are indicated 
in black between the preceding and following amino acids in red in the wild type sequence, 
and are indicated by a square. The preceding and following amino acids are still in red and 
marked by a square in the mutant protein sequence. The in frame deletion of these six 
amino acids results in a truncated peptide of 520 amino acids. The conservation of the 
deleted six amino acids across nine species is also shown using the Clustal W method.  (C) 
Chromatograms for the c.1509dupA variant. The wild type sequence is on top of the mutant 
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sequence. The mutant sequence is shown in forward and reverse. The change in the protein 
sequence is also illustrated. The position of the known substitution from a glycine to an 
adenine (rs10684) at aa 503 (p.R503K) is marked by a square on the wild type and the 
mutant forward sequences. (D) Complete protein sequence of the wild type 526 amino 
acids in FUS on top, followed by the mutant sequence below. The first 501 amino acids of 
the wild type sequence are conserved in the mutant sequence; the last 25 amino acids of the 
protein in the wild type state are marked by a square. The last 14 new amino acids in the 
mutant state are in red and marked by a square. This mutant protein results in a truncated 
peptide of 515 amino acids. The conservation of the last 25 amino acids of the protein 
across nine species is also shown using the Clustal W method.  
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2.2.10 Supplemental material 
Table VII Summary of amplicons sequenced and analyzed in FUS for SALS and control 
samples 
 SALS Controls Total 
Amplicons tested 5 448 5 400 10 848 
Amplicons amplified 5 232 5 200 10 432 
Percentage amplified 96.04% 96.30% 96.17% 
The number of samples tested is based on the amplification of the twelve fragments needed 
to cover the entire coding region of the FUS gene in 454 SALS patients and 450 control 
participants. 
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Table VIII Clinical profile of SALS patients with novel coding variations in the FUS gene 
Sample Gender Origin 
 
Coding variant Age of 
onset 
Site of 
onset 
Duration 
       
R2592 M France p.P18S 36 Right 
inferior 
limb 
Still alive 
in 1990, 
date of 
death 
unknown 
X4981 M France p.P18S 74 Inferior 
limbs 
3 years 
X5055 M France p.G144_Y149del 57 Inferior 
limbs 
56 months 
X4904 M France p.G226S 
 
62 Bulbar 5 months 
R31291 M Canadian p.R502fs 49 Left 
upper 
limb 
Onset 
2005 
still alive 
R13291 M French-
Canadian 
p.Q519X 20 Right 
upper 
limbs 
1 year 
Only information regarding SALS sample with mutations not found in our control 
population is listed here. 
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2.3 Identification of a FUS splicing mutation in a large family 
with amyotrophic lateral sclerosis 
 
Véronique V. Belzil1, Judith St-Onge1, Hussein Daoud1, Anne Desjarlais1, Jean-Pierre 
Bouchard2, Nicolas Dupré2, William Camu3, Patrick A. Dion1,4 and Guy A. Rouleau1,5,6. 
 
1Center of Excellence in Neuromics of Université de Montréal, CHUM Research Center, 
Montreal, Quebec, H2L 4M1, Canada. 2Université Laval, Faculty of Medicine, CHA - 
Enfant-Jésus Hospital, Quebec, G1J 1Z4, Canada. 3ALS Center, Department of Neurology, 
CHU Gui de Chauliac, Montpellier, France. 4Université de Montréal, Faculty of Medicine, 
Department of Pathology and Cellular Biology, Montreal, Quebec, H3C 3J7, Canada. 
5Université de Montreal, Faculty of Medicine, Department of Medicine, Montreal, Quebec, 
H3C 3J7, Canada. 6Research Center, CHU Sainte-Justine, and Department of Pediatrics and 
Biochemistry, Université de Montreal, Montreal, Quebec, H3T 1C5, Canada. 
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2.3.1 Rationale 
The previous study contributed to approximate at 1.3% the frequency of FUS 
mutations in sporadic ALS cases in the French and French-Canadian populations. The 
percentage of mutations found differed from other reports;5, 7, 251, 252 it is slightly higher. 
Another concern was that our first report found only one mutation in one FALS sample 
after testing 80 patients, representing only 1% of the samples tested. This is significantly 
lower than what was previously reported in different populations,4-6, 71, 103, 253, 254 but lower 
percentages have also been published.7, 251, 255, 256  
 
Interestingly, higher FUS mutation proportions were found in FALS or SALS cases 
when testing more homogenous populations. For instance, we identified a higher proportion 
of mutations in sporadic cases because the tested cohort was only composed of French and 
French-Canadian samples. A group from the Netherlands reported FUS mutations in 7.7% 
of their FALS samples4, while a German group found variants in about 7% of their FALS 
tested cohort.253 This is definitely higher than what have been published so far. On the 
contrary, lower incidence of FUS mutations in FALS cases was found in Belgium, and this 
can be explained by the fact that the population is composed of individuals of different 
origins, including Dutch, French, German, Moroccan, Italian, Spanish and Turkish. The 
same type of heterogeneity is found in Canada since North America was colonized by 
different countries and was mainly populated by multicultural immigration. Because of this, 
it is difficult to categorize specifically the origins of inhabitants. Considering that our first 
tested FALS cohort was composed of European descents samples from different origins, 
the genetic heterogeneity of the cohort can explain the lower proportion of mutated FALS 
cases identified. 
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Considering this, we decided to better evaluate the proportion of FUS mutations in a 
larger FALS cohort still of European descents, and tested 154 additional individual FALS 
samples. 
 
2.3.2 Contribution of authors 
Belzil : Study design, data generation and analysis, statistical analysis, manuscript writing. 
St-Onge : Data generation and analysis, manuscript revision. 
Daoud : Manuscript revision. 
Anne Desjarlais : Clinical information organization, manuscript revision. 
Bouchard, Dupré, Camu : Clinical evaluation, sample collection, manuscript revision. 
Dion & Rouleau : Sample collection, experiment supervision, manuscript revision. 
 
2.3.3 Abstract 
Background: Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease 
characterized by the degeneration of upper and lower motor neurons. Genetic studies have 
led, thus far, to the identification of twelve loci and nine genes for familial ALS (FALS). 
While the distribution and impact of SOD1 mutations has been extensively examined for 
over a decade, the recently identified FALS associated FUS gene has been less studied. 
Therefore, we set out to screen our collection of FALS cases for FUS mutations. Methods: 
All 15 exons of FUS were amplified and sequenced in 154 unrelated FALS cases and 475 
ethnically matched healthy individuals. Results: One substitution located in the acceptor 
splice site of intron 14 was identified in all affected members of a large family, causing the 
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skipping of the last 13 amino acids of the protein and the translation of 7 novel amino 
acids, resulting from the new transcription of a part of the 3’UTR. Conclusion: Our study 
identified a new splicing mutation in the highly conserved c-terminal of the FUS protein. 
Thus far most FUS mutations are missenses and our findings, combined with those of 
others, confirm the importance of the C-terminal portion of the protein, adding additional 
support for FUS mutations playing a critical role in ALS. 
 
2.3.4 Short communication 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting the 
upper and lower motor neurons. Specifically, the neurons of the motor cortex, brain stem, 
and spinal cord are progressively involved, causing gradual spasticity and muscle weakness 
starting in the limbs in 75% of cases and in the bulbar region in 25% of cases. 90% of 
patients are believed to be sporadic (SALS), without any family history of the disease, 
while the other 10% of cases are familial (FALS), primarily segregating in an autosomal 
dominant manner.249 SALS and FALS patients are clinically indistinguishable, except for 
the mean age of onset which is 56 years old for SALS, compared to an average of 46 years 
old for FALS.25 The overall prevalence is 4-6/100,000 and the incidence is 1-2/100,000,257 
which make ALS the most common of motor neuron diseases. 
 
Mutations in the copper superoxide dismutase 1 (SOD1) gene were first shown to be 
ALS causative over 15 years ago and they account for 15-20% of all FALS cases, 
representing a proportion of 1-2% of all ALS cases.60 In the last two years, the 
identification of ALS causative mutations in the TAR-DNA binding protein (TARDBP 
encoding TDP-43) gene in both SALS and FALS cases102 and in FUS/TLS encoding FUS,6, 
103 thus far mostly but not exclusively in FALS, opened a new era for the investigation of 
mechanisms underlying the disease. While SOD1 mutations have been reported throughout 
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the full length of the protein, TARDBP and FUS mutations are mostly clustered to specific 
regions. For TARDBP, most of the mutations identified are in the glycine rich region 
encoded by exon 6, and for FUS/TLS, which also contains a glycine rich region, mutations 
are mostly in the extreme C-terminal part of the protein.237 The aim of this study was to 
evaluate the proportion of FUS mutations in a portion of our FALS cohort and to see if any 
mutations identified would be clustered to the same region. 
 
The 15 coding exons of FUS were amplified and sequenced in 154 unrelated FALS 
cases, and only one variant was identified. It is an unreported substitution of an adenine to a 
cytosine in the acceptor splice site of intron 14 (c.1542-2A>C). The variant was present in 
six samples of a large ALS family (figure 5) recruited in France: II:5, III:8, IV:1, IV:3, 
IV:4, and IV:6. Two of those individuals had an ALS phenotype (II:5, III:8), while the four 
unaffected mutation carriers are in the fourth generation and are younger than the average 
age of onset of the first ALS symptoms. By carrying the mutation, they confirm that their 
three affected fathers likely had the substitution. In addition, three mothers married to 
affected fathers (II:4, III:1, and III:7) were tested and were negative for the mutation. We 
prepared cDNA using total RNA from the immortalized lymphoblast cell lines of the two 
affected individuals with the adenine to cytosine substitution. These cDNAs were PCR 
amplified, and two products of 425 and 167 bp were observed on agarose gel (figure 6A), 
demonstrating that the mutant allele was not degradated by nonsense mediated mRNA 
decay. The heterozygous sequence trace was analyzed as well as the separate sequence of 
the two different alleles after a gel extraction of the two products (figure 6B). Sequencing 
showed that patients with the c.1542-2A>C change expressed a mutated allele missing the 
40 pb coding sequence of exon 15 as well as the first 203 bp of the 3’UTR. More precisely, 
the sequence of the mutant mRNA brings together the last two bp of amino acid 514 
located in exon 14 and the nucleotide at the c.*204 position in the 3’UTR, as an AG 
alternative acceptor site located at position c.*202_*203 is encountered (figure 6C); 
translation subsequently ends with a stop codon at position c.*297. Consequently, the 
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mutant protein undergoes a silent change at amino acid 514 (p.R514R) followed by 7 new 
amino acids (SMSRSGR) at the end of the protein. The adenine of the wild type acceptor 
site of intron 14 located at base pair 31,110,219 on chromosome 16 is highly conserved 
across species and is not listed as a known SNP. The Alternative Splice Site Predictor 
(ASSP) bioinformatics program attributed a score of 15.533 to the wild type AG acceptor 
splice site, and a score of 4.249 for the acceptor splice site with the cytosine substitution. 
The alternative AG acceptor splice site located in the 3’UTR at position c.*202_*203 had a 
score of 4.620 and is suggested to be responsible for this new isoform. Since this FUS 
mutation segregates in all affected individuals of the family as well as in the children of 
deceased affected members, and was not present in 475 control participants, we believe that 
it is likely responsible for the ALS phenotype observed in this family. 
 
The substitution is located in the RGG-domain enriched in arginine-glycine-glycine 
motifs, where most other FUS mutations were reported. Importantly, truncated proteins 
were previously observed with the two other major ALS causative genes.63, 113, 258 But more 
interestingly, this is the second splicing mutation reported in FUS as another one was 
recently shown to lead to the skipping of exon 14 after the substitution of the adenine 
located in the acceptor splice site of intron 13.259 Unfortunately, no clinical information 
could be retrieved for the family presented in our study, so we were unable to compare the 
disease evolution caused by our splicing mutation in intron 14 with the splicing mutation in 
intron 13 reported by Dejesus-Hernandez et al. The splicing mutation identified here 
removes the last 13 amino acids that partly encode the c-terminal portion of FUS, in which 
a number of mutations have been associated with ALS. Our finding reinforces the notion 
that this portion plays a key role in the pathology of ALS, most likely by affecting the RNA 
binding domain it encodes for. In the future, such splicing defect causative mutations may 
become treatable through drugs or gene therapies aimed at correcting splicing, as explored 
for a number of disorders.260-262 
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2.3.6 Tables and Figures 
Figure 5 Pedigree of the family with the c.1542-2A>C variant in FUS 
Black symbols represent affected individuals, while open symbols represent unaffected 
family members. Symbols with dots represent unaffected individuals carrying the 
substitution. Slashed symbols indicate deceased individuals. Red square around the 
individual III:8 symbol marked the sample sequenced in the primary screening and 
asterisks indicate family members for whom exon 15 of the FUS gene was sequenced in the 
secondary screening. Symbols with two asterisks represent individuals for whom cDNA 
was amplified. Genotypes at position c.1542-2 are indicated in black for the wildtype allele 
and in red for the mutant allele. Genotypes in parentheses are inferred. 
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Figure 6 Splicing mutation in FUS: agarose gel, chromatograms and schematic 
representation 
 
(A) Agarose gel electrophoresis of FUS cDNA amplified in one unrelated control, and two 
affected family members (II:V, III:VIII), showing the wild type allele (425bp) and the 
mutant allele (167bp) for the fragment amplified using foward primer 5’-
GAGGGGGACCAGGTGGCTCTCAC in exon 14 and reverse primer 5’-
TCATTTGGCCTTCTCCCCGAACAC in 3’UTR. (B) cDNA sequence chromatogram of 
the wildtype and mutant alleles in one patient, confirming the skipping of exon 15 and the 
first 203bp of the 3’UTR. (C) Schematic (not to scale) representation of exons 14, 15, and 
3’UTR of the FUS gene for the wildtype and mutant alleles. In the mutant allele, a part of 
the 3’UTR is translated which adds 7 new amino acids to the protein (SMSRSGR). 
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2.4. Novel FUS deletion in a patient with juvenile amyotrophic 
lateral sclerosis 
 
Véronique V. Belzil, M.Sc.1, Jean-Sébastien Langlais2, M.D., M.Sc., Hussein Daoud, 
Ph.D1, Patrick A. Dion, Ph.D.1,3, Bernard Brais2, M.D.1, and Guy A. Rouleau, M.D., 
Ph.D.1,4,5. 
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Canada. 4Université de Montreal, Faculty of Medicine, Department of Medicine, Montreal, 
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2.4.1 Rationale 
Many years ago, juvenile amyotrophic lateral sclerosis (JALS) has been linked to 
the ALS2,84 ALS490 and ALS595 loci and mutations have been identified respectively in the 
ALSIN,86, 263 SETX264-266 and SPG11267 genes. More recently, ALS families with a few 
affected members developing the first symptoms before 25 years of age have been linked to 
the X chromosome and mutations have been found in the UBQLN2 gene.20 Noteworthy, the 
ALSIN, SETX, and SPG11 genes have also been associated with at least one other 
phenotype. Precisely, mutations in ALSIN have been identified both in juvenile primary 
lateral sclerosis (PLS)88, 263 and infantile onset ascending spastic paraplegia (IAHSP) 
cases,268 mutations in the SETX gene were found in ataxia-ocular apraxia-2 patients 
(AOA2), and mutations in SPG11 were first identified in individuals affected with 
hereditary spastic paraplegia-11 (HSP-11).269 This suggests that ALS, PLS and HSP are 
certainly part of a disease continuum, as the same biological pathway must contribute in 
different ways to define one specific phenotype. Consequently, a better understanding of 
the pathological cascade involved in one disease might help to develop therapeutics for a 
larger spectrum of neurodegenerative diseases. 
 
In 2009, mutations in FUS were identified in FALS cases by two groups.6, 103 We 
noticed already that some mutated individuals in one of these reports started to develop 
ALS symptoms much earlier than the mean age of disease onset. Since then, many familial 
as well as sporadic FUS mutated cases have been identified with an unusual young age of 
onset. Specifically, in our first report, our group identified two sporadic patients with FUS 
missense mutations who started to experience ALS symptoms at 26 and 32 years of age. In 
addition, in our second report, we found two other mutated sporadic patients with a 
nonsense and a missense mutation, who respectively developed the disease at 20 and 36 
years of age. A group from the US also reported a sporadic patient having a splice mutation 
with a disease onset at 20.259 In addition, an Italian group reported an 11 year old girl with a 
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missense mutation in FUS. The affected little girl who developed ALS was characterized 
by a very rapid progression.270 Three FUS mutated families with several members 
developing symptoms before the age of 30 years old have also been reported by a group 
from the US.71 
 
Of interest, a group from the UK reported four FUS mutated sporadic patients with 
an age of onset ranging from 17 to 22 years old, also with a rapid disease progression.271 
This group reported the presence of basophilic inclusions in their patients, which were 
positive for FUS protein but negative for TDP-43 in glia and neuronal cytoplasm and 
nuclei. A US group also observed the same basophilic inclusions in spinal motor neurons 
but not in glial cells of two juvenile ALS patients aged 13 and 21. A FUS missense 
mutation was identified in the 13 years old little girl.272 This distinct JALS phenotype with 
basophilic inclusions characterized by predominant lower motor neurons involvement has 
already been reported in the past.273-275 These motor neuron deposits are particular to 
juvenile ALS and are usually not found in neurons of pure adult onset ALS patients, as no 
abnormal accumulation of FUS has been found.272 Only two groups reported two adult-
onset patients exhibiting features resembling JALS with basophilic inclusions.276, 277 
Basophilic inclusions not only contain aggregates of FUS, but also aggregates of 
intracellular organelles,272 which explains the rapid progression experienced by patients and 
differentiate the pathology from what is observed in neurons of pure ALS cases.  
 
While JALS associated with mutations in the ALSIN, SETX, and SPG11 genes is 
characterized by a disease onset before the age of 25 and a slow progression, JALS patients 
with mutations in FUS generally develop the disease before 30 years of age, experience a 
very fast progression with a predominant involvement of lower motor neurons, and have 
FUS positive basophilic inclusions in their spinal neurons. The same phenotype has been 
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found in different populations, this type of JALS is thus not specific to a particular world 
region. 
 
An 18 years old patient displaying an ALS phenotype with an extremely rapid 
progression was hospitalized at our Research Centre hospital. The assigned clinician 
contacted us for screening of the FUS gene, considering the particular phenotype of the 
patient and the similarity with other FUS mutated JALS cases in the literature. This case 
study is presented here. 
 
2.4.2 Contribution of authors 
Belzil : Study design, data generation and analysis, manuscript writing. 
Langlais: Clinical evaluation, sample collection, manuscript writing and revision 
Daoud : Manuscript revision. 
Brais: Clinical evaluation, manuscript revision. 
Dion & Rouleau : Experiment supervision, manuscript revision. 
 
2.4.3 Abstract 
Objective: Juvenile Amyotrophic Lateral Sclerosis (JALS) refers to a form of Amyotrophic 
Lateral Sclerosis (ALS) in which a progressive upper and lower motor neuron degeneration 
begins before the age of 25. It is generally associated with slow disease progression. During 
the last decade a number of genes have been reported to cause JALS. Mutations in the 
ALSIN gene causes JALS type 2 (ALS2), as well as juvenile primary lateral sclerosis 
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(JPLS) and infantile-onset ascending spastic paralysis (IAHSP). Mutations in the SETX 
gene can also sometimes lead to JALS. Conversely, mutations in SOD1, TARDBP and FUS 
typically cause pure ALS with an adult onset between 46 and 56 years of age, and usually 
rapid progression over a 3 to 5 year period. Recently, a few mutations in FUS have been 
associated with a juvenile onset of ALS characterized by a very rapid progression.  
Design/Subject: We sequenced all the coding exons of SOD1, TARDBP and FUS in one 18 
years old patient experiencing a rapid degeneration of upper and lower motor neurons. 
Results: A novel one base pair deletion was detected in exon 14 of the FUS gene, leading to 
a frameshift and the integration of 33 new amino acids. The variant p.R495QfsX527 is 
located in the highly conserved, extreme c-terminal of the FUS protein, where most of the 
mutations in FUS have been identified. The variant was also identified in the unaffected 47 
years old mother of the patient who remains asymptomatic. Conclusions: Our finding, 
along those from others, further confirms that FUS mutations can lead to an early onset 
rather malignant form of ALS. In addition, our data lends additional support to the notion 
that disruption of the conserved c-terminal of FUS is critical for developing ALS. 
 
2.4.4 Background 
Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease affecting 
the upper and lower motor neurons. The mean age of symptom onset is 45 years old for 
cases with a previous family history, and 55 years old for sporadic cases.25 Affected 
individuals generally have a pure ALS phenotype, with degeneration affecting mainly 
neurons of the motor cortex, brain stem, and spinal cord. Patients usually die from 
respiratory failure after a three to five years of disease progression, and no effective 
treatment currently exists. Approximately 10% of ALS patients have other family members 
affected with the disease249. Mutations in the SOD1 gene explain approximately 2% of all 
ALS cases60, while variants in TARDBP and FUS each explain about 1-3% of overall 
cases106. On rare occasions, the first symptoms of motor neuron degeneration start before 
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25 years of age, usually with slower disease progression compared to later onset typical 
ALS278.  This juvenile type of ALS has been associated in the past with mutations in the 
SETX gene91 or the  ALSIN gene for ALS286. Mutations in ALSIN are also known to cause 
juvenile primary lateral sclerosis (JPLS) and infantile-onset ascending spastic paralysis 
(IAHSP)268. Since the report of FALS cases with mutations in FUS in 20106, 103, a few 
groups identified FUS mutations in ALS patients with an age of onset before the age of 25 
with an unusual and unexpected rapid progression71, 104, 259, 271. Here, we report an 18 years 
old male with a deletion in exon 14 of the FUS gene experiencing a very rapidly 
progressing disease.  
 
2.4.5 Case presentation 
The patient is a 19-year-old man with a past history of mild learning difficulties 
who had been working in commercial toxic waste recycling for less than a year. The patient 
first developed a painful right shoulder and arm weakness at the end of August 2009 which 
progressed rapidly, and in less than a month included neck weakness. At the beginning of 
December 2009, right arm muscle atrophy was noticed by members of his family, which 
prompted him to seek medical attention. A complete neurological exam and work-up was 
done including brain and spine MRI, repeated EMGs, toxicology screening, lumbar 
puncture, and biochemical blood tests. The general medical examination was normal. On 
neurological examination, he had a normal mental status. Examination of the cranial nerves 
showed tongue atrophy and fasciculations, bilateral facial weakness with right side worse 
than left, severe weakness and atrophy, and fasciculations of the sternocleidomastoids and 
trapezius with right side much worse than left. The remainder of the cranial nerves were 
normal. Motor examination showed atrophy and severe weakness of the right shoulder and 
upper arm including supraspinatus, infraspinatus, subscapularis, deltoid, pectoralis, and 
biceps. He had moderate weakness and atrophy of his right triceps, wrist and finger 
extensors and flexors, as well as interossei of the hands. There was normal bulk, tone and 
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strength of his left side and right leg. He was areflexic in the right arm, with mild 
hypereflexia in the left arm, knees and ankles, with equivocal plantar responses. The 
cerebellar exam was normal, with the exception of the right arm, which was not testable. 
The sensory exam was normal as well as his gait. The brain and spine MRI were normal. 
The lumbar puncture as well as the detailed biochemical tests and toxicology screen were 
normal. An EMG showed normal conduction velocities and normal needle exam of the left 
arm, shoulder and left leg. There was some denervation in muscles of the right leg and 
severe denervation in muscles of the right shoulder and arm. In March 2010, the patient 
was suspected of having juvenile onset ALS and was put on Riluzole. In May 2010, he 
developed dysphagia and dysarthria leading to anorexia and severe weight loss. In August 
2010, a control neurological exam showed a 36 kg young man with diffuse severe muscle 
atrophy. Muscle weakness was asymmetric with a profound right upper limb weakness and, 
to a lesser degree, bilateral leg involvement. The patient rapidly progressed to respiratory 
failure requiring mechanical ventilation. Repeated neurological exams showed no cognitive 
or sensory symptoms or signs. Although follow-up visits were scheduled, the patient was 
lost to follow up. In summary, the patient mostly displayed a lower motor neuron 
phenotype, with the upper limbs and bulbar regions principally affected. Upper motor 
neurons seemed to be mildly affected. 
 
When going back to the patient’s clinical history, he was generally in good health 
for his first 17 years of life. He consulted for dysphasia at the age of six, was prescribed 
Ritalin between six and 16 years of age, but did not show any previous signs of paralysis, 
progressive weakness or neurological symptoms. However, he attended welding school 
when he was 16, and worked with recycling hazardous material at age 17. 
 
While the patient had no apparent family history of motor neuron diseases, it is 
noteworthy that his mother was diagnosed with an Arnold-Chiari malformation at the age 
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of 13 years old; she actually experienced equilibrium problems and one cerebellar ataxia 
episode at that time. The mother’s parents were not reported to have developed any 
neurodegenerative symptoms. Other family members including the patient’s father and 
brother are still in good health.  
 
2.4.6 Methods 
DNA from the patient and his parents was extracted from peripheral blood using 
standard protocols. Primers for SOD1, TARDBP and FUS were designed using the 
ExonPrimer software from the UCSC human genome browser website 
(http://genome.ucsc.edu/cgi-bin/hgGateway). All 26 exons of the three genes were 
amplified for the patient for a total of 23 fragments, and the one fragment containing the 
mutation in the patient was amplified in his two parents. Amplification was performed by 
polymerase chain reactions (PCRs) using the AmpliTaq Gold DNA Polymerase (Applied 
Biosystems, Foster City, California, USA) as per manufacturer’s instructions. The PCR 
product contained a minimum of 50 bp from each of the flanking introns. Products were 
directly sequenced in forward and reverse at the Genome Quebec Innovation Centre 
(Montréal, Québec, Canada) using a 3730XL DNA analyzer (Applied Biosystems, Foster 
City, California, USA).  Mutation surveyor software (version 3.10) was used for mutation 
detection analyses (SoftGenetics, Pennsylvania, USA). All exons of FUS were also 
amplified in 96 French-Canadian and 380 French control participants, and have already 
been published104. 
 
2.4.7 Results 
A novel one base pair deletion of a guanine in exon 14 of the FUS gene 
(c.1484delG) (Figure 7A) was identified and is predicted to cause a shift in the reading 
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frame resulting in the inclusion of 33 new amino acids (p.R495QfsX527), which modifies 
the highly conserved c-terminal of the protein (Figure 7B) that is believed to play a crucial 
role in RNA processing106. The final mutated protein is predicted to have one more amino 
acids than the wild type, resulting in a probable change in the c-terminal function or 
interaction abilities. The variant was also identified in the 47 years old mother, who did not 
show any signs of motor neurons degeneration.  
 
Interestingly, Elden et al. recently found that intermediate-length polyQ tracts 
(ranging between 24 and 33 repeats) in ATXN2 confer an increased risk for developing 
ALS126. We decided to test the length of the repeat in ATXN2 in the 18 years old patient and 
his parents, the hypothesis being that the affected juvenile ALS case developed the 
symptoms earlier than his mother because he inherited an intermediate-length polyQ tract 
from his father who does not carry the FUS mutation. We amplified the ATXN2 CAG 
repeats by polymerase chain reaction. We determined the CAG repeat sizes by capillary 
electrophoresis by incorporating a VIC-labeled M13 universal primer into the PCR 
reaction. PCR products were then diluted (1:20) and mixed with LIZ-500 size standard 
(Applied Biosystems) and processed for size determination on an ABI 3730 DNA analyser. 
Repeat sizes were determined using the GeneMapper Software Version 4.0 (Applied 
Biosystems). All three individuals had both the (CAG)21 and (CAG)22 alleles, which are the 
most common in the general population. The experiment was repeated twice, yielding the 
same results. 
 
2.4.8 Comments 
A novel one base pair deletion was detected in exon 14 of the FUS gene, leading to 
a frameshift and the integration of 33 new amino acids. The variant c.1484delG 
(p.R495QfsX527) is located in the highly conserved, extreme c-terminal of the FUS 
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protein, where most of the mutations in FUS have been identified. The variant was also 
identified in the unaffected 47 years old mother of the patient, who remains well. Separate 
deletions were already reported in familial ALS cases one base pair upstream (c.1483delC), 
and one base pair downstream stream (c.1485delA), respectively producing 
p.R495EfsX527 and p.G497Afs52771. This confirms the importance of a conserved c-
terminal for the normal functioning of the FUS protein. Additionally, the same group 
published a nonsense substitution at position c.1483C>T that was shown to produce a 
truncated protein (p.R495X)71, further reinforcing the importance of this region. What is 
specifically interesting is the age of onset and disease duration associated with the 
p.R495EfsX527, p.G497Afs527 and the p.R495X reported mutations. In fact, the two 
affected members of the family with the p.R495EfsX527 mutation displayed a significant 
difference in terms of age of onset and duration, since one develop the first symptoms at 23 
years of age and the disease progressed over a 48 month period, while the other developed 
ALS at 72 years old and died 12 months after symptom onset. On the other hand, the seven 
members of the family in whom the nonsense p.R495X mutation segregated had an early 
age of onset but varied in terms of disease duration. Precisely, five members developed 
ALS at age 14, 24, 27, 39 and 44, while two other members with the variant were still 
unaffected at age 57 and 61. Moreover, the p.G497Afs527 mutation segregated in three 
members of another family who experienced the first symptoms at age 13, 29 and 29. The 
disease progressed very rapidly, over a 12, 13 and 18 months period in those patients.  
 
In addition, another group reported a sporadic ALS affected female with a FUS 
p.G466VfsX14 splice mutation who experienced the first symptoms at 20 years old; the 
disease progressed for a 22 months period259. Interestingly, our group also previously 
published one French-Canadian sporadic ALS case with a FUS p.Q519X mutation. This 
patient started to develop motor neuron symptoms at 20 years old, and the disease 
progressed rapidly over 12 month period104, still underlying the fact that a mutation in that 
specific region gave rise to an early ALS onset often characterized by a rapid progression. 
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The example of the published FALS and SALS patients just described along with 
our reported juvenile case underscore the importance of the last 32 amino acids of the FUS 
protein, and demonstrate that despite an existing variability in terms of age of onset, it 
seems that patients carrying such mutations frequently develop ALS at an earlier age while 
the disease progresses more rapidly. However, other genetic modifiers might influence the 
age at which the first ALS symptoms will appear. It is interesting to note that an 
intermediate-length of the polyQ tracts in ATXN2 is not an age of onset modifier in our 
juvenile patient. On the other hand, the patient was highly exposed two years before 
developing the first symptoms to welding material in an industry as well as to heavy 
metals, solvents, pesticides, and agricultural chemicals, all of which have been reported to 
be associated with ALS179, 279, 280. While detailed biochemical tests and toxicology screen 
were normal, unknown genetic variants already present in the patient leading to a certain 
vulnerability to toxic exposition, or mutations caused by such environmental exposition 
could explain why the patient developed the first signs of ALS while his mother remains 
well. However, it cannot be ruled out that other susceptibility variants in other genes 
explain the early onset. It could also be hypothesized that the mother carries a protective 
variant, preventing the early onset of the disease. 
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2.4.10 Tables and Figures 
Figure 7 Chromatograms, protein sequence and amino acid conservation in JALS FUS 
mutated sample 
 
(A) Chromatograms for the c.1484delG variant. The wild type sequence is on top, followed 
by the mutant sequence in forward and reverse. (B) Complete protein sequence of the wild 
type 526 amino acids of FUS on top, followed by the 527 amino acids mutant sequence 
below. The first amino acid affected by the nucleotide deletion is marked by a red rectangle 
on the reference sequence, and the highly conserved extreme c-terminal is between red 
brackets on the same sequence. The 33 new amino acid of the mutant sequence are in red in 
the protein sequence box and in the conservation across species box. The cluster analysis 
was performed using the Clustal W method, and show that the last 32 amino acid of the 
FUS protein are highly conserved across nine species. The closest homologues were 
retrieved by use of NCBI’s BLAST program. 
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Chapter 3 : New genetic avenues for the SOD1 gene 
 
3.1 A mutation that creates a pseudoexon in SOD1 causes familial ALS. Published in 
Annals of Human Genetics. November 2009;73(Pt 6):652-7. 
 
3.2 No effect on SOD1 splicing by TARDBP or FUS mutations. Published in Archives of 
Neurology. March 2011;68(3):395-6. 
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3.1 A mutation that creates a pseudoexon in SOD1 causes 
familial ALS 
 
Paul N. Valdmanis1, 2, Veronique V. Belzil1, James Lee1, Patrick A. Dion1, Judith St-Onge1, 
Pascale Hince1, Benoit Funalot, Philippe Couratier3, Pierre Clavelou4, William Camu5, Guy 
A. Rouleau1 
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France. 4 ALS center, CHU de Clermont-Ferrand, France. 5 ALS Center, CHU and 
University of Montpellier, Montpellier, France. 
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3.1.1 Rationale 
Mutations in the SOD1 gene have first been identified in 1993,60 explaining about 
20% of FALS and 3% of overall ALS cases.65 Almost 19 years later, more than 168 
mutations have been identified in this 154 amino acids gene.281 There is no mutation cluster 
as variants, mostly missense mutations, are present in all five exons of the gene. Until the 
end of 2011, SOD1 was the gene explaining the larger proportion of ALS cases. 
Considering that mutations are estimated to be found in 1:5 FALS patient, FALS samples 
in labs all over the world are screened systematically for SOD1coding mutations before 
being used for other ALS screening. But what about possible noncoding mutations? What if 
the SOD1 mutation proportion has been underestimated? 
 
While it was believed for a long time that causative mutations can only be located in 
the coding regions of genes, it is now well known that mutations in cis-acting regulatory 
sequences influence the expression of genes and are a significant cause of diseases. It is 
proven that humans are more polymorphic at functional regulatory sites than they are in 
coding regions.282 Precisely, cis-regulatory mutations disturb a wide range of physiological, 
morphological, or neurological phenotypes and can increase or decrease the amount of 
transcribed products.283 According the Human Gene Mutation Database (HGMD), about 
2158 regulatory mutations actually cause human inherited disorders, which represent 
approximately 1.8% of all disease causing mutations (updated Sept 30th, 2011).284 For 
instance, Mendelian disorders such as β-thalassemia, hemophilia and atherosclerosis are 
respectively caused by regulatory mutations in the beta-chain of hemoglobin (HBB), 
coagulation Factor IX and low-density lipoprotein receptor (LDLR) genes.283 Although 
trans-acting determinants are more numerous and code, among other things, for 
components of the splicing machinery, cis-acting elements have a stronger influence on 
gene expression.285 In addition, mutations in cis-regulatory elements can result in a 
misregulation of splicing or alternative splicing of the nearby genes.286  
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We present here a family with several members affected with ALS linked to 
chromosome 21. However, no SOD1 mutation was identified. The same problem was 
encountered in the past by another lab when studying a group of individuals from 
Melanesia with α-thalassemia. The patients showed an important reduction in α-globin 
transcription despite the absence of known mutations.287 A SNP segregating in all affected 
individuals was finally identified, this regulatory mutation creating a new GATA-1-binding 
site. This change caused the recruitment of an erythroid-specific transactivation complex, 
which interfered with normal transcription of the α-globin genes.287 In the same way, 
considering this, we believed that a regulatory or splicing mutation in SOD1 was carried by 
the affected members of this family which might cause the ALS phenotype. This hypothesis 
was explored in the next paper. 
 
3.1.2 Contribution of authors 
Valdmanis & Belzil : Study design, data generation and analysis, manuscript writing. 
Lee, St-Onge & Hince : Technical support, manuscript revision. 
Funalot, Couratier, Clavelou, Camu : Clinical evaluation, sample collection, manuscript 
revision. 
Dion & Rouleau : Experiment supervision, manuscript revision. 
 
3.1.3 Abstract 
Amyotrophic lateral sclerosis (ALS) is an adult onset neurodegenerative disease 
which targets motor neurons of the cortex, brainstem and spinal cord.  About 5-10% of all 
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amyotrophic lateral sclerosis cases are familial (FALS), and 15-20% of FALS cases are 
caused by mutations in the zinc-copper superoxide dismutase gene (SOD1).  We identified 
a large family from France with ten members affected with ALS.  Linkage was established 
to the SOD1 locus on chromosome 21 and genomic and cDNA sequencing was performed 
for the SOD1 gene.  This revealed an activated pseudoexon between exons 4 and 5 that was 
present in two tested members of the family.  Translation of this 43 base pair exon results in 
the introduction of seven amino acids before a stop codon is present, leading to a 
prematurely truncated SOD1 protein product of 125 amino acids.  Sequencing intron 4 in a 
patient revealed a heterozygous change 304 bp before exon 5 (c.358-304C>G), but only 5 
bp after the cryptic exon, thus causing this alternative splice product.  This mutation 
segregated in all affected individuals of the family. This adds an additional genetic 
mechanism for developing SOD1-linked ALS and is one which can be more readily 
targeted by gene therapy.  
 
3.1.4 Introduction 
Amyotrophic lateral sclerosis (ALS) is caused by the degeneration of motor neurons 
in the brainstem, spinal cord and motor cortex.  Mutations in the copper-zinc superoxide 
dismutase (SOD1) gene account for 15-20% of familial ALS cases.  The locus for SOD1-
linked ALS on chromosome 21 was identified by linkage analysis in 1991 288 followed by 
the identification of mutations in the SOD1 gene two years later 60.  Following this 
discovery, the screening of the SOD1 gene for mutations has been a standard procedure to 
determine which families have mutations in SOD1, and which families have another 
genetic cause.  The use of non-SOD1 families has led to the identification of loci on 
chromosome 18, 20, and 9 and in mutations in the FUS, DCTN, ANG, and TARDBP genes 
6, 21, 89, 98, 101-103, 111, 148, 289.  Meanwhile, several groups have more extensively analyzed the 
SOD1 locus on chromosome 21 to determine if additional genetic information could be 
extracted from the region.  This includes the examination of nearby genes and SNPs 
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surrounding SOD1 which could act as modifiers or susceptibility factors for the 
development of ALS.  In addition, certain families display unconventional (i.e. non-
dominant) inheritance patterns, and additional genetic factors within or near SOD1 may 
influence penetrance in these families.  Recessive pedigrees have been identified 
harbouring the D90A SOD1 mutation and the compound heterozygous D90A/D96N 
mutations 66, 74. 
 
We have identified a family with ALS from France that maps to chromosome 21 
and has a heterozygous mutation in the middle of intron 4 of SOD1 that leads to the 
inclusion of a cryptic exon in the SOD1 mRNA and a prematurely truncated protein 
product.   
 
3.1.5 Materials and Methods 
Blood samples were collected from 23 individuals (five affected individuals) who 
signed a consent form which was approved by the ethics review board of the Centre 
Hospitalier Universitaire de Montreal.  DNA from seven individuals (three affected, four 
unaffected) was sent for a 550-marker eight centiMorgan (cM) whole genome scan by 
DeCODE genetics (Reykjavik, Iceland).  Genome scan results were analyzed using 
Genehunter v2.1 with an autosomal dominant mode of inheritance, a disease frequency of 1 
in 10,000, 90% disease penetrance, equal allele frequencies and equal male to female 
recombination rates.  Subsequent two-point analysis was performed using the MLINK 
program from the LINKMAP software package 290.  Polymerase-chain reactions were 
performed using 50 ng of DNA, and amplified on Perkin Elmer 9600 thermocyclers (Perkin 
Elmer Applied Biosystems, Foster City, CA) using the following protocol: DNA melting at 
94°C for 5 minutes followed by 30 replication cycles (30 seconds at 72°C, 40 seconds at 
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55°C and 40 seconds at 72°C) and a 10 minute final extension step at 72°C.  PCR products 
were sequenced at the Genome Quebec Centre for Innovation. 
 
3.1.6 Results 
DNA from five affected individuals in the family, two at-risk individuals and one 
control were sequenced for the five exons of SOD1 using two different sets of non-
overlapping primers.  No coding mutations were detected, so seven members from the 
family were sent for a 550 microsatellite marker genome-wide scan (DeCODE genetics).  
The highest LOD score was present on chromosome 21, a 25 Mb (32.1 centiMorgan) 
interval from marker D21S1432 to D21S266 (Figure 8).  This region contains 134 RefSeq 
genes including SOD1, found at Mb 31.95 on chromosome 21.  Fine mapping of additional 
markers in all collected individuals in the family yielded a maximum LOD score of 2.84 at 
marker D21S263 (Table IV).  There was only one other region – on chromsome 12 - in the 
genome scan with a LOD score above 1.0 (but below 1.5).  By genotyping the complete 
family, we were able to exclude the chromosome 12 region and confirm that the family 
maps to chromosome 21.  This led us to believe that a mutation may be present in a non-
coding sequence or an intergenic region surrounding SOD1. 
 
We obtained immortalized lymphoblast cell lines from two of the patients (provided 
by Genethon , Evry,  France) in order to extract mRNA.  The SOD1 sequence was tested by 
cDNA analysis using two primer pairs that covered the SOD1 mRNA.  This led to the 
identification of two bands in a patient sample when the products using a forward primer in 
exon 4 (5’-GACTTGGGCAATGTGACTGCTGAC) and a reverse primer in exon 5 (5’-
TGCCATACAGGGTTTTTATTCACA) were run on gel (Figure 9A).  Analysis of the sequence 
trace resolved the two alleles in heterozygous state, which appeared at the junction of exons 
4 and 5.  This sequence consisted of 43 nucleotides which map to a region in intron 4 that is 
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744 base pairs after exon 4 and 308 base pairs before exon 5 (Figure 9B).  Thus, the 
patients contain a gene product that skips from the end of exon 4 to a novel 43 base pair 
cryptic exon, before proceeding to exon 5 (r.357_358ins357-351_358-309 of RefSeq 
NM_000454).  Importantly the novel exon contains a canonical AG/GT splice sequence 
flanking the exon (Figure 9B) and no expressed sequence tags from human or other species 
align to this intronic region.  Translation of the protein product reveals that the novel exon 
leads to the addition of seven novel amino acids (QLKKLPK) after codon 118 before 
reaching a stop codon.  By sequencing the region surrounding this pseudoexon, we were 
able to detect a heterozygous change (c.358-304C>G) which is only five base pairs after the 
end of the cryptic exon.  This cytosine is at base pair 31,962,351 on chromosome 21 based 
on NCBI build 36.1, is not listed as a known SNP and is not in a region of extensive 
interspecies homology.  This mutation segregated in all affected individuals, thus we 
hypothesize that it is the cause of the inclusion of the cryptic exon and the genetic cause of 
ALS for this family. 
 
These results were confirmed in a bioinformatic manner by use of the Berkeley 
Drosophila Genome Project (BDGP) which examines splice site prediction in humans 291.  
The wildtype sequence of SOD1 intron 4 includes a potential acceptor splice site sequence 
of the cryptic exon 4b (probability of 0.70).  The donor splice site corresponding to the 
cryptic exon was predicted with a score that increased from 0.43 for the wildtype ‘C’ allele 
to 0.99 for the mutated ‘G’ residue.  By comparison, the probability of the correct donor 
and acceptor sequences at the end of exon 4 and the beginning of exon 5 were 0.99 and 
0.97 respectively.  These findings were validated by a second splice site program, 
NetGene2 292 which also predicted that the mutation would create a novel donor site, with a 
confidence score of 0.63, at the location determined by cDNA analysis. 
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3.1.7 Discussion 
The identification of a novel alternative exon for SOD1 is surprising considering 
that this gene has been extensively studied since its discovery for ALS, and no alternate 
exons have been described.  In addition, alternative splicing does not appear to be a 
prominent feature of SOD1 despite one publication which examined alternative forms 293.  
It may be possible that additional families with ALS have a SOD1 mRNA product that 
includes this novel exon.  However, this will remain a type of mutation which is difficult to 
detect given the amount of intronic sequence which could potentially bear a mutation and 
the fact that detection or confirmation of such a mutation is dependent on the availability of 
cell lines for cDNA analysis.  The identification of the mutation in this family likely would 
have gone unnoticed, except that enough individuals were collected to convince us that a 
mutation truly was present in the SOD1 gene.  To date, all the mutations described for 
SOD1 have been exonic amino acid mutations, small (<10bp) exonic deletions, or intronic 
changes near exons.  Additional mutations have been reported in intron 4 including a 
heterozygous change nine base pairs after exon 4 leading to the addition of three amino 
acids to the SOD1 protein 294 and another change 11 base pairs before exon 5 which led to a 
premature truncation product 258.  While none of these caused the creation of a pseudoexon, 
they do suggest that the intron is prone to variation which can influence its proper splicing.  
The identification of a novel mode of action for SOD1 mutagenesis could promote the 
discovery of additional mutations in a likewise manner, thus increasing the proportion of 
familial ALS which is accounted for by mutations in SOD1. 
 
The identification that a relatively deep intronic variant in SOD1 can nonetheless 
cause ALS begs the question: how can these intronic variants be detected in the future, 
particularly in the context of large-scale DNA diagnostics?  In many cases, generation of 
lymphoblasts from peripheral blood and subsequent RNA extraction and cDNA analysis of 
SOD1 is a lengthy procedure and is not practically feasible for each patient.  However, in 
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cases of large families with ALS in which suggestive linkage to chromosome 21 can be 
established, this may be a necessary option.  Intron 4 of SOD1 where most of the intronic 
variants have been detected is relatively small at 1095 base pairs.  Thus it is a more 
reasonable option to completely sequence this intron with two or three sets of primer pairs 
to search for intronic variants that influence proper splicing.  The implementation of such a 
strategy needs to be weighed with the fact that the proportion of intronic variants is likely 
much less than exonic changes. 
 
This intronic variant in SOD1 that leads to ALS makes for a prime candidate to 
selectively silence the mutant copy of SOD1 in this family.  Over twenty reports of cryptic 
or pseudoexons have been documented 295.  Silencing of the allele by antisense morpholino 
oligonucleotides have been described for deep intronic variants in proprionic and 
methylmalonic acidemia 296.  While the number of individuals with mutations like this one 
in SOD1 is likely rare, this mutation remains a potential target for allele-specific therapy. 
 
3.1.8 Acknowledgments 
 We would like to thank this family for their participation.  P.N.V received support 
from the Fonds de Recherche en Sante Quebec (FRSQ), V.V.B and G.A.R received support 
from the Canadian Institute of Health Research (CIHR).  We are grateful to the Association 
Française contre les Myopathies and the Association pour la Recherche contre la Sclérose 
Latérale Amyotrophique for their financial support.  We would also like to thank Isabelle 
Bachand for technical support.  Guy A. Rouleau takes responsibility for the integrity of the 
data and the accuracy of the data analysis. 
  
 
95
3.1.9 Tables and Figures 
Table IX LOD scores for markers surrounding SOD1 on chromosome 21 
marker Mb θ = 0 
θ = 
0.01 
θ = 
0.05 
θ = 0.1 θ = 0.2 θ = 0.3 θ = 0.4 
D21S272 24.3 -1.62 -0.30 0.30 0.49 0.54 0.44 0.25 
D21S213 30.1 2.03 2.00 1.87 1.70 1.31 0.86 0.4 
D21S1270 30.6 1.40 1.38 1.28 1.15 0.84 0.53 0.24 
D21S263 31.1 2.84 2.79 2.57 2.28 1.69 1.08 0.49 
D21S224 32.8 1.28 1.27 1.17 1.03 0.68 0.33 0.08 
D21S219 34.0 2.57 2.52 2.29 2.00 1.40 0.79 0.26 
D21S266 41.6 -3.54 -0.85 -0.22 -0.02 0.10 0.10 0.06 
LOD scores are calculated at various recombination distances (θ) from each marker.  
Marker locations are listed in megabase pair (Mb) positions on chromosome 21.  LOD 
scores from marker D21S266 are from the genome scan, the rest are from all genotyped 
individuals in the family. 
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Figure 8 Pedigree of the family with the haplotype on chromosome 21 
 
Family members with affected status are filled in and obligate carriers are marked with a 
dot.  The sex of individuals is masked and those in the bottom generation are omitted to 
maintain confidentiality.  A diagonal line indicates a deceased individual.  Genotypes in 
parentheses are inferred and those with a question mark were not typed.  The vertical black 
bar indicates the haplotype on chromosome 21 which segregates among affected 
individuals. 
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Figure 9 Novel pseudoexon in SOD1: agarose gel and schematic representation 
A) Sequence produce on an agarose gel indicating the wildtype and cryptic exon allele in 
the patient and only wildtype allele in the controls.  B) A schematic of SOD1 exons (thick 
boxes) and introns (lines) and the splicing which occurs normally in SOD1 and in this 
examined family.  Numbers refer to the size of each segment.  An asterix marks the spot 
where a stop codon is present.  The corresponding protein is listed to the right of the gene.  
The inserted pseudoexon sequence of the region between exon 4 and exon 5 is also 
displayed with exonic sequence in uppercase lettering and the c.358-304C>G variant, 
which is underlined 5 base pairs after exon 4b.  The predicted premature stop codon is in 
bold. 
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3.2 No effect on SOD1 splicing by TARDBP or FUS mutations 
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Department of Pathology and Cellular Biology, Montreal, Quebec, H3C 3J7, Canada. 
3Université de Montreal, Department of Medicine, Faculty of Medicine, Montreal, Quebec, 
H3C 3J7, Canada. 4Research Center, CHU Sainte-Justine, Montreal, Quebec, H3T 1C5, 
Canada. 
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3.2.1 Rationale 
Approximately 94% of human genes are alternatively spliced, and it is estimated 
that about 50% of disease-causing mutations affect splicing. 297-299 Like mentioned in the 
previous section, mutations in both cis-acting elements and trans-acting components can 
disrupt gene splicing or regulation of alternative splicing. Specifically, cis-acting elements 
are required for accurate pre-mRNA processing, while trans-acting components are 
essential for splicing regulation. Splicing mutations can directly cause disorders, or 
contribute to the phenotype by influencing disease susceptibility or modulating disease 
severity.286 
 
Recent reports in neurodegenerative disorders research underlined the contribution 
of RNA-binding protein in alternative splicing regulation and other RNA-processing 
events.286 Precisely, there are a few examples of mutations in genes essential for splicing, 
and this is the case for ALS. TDP-43 is a trans-acting splicing regulator and a member of 
the hnRNP family. The protein encoded by TARDBP has been involved in the mechanism 
of cystic fibrosis after the demonstration of its binding to a repetitive (UG)n element in 
intron 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which 
have been found to promote exon 9 skipping while decreasing the expression of the 
encoded protein.300 TDP-43 is also known to play a role in FTD and ALS, as it is 
abnormally included in ubiquitinated protein aggregates localized in the cytoplasm of 
neurons and glial cells.112, 301 Mutations in TARDBP as well as in FUS, another RNA-
binding protein with similar functions,237 have been reported in both ALS and FTD 
patients.6, 101-103, 302, 303 This suggests that splicing abnormalities and other RNA-processing 
events might explain neurodegeneration. 
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The RNA targets of TDP-43 and FUS still need to be identified, and we hypothesized that 
SOD1 was one of them. This hypothesis is tested in the work presented next. 
 
3.2.2 Contribution of authors 
Belzil : Study design, data generation and analysis, manuscript writing. 
Daoud: Manuscript revision. 
Dion & Rouleau : Experiment supervision, manuscript revision. 
 
3.2.3 Abstract 
There was no abstract included in the manuscript since it was published in a 
research letter format. 
 
3.2.4 Introduction 
Amyotrophic lateral sclerosis (ALS) is characterized by a neuronal loss in the motor 
cortex, brain stem and spinal cord, that progresses over a three to five year period. 
Approximately 90% of cases are considered to be sporadic (SALS), while the other 10% of 
cases are familial (FALS)304. Extensive research has been conducted on the SOD1 gene after 
mutations were identified more than seventeen years ago in 15-20% of FALS cases, as well as a 
small number of SALS cases in later reports304. In the last two years, mutations in TARDBP, 
which encodes TDP-43, and in FUS have been identified in both FALS and SALS cases6, 101, 
250. Both genes encode for RNA/DNA binding proteins, are mainly localized in the nucleus, and 
are implicated in the regulation of RNA processing305. Specifically, TDP-43 and FUS have 
  
 
101
been shown to be associated with other splicing factors and are believed to play a role in 
splicing regulation, as variation in their expression level influences the splicing of certain 
targets305. Interestingly, mutant TDP-43 proteins identified in ALS patients were recently 
reported to be more stable than wildtype TDP-43 and to display an enhanced interaction 
with FUS polypeptides306. Particularly, it was reported that the FUS protein interacts more 
predominantly with mutant TDP-43, which display an increased half-life by comparison to 
wild type TDP-43. The authors concluded on a note about the efforts needed to determine 
whether the increased association affects the RNA targets for TDP-43, FUS, or both306. 
Considering that abnormal RNA processing and splicing patterns are involved in 
neurodegenerative diseases304, and that variation in the RNA splicing of SOD1 can cause 
familial ALS by destabilizing the resulting protein304, our aim was to assess if TARDBP and/or 
FUS ALS predisposing mutations which are known to lead to the accumulation of TDP-43 or 
FUS aggregations in the cytoplasm, may lead to aberrant SOD1 RNA splicing events, and to 
determine if SOD1 could be an RNA target for TDP-43, FUS, or both. 
 
3.2.5 Methods 
We studied total RNA prepared from immortalized lymphoblastoid cells of one healthy 
control individual, as well as seven different TARDBP (p.D169G,p.G287S, p.G348C, p.R361S, 
p.Y374X, p.A382T, p.N390D) and four different FUS (p.P18S, p.G174del, c.1542-2A>C, 
p.R521H,) mutated individuals. Protocols were approved by the ethics committee and the 
institutional review board of the University of Montreal. All patients gave written informed 
consent after which patient information and blood were collected. mutated individuals The 
second set of primers amplified a product of 528 bp (c.398-462), starting at the beginning of 
exon 4 and ending at the end of the 3’UTR. 
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3.2.6 Results 
Agarose gel electrophoresis showed that only one product was amplified for each of the 
cDNA amplified (figure 10). In addition, no variation was found in the sequence traces of the 
SOD1 cDNA products.  
 
3.2.7 Comments 
We can thus conclude that TARDBP or FUS ALS-predisposing mutations do not affect 
the splicing of SOD1 and that, while it can’t be excluded that there may be a common ALS 
pathogenic pathway, it appears that mutant TARDBP and FUS do not act by affecting the 
splicing of the most frequently mutated gene, SOD1, in ALS. 
 
3.2.8 Acknowledgments 
We would like to thank the patients involved in this study. VVB, HD and GAR are 
supported by the Canadian Institutes of Health Research. Guy A. Rouleau had full access to 
all of the data in the study and takes responsibility for the integrity of the data and the 
accuracy of the data analysis. 
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3.2.9 Tables and Figures 
Figure 10 Agarose gel electrophoresis of SOD1 mRNA in TARDBP and FUS mutated 
samples 
 
 
The first amplified product of 423 bp for the control and the eleven TARDBP or FUS mutants is 
shown on top.  The second product of 528 bp is shown under the first product for the same 
samples. 
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Chapter 4 : Contribution of mutations in new candidate 
genes to ALS 
 
4.1 Analysis of OPTN as a causative gene for amyotrophic lateral sclerosis. Published in 
Neurobiology of Aging. March 2011;32(3):355. 
 
4.2 Genetic analysis of SIGMAR1 as a cause of familial ALS with dementia. Submitted to 
European Journal of Human Genetics, December 27, 2011. 
 
4.3 Analysis of the SORT1 gene in familial cases of amyotrophic lateral sclerosis. Accepted 
in Neurobiology of Aging, January 20, 2012. 
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lateral sclerosis 
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4.1.1 Rationale 
It is well known that inherited disease mutations are not always expressed in the 
same way in all individuals based on the principles of penetrance, expressivity and 
influence of modifier genes. Precisely, penetrance measures the fraction of a population 
who carry a disease-causing allele and develop the disease phenotype, while expressivity 
evaluates the extent to which a genotype shows its phenotypic expression. The action of 
gene modifiers, on the other hand, can be responsible for differences in penetrance and 
expressivity parameters.307 A good example is the divergence found in FALS pedigrees, 
where mutation carriers start to develop the disease at different ages, notice muscle 
weakness in different regions of their body, experience a different disease progression, and 
sometimes even develop another completely different neurodegenerative phenotype. 
 
During the last four years, we witnessed exciting advancements in the genetics of 
ALS as novel mutations in several new genes have been identified. While these findings 
have been replicated in different populations for some of the genes, the implication of other 
was controversial and further reports were needed. One example is a publication from a 
Japanese group in 2010, identifying OPTN mutations in ALS patients.121 Interestingly, the 
OPTN gene has been linked to two other phenotypes. However, contrary to the other ALS 
genes associated with various motor phenotypes, the three other conditions in which OPTN 
mutations were found are completely different from ALS. Specifically, OPTN mutations 
have been first involved in primary open-angle glaucoma (POAG) in 2002122 and then 
associated with Paget’s disease of bone (PDB) in 2010.308 Based on our scepticism towards 
the OPTN involvement in ALS, we decided to screen for possible mutations a sub-group of 
our FALS cohort. 
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4.1.2 Contribution of authors 
Belzil : Study design, data generation and analysis, manuscript writing. 
Daoud: Manuscript revision. 
Desjarlais: Clinical information organization, manuscript revision. 
Bouchard, Dupré & Camu: Clinical evaluation, sample collection, manuscript revision. 
Dion & Rouleau : Sample collection, experiment supervision, manuscript revision. 
 
4.1.3 Abstract 
Mutations in the OPTN gene are well known to be associated with the development 
of glaucoma.  Recently, unique variations in the same gene have been reported in familial 
and sporadic Japanese cases of amyotrophic lateral sclerosis. We set out to evaluate the 
frequency of OPTN mutations in a sample of our FALS and SALS cohorts. All coding 
exons of the OPTN gene were amplified and sequenced in 95 unrelated FALS and 95 SALS 
cases of European descent. Two variants were newly identified in two individual FALS 
cases. Unique variations in the OPTN gene are rare in FALS cases and were not identified 
in any SALS patients, all of European descent. 
 
4.1.4 Introduction 
Amyotrophic lateral sclerosis (ALS) is a severe progressive adult onset 
neurodegenerative disease characterized by the death of motor neuron located in the motor 
cortex, brain stem, and ventral horn of the spinal cord. Muscle weakness and spasticity 
usually progress over a 3 to 5 year period, typically resulting in death from respiratory 
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failure. Three genes are considered to be definitely implicated in a small proportion of 
classical ALS: SOD1, TARDBP, and FUS.309 However, overall, no genetic causative 
variations have been found for the majority of patients affected with ALS. On the other 
hand, mutations in the OPTN gene are known to predispose to glaucoma.122 Surprisingly, a 
recent study of Japanese ALS patients identified two different variations in the OPTN gene 
in two recessively inherited familial ALS (FALS) cases as well as in one sporadic ALS 
(SALS) patient.121 They also identified one mutation transmitted in an autosomal dominant 
way with incomplete penetrance in two individual FALS patients. In order to confirm those 
findings in our familial and sporadic ALS cohorts, we sequenced the entire open reading 
frame of the OPTN gene in 95 FALS and 95 SALS patients of European descent. 
 
4.1.5 Results and Discussion 
Three variants were found in the same three exons in which variants were 
previously identified in ALS cases. First, the p.K59N missense was identified in one FALS 
patient, but was also found in one control participant out of 190 controls tested. Second, a 
substitution from a guanine to an adenine was identified in the donor splice site located in 
intron 12 of one FALS case. The substitution was followed by the insertion of another 
adenine (c. 1242+1G>A_insA), which might cause a frameshift and the inclusion of 3 new 
amino acids before a stop codon is encountered (NIHX). The end product is predicted to be 
a truncated protein of 417 amino acids instead of the 577 amino acids protein found in the 
wildtype state. The substitution was not present in 190 matched controls. Third, previously 
unreported missense p.A481V variant was identified in one FALS patient, and was not 
found in 190 control participants.  
 
It is interesting to note that the OPTN variants identified in our study are only from 
dominant FALS, while those reported in the Japanese families were found both in dominant 
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and recessive families.  It is true that our FALS kindreds are primarily dominant, which 
might explain why no mutations were found in recessive FALS. However, no variants were 
found in the SALS cases, some of which may well represent recessive ALS cases. 
Considering that primary open angle glaucoma (POAG) is the most common type of 
glaucoma, that it is found in comorbidity with normal tension glaucoma (NTG) in 90% of 
the Japanese affected with POAG, that POAG with NTG is more frequent in Japanese than 
Caucasians,310 and that we identified two times less variations in our FALS Caucasian 
cohort (2%) than in the original Japanese FALS report (4.4%), one could speculate that the 
variations identified are actually associated with a genetic predisposition to glaucoma 
instead of being ALS causative. 
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4.1.6 Supplementary material 
Complete manuscript: long version submitted as supplementary material. 
 
Abstract 
Background:  Mutations in the OPTN gene are well known to be associated with the 
development of glaucoma.  Recently, unique variations in the same gene have been 
reported in familial and sporadic Japanese cases of amyotrophic lateral sclerosis, a severe 
degenerative disease affecting the neurons of the motor cortex, brain stem, and spinal cord. 
Therefore, we set out to evaluate the frequency of OPTN mutations in a sample of our 
FALS and SALS cohorts. Methods: All coding exons of the OPTN gene were amplified 
and sequenced in 95 unrelated FALS and 95 SALS cases of European descent. Results: 
One substitution followed by one base pair insertion which affect the donor splice site of 
intron 12, as well as one unreported missense in exon 14 were newly identified in two 
individual FALS cases. Conclusion: Unique variations in the OPTN gene are rare in FALS 
cases and were not identified in any SALS patients, all of European descent. 
 
Introduction 
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or 
maladie de Charcot, is a severe progressive adult onset neurodegenerative disease 
characterized by the death of motor neuron located in the motor cortex, brain stem, and 
ventral horn of the spinal cord. Muscle weakness and spasticity usually progress over a 3 to 
5 year period, typically resulting in death from respiratory failure. About one affected 
individual out of ten have a family history of the disease (FALS). Twelve loci and nine 
genes have been so far identified in FALS cases. Three of these genes are considered to be 
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definitely implicated in classical ALS: SOD1, TARDBP, and FUS. Since the identification 
of mutations in the SOD1 gene in 1993,60 the proportion of ALS patients with SOD1 
mutations have been evaluated in many different populations, with variations in the SOD1 
gene explaining about 1-3% of cases65. More recently, mutations in the TARDBP gene 
encoding the TDP-43 protein and in the FUS genes have been identified in ALS, together 
representing approximately 5-10% of FALS cases.309 Overall, no genetic causative 
variations have been found for the majority of patients affected with ALS.  
 
Mutations in the OPTN gene121 are known to predispose to glaucoma, usually in 
families with an autosomal dominant inheritance and an adult age of onset. Surprisingly, a 
recent study of Japanese ALS patients identified two different variations in the OPTN gene 
in two recessively inherited FALS cases as well as in one sporadic ALS (SALS) patient. 
They also identified one mutation transmitted in an autosomal dominant way with 
incomplete penetrance in two individual FALS patients. In order to confirm those findings 
in our familial and sporadic ALS cohorts, we sequenced the entire open reading frame in 
190 unrelated cases of ALS of European descent. One previously unreported missense 
variant in exon 14 and one novel substitution followed by an insertion located in the donor 
splice site of intron 12 were identified in two individual with FALS.  No mutations or 
splice site variations were identified in SALS. 
 
Materials and Methods 
Standard Protocol Approvals, Registrations, and Patient Consents 
Protocols were approved by the ethics committee on human experimentation of the 
Centre Hospitalier de l’Université de Montréal.  All patients gave written informed consent 
after which patient information and blood were collected.  
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Subjects 
All ALS patients participating in this study were recruited through clinics in France 
and Canada and independently ascertained by trained neurologists. DNA was extracted 
from peripheral blood using standard protocols. A total of 95 unrelated FALS and 95 SALS 
cases, all of European descent, were screened for the 13 coding exons of the OPTN gene. 
The three exons of the gene in which we identified variations were the same in which 
variants were previously identified in Japanese ALS patients;121 we therefore sequenced 
exons 5, 12, and 14 in 190 controls of the same ethnic origin. 
 
Gene Screening.  
Using 13 sets of primers, the open reading frame of the OPTN gene was amplified 
in each sample.  The PCR product contained a minimum of 50 bp from each of the flanking 
introns. Primers were designed using the ExonPrimer software from the UCSC human 
genome browser website (http://genome.ucsc.edu/cgi-bin/hgGateway). Amplification was 
conducted by polymerase chain reactions (PCRs) using the AmpliTaq Gold DNA 
Polymerase (Applied Biosystems, Foster City, California, USA) as per manufacturer’s 
instructions. PCR products were amplified with the same procedure of direct sequencing in 
patients and controls, and were sequenced at the Genome Quebec Innovation Center 
(Montréal, Québec, Canada) using a 3730XL DNA analyzer.  Mutation surveyor software 
(version 3.10) was used for mutation detection analyses (SoftGenetics, Pennsylvania, 
USA). 
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Bioinformatics prediction programs. 
Prediction scores of functional effects for non synonymous SNPs were obtained 
using Polyphen prediction247 and SIFT bioinformatics311 programs.  
 
Results 
The entire coding region of the OPTN gene was amplified and sequenced in 95 
FALS and 95 SALS patients.  Three variants were found in the same three exons in which 
variants were previously identified in ALS cases.  First, the p.K59N missense was 
identified in one FALS patient, but was also found in one control participant out of 190 
controls tested.  The amino acid change is predicted to be possibly damaging by the 
Polyphen prediction program, and the SIFT bioinformatics program concluded that the 
change does affect the protein function.  The control with the p.K59N variant was a female 
in her 80’s at the time of collection, without any motor disease symptoms. Second, a 
substitution from a guanine to an adenine was identified in the donor splice site located in 
intron 12 of one FALS case.  The substitution was followed by the insertion of another 
adenine (c. 1242+1G>A_insA), which might cause a frameshift and the inclusion of 3 new 
amino acids before a stop codon is encountered (NIHX).  The end product is predicted to be 
a truncated protein of 417 amino acids instead of the 577 amino acids protein found in the 
wildtype state. The substitution was not present in 190 matched controls. Unfortunately, we 
were unable to prove the frameshift at the RNA level, considering that immortalized 
lymphoblast cell lines were not available for the patient, and DNA from other family 
members was not obtainable. Third, previously unreported missense p.A481V variant was 
identified in one FALS patient, and was not found in 190 control participants. Polyphen 
prediction program concluded that the change is possibly damaging, and SIFT 
bioinformatics program predicted that the amino acid change do affect the protein function. 
All the variants identified are listed in supplementary material table X. 
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Discussion 
Three new OPTN variants were identified in three FALS cases, and nothing was 
found in the 95 SALS patients tested. The three exons of the gene where those three 
variants were identified were the same in which the first report identified variations. Two of 
the three variants, c.1242+1G>A_insA and p.A481V, were not found in 190 control 
participants. Since the p.K59N variant was identified in one control participant having no 
symptoms of motor neuron diseases, the change is believed to be benign. No clinical 
information regarding possible glaucoma was available for the patient or the control with 
the mutation, and the missense was not previously reported in any glaucoma patients. The 
donor site substitution in intron 12 followed by the adenine insertion was found in a family 
with autosomal dominant transmission. The subject’s mother, two aunts, as well as her two 
brothers were also affected. Unfortunately no DNA samples were available from these or 
any other family members. The two parents of the FALS sample with the p.A481V 
missense both developed ALS, so cases of conjugal ALS. Common environment exposure 
could be an alternative explanation for the ALS in this family, as no other family members 
of the same or previous generations were affected.  No information was available 
concerning the possibility of a consanguineous marriage.  
 
It is interesting to note that the OPTN variants identified in our study are only from 
dominant FALS, while those reported in the Japanese families were found both in dominant 
and recessive families.  It is true that our FALS kindreds are primarily dominant, which 
might explain why no mutations were found in recessive FALS.  However, no variants 
were found in the SALS cases, some of which may well represent recessive ALS cases. 
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Primary open angle glaucoma (POAG) is the most common type of glaucoma, and 
is found in comorbidity with normal tension glaucoma (NTG) in 90% of the Japanese 
affected with POAG.310 Considering that POAG with NTG is more frequent in Japanese 
than Caucasians, and that we identified two times less variations in our FALS Caucasian 
cohort (2%) than in the original Japanese FALS report (4.4%), one could speculate that the 
variations identified are actually associated with a genetic predisposition to glaucoma 
instead of being ALS causative.   
 
Overall, our data suggest that OPTN mutations are at most a rare cause of FALS in 
subjects of European descent. Additional work is needed to clearly define the role of OPTN 
gene mutations in the ALS pathogenesis. 
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Table X Description of genetic variations in OPTN found in FALS/SALS patients and 
control participants 
# Location 
 
Coding DNA 
variant 
Non-
synonymous 
Variant 
 
FALS 
(n=95) 
SALS 
(n=95) 
Controls 
(n=190) 
Status 
 
1 
2 
3 
x4 
x4 
x5 
102G>A 
123 G>A 
177G>C 
T34T 
L41L 
K59N 
32 
0 
1 
31 
2 
0 
n/a 
n/a 
1 
Reported312, 313 
rs11591687 
new 
4 
5 
6 
7 
x5 
x12 
x13 
x14 
293T>A 
1242+1G>A_insA 
1328delA 
1442C>T 
M98K 
n/a 
Q443fs 
A481V 
6 
1 
0 
1 
3 
0 
1 
0 
23 
0 
n/a 
0 
Reported122, 313 
new 
rs67884543 
new 
When numbering the mRNA, +1 represents the A of the ATG. The start methionine is amino 
acid number 1. 
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4.2 Genetic analysis of SIGMAR1 as a cause of familial ALS with 
dementia 
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4.2.1 Rationale 
ALS and FTD are two phenotypes clearly linked based on the fact that a few 
families have been identified with members affected with either one or both disorders20, 21, 
146-148 and that TARDBP, FUS, VCP, CHMP2B and UBQLN2 mutations have been 
identified in both ALS and FTD patients.6, 20, 101-103, 132, 133, 141, 145, 302, 314 While the GRN 
gene is not typically involved in ALS, mutations in this gene have been reported in FTD 
patients showing some motor neuron deficits.315, 316 In addition, about 5% of patients with 
ALS develop FTD, and up to 50% of ALS cases do experience some cognitive 
impairment.19 However, the exact frequency of FTD or cognitive impairment in ALS 
patients still needs to be clarified.  
 
In 2006 and 2007, linkage to chromosome 9p has been established using large 
families from the UK, US, France and Canada, this way identifying the 9p13.3–21.3 ALS-
FTD locus. 21, 147, 148 There was an overlap of 9 cM (8.8 Mb) between the three reported 
regions, precisely encompassing 36 genes. Concerted efforts to identify the causative gene 
in the region have been made considering the possibility of a major locus on this 
chromosome, but no mutations were identified after screening the entire region. In 2010, 
two groups conducted a genome-wide association study using samples from the UK and 
Finland and found a significant association to chromosome 9p21.154, 155 This finding further 
emphasized the importance of the 9p13.3–21.3 locus. Also importantly, the ubiquitin/TDP-
43 pathology has been observed and confirmed in some ALS/FTD families linked to the 
same locus.150 Later in the same year, a variant in the 3’-untranslated region (UTR) of the 
SIGMAR1 gene was reported in affected members of a large FTLD-MND pedigree.317 Two 
additional 3’UTR variants were also identified in two other but independent FTLD 
families. While the gene is also located on the chromosome 9p, the UTR variants were 
mostly present in individuals affected with FTD, and its implication in the ALS phenotype 
was questionable. 
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Very recently, two groups identified C9ORF72 expansions as responsible for the 
ALS-FTD phenotype linked to this chromosome 9p locus. 158, 159 More importantly, this 
variant was believed to explain 3% of sporadic FTD, 11.7% of familial FTD, 4.1% of 
sporadic ALS, and 23.5% of familial ALS.158 The noncoding hexanucleotide repeat 
expansions located in intron 1 of the C9ORF72 gene are the most common cause of 
familial ALS and familial FTD identified to date. This expanded region is now considered 
to be a major cause of ALS and FTD, and reinforce the previously discussed idea that cis-
acting elements are essential for accurate pre-mRNA processing. Recently, a 
consanguineous family with members affected with JALS was reported to carry a 
SIGMAR1 coding variant.318 We present here the screening of the SIGMAR1 gene that was 
conducted before the finding of the C9ORF72 repeat expansions and before the report of 
the homozygous SIGMAR1 variant in JALS, when we wanted to validate the SIGMAR1 
implication in the disease. 
 
4.2.2 Contribution of authors 
Belzil : Study design, data generation and analysis, manuscript writing. 
Daoud: Manuscript revision. 
Camu: Clinical evaluation, sample collection, manuscript revision. 
Strong: Clinical evaluation, sample collection, manuscript revision. 
Dion & Rouleau : Sample collection, experiment supervision, manuscript revision. 
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4.2.3 Abstract 
Amyotrophic lateral sclerosis (ALS) is the most common of the motor neuron 
diseases (MND), while frontotemporal lobar degeneration (FTLD) is the second most 
common cause of early-onset dementia. Many ALS families also segregating FTLD have 
been reported, particularly over the last decade. Recently, mutations in TARDBP, FUS/TLS 
and C9ORF72 have been identified in both ALS and FTLD patients, while mutations in 
VCP, a FTLD associated gene, have been found in ALS families. Distinct variants located 
in the 3’-untranslated region (UTR) of the SIGMAR1 gene were previously reported in 
three unrelated FTLD or FTLD-MND families. We directly sequenced the coding and UTR 
regions of the SIGMAR1 gene in a targeted cohort of 25 individual familial ALS cases of 
Caucasian origin with a history of cognitive impairments. This screening identified one 
variant in the 3’-UTR of the SIGMAR1 gene in one ALS patient, but the same variant was 
also observed in one out of 380 control chromosomes. Subsequently, we screened the same 
samples for a C9ORF72 repeat expansion: 52% of this cohort was found expanded, 
including the sample with the SIGMAR1 3’UTR variant. Consequently, coding and non-
coding variants located in the 3’-UTR region of the SIGMAR1 gene are not the cause of 
FTLD-MND in our cohort, and more than half of this targeted cohort is genetically 
explained by C9ORF72 repeat expansions. 
 
4.2.4 Introduction 
Amyotrophic lateral sclerosis (ALS) is the most common of the motor neuron 
diseases (MND), with an incidence of 1.2/100,000 person-years,319 while frontotemporal 
lobar degeneration (FTLD) is the second most common cause of early-onset dementia with 
an incidence of 3.5/100,000 person-years.320 Interestingly, up to 50% of ALS patients are 
deemed likely to develop some cognitive impairments.19 In 2006 the TDP-43 protein was 
found to be an important constituent of aggregates in neurons of MND-FTLD patients,112 
  
 
121
which suggested a common pathological pathway for the two conditions. Mutations in the 
TARDBP gene encoding the TDP-43 protein,101, 302 and in the FUS/TLS gene encoding the 
FUS protein6, 303 have been identified in both ALS and FTLD patients, while mutations in 
ALS cases have recently been reported in VCP,133 in which mutations have been previously 
associated with FTLD,132 Furthermore, neurons of ALS and FTLD patients both display a 
nuclear clearing and cytoplasmic sequestration of normal cellular TDP-43 or FUS 
proteins,237 which are encoded by genes that, when mutated, are estimated to account for up 
to 5-10% of all ALS cases.6, 101 Twelve families linked to a locus on chromosome 9p have 
been reported to have members with either MND or FTLD, while a few members display 
both phenotypes.21, 147-150, 153 The causative pathogenic hexanucleotide repeat in the gene 
C9ORF72 was recently identified by two different groups.158, 159 One of these reports found 
that this repeat expansion explains approximately 3% of sporadic FTD, 11.7% of familial 
FTD, 4.1% of sporadic ALS, and 23.5% of familial ALS cases.158 The second report shows 
that the repeat expansion is detectable in about 50% of familial and 20% of sporadic 
Finnish cases, in more than one third of familial cases of wider European ancestry, and in 
more than 29% of the Finnish FTD population among which 36% have a family history.159 
In addition, recently, a variant in the 3’-untranslated region (UTR) of the SIGMAR1 gene, 
encoding a receptor protein playing an important role in various cellular functions, was 
reported to segregate in a FTLD-MND pedigree.317 Two additional 3’-UTR variants were 
identified by the same group in two unrelated FTLD families thought to be linked to the 
chromosome 9p locus, but no segregation could be observed in these. Another group 
recently conducted homozygosity mapping in a large consanguineous family with six 
members affected with juvenile ALS. They identified a SIGMAR1 missense mutation in all 
affected individuals.321 Considering the finding of variants in the SIGMAR1 gene and the 
recent publication of hexanucleotide repeat expansions in C9ORF72 located in the same 
chromosomal region, we wanted to evaluate the potential contribution of SIGMAR1 
variants in ALS patients of European descents. We selected 25 individual familial ALS 
cases with a family history of cognitive impairments, and directly sequenced the entire 
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coding and UTR regions of the SIGMAR1 gene. We also evaluated this specific targeted 
cohort for C9ORF72 repeat expansions. 
 
4.2.5 Materials and Methods 
4.2.5.1 Standard Protocol Approvals, Registrations, and Patient Consents. 
Protocols were approved by the ethics committee on human experimentation of the 
Centre Hospitalier de l’Université de Montréal. All patients gave written informed consent 
after which patient information and blood were collected.  
 
4.2.5.2 Subjects 
Clinical information from 260 familial ALS cases of Caucasian origin not mutated 
in SOD1, TARDBP or FUS was analyzed; 25 families were found to have a history of 
cognitive impairments. One affected member from each family was selected for sequencing 
the entire coding and UTR regions of the SIGMAR1 gene (NM_005866.2 ). In addition, 190 
control participants were sequenced for one fragment encompassing the first 396 bp of the 
3’-UTR, in which one novel substitution was identified in one familial ALS patient. 
Moreover, the same patients were assessed for the presence of expanded hexanucleotide 
repeat in C9ORF72 (NM_001256054.1). 
 
4.2.5.3 Gene Screening.  
Six sets of primers were used for each sample to amplify the open reading frame of 
the SIGMAR1 gene (Table 1). The PCR products containing the exons included a minimum 
of 50 bp from each of the flanking introns. Primers were designed using the ExonPrimer 
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software from the UCSC human genome browser website (http://genome.ucsc.edu/cgi-
bin/hgGateway). Amplification was conducted by polymerase chain reactions (PCRs) using 
the AmpliTaq Gold DNA Polymerase (Applied Biosystems, Foster City, California, USA) 
as per manufacturer’s instructions. PCR products were amplified with the same procedure 
of direct sequencing in patients and controls, and were sequenced at the Genome Quebec 
Innovation Center (Montréal, Québec, Canada) using a 3730XL DNA analyzer. Mutation 
surveyor software (version 3.10) was used for mutation detection analyses (SoftGenetics, 
Pennsylvania, USA). 
 
4.2.5.4 Hexanucleotide repeat analysis 
We performed a repeat-primed PCR assay using the FastStart PCR Master Mix 
(Roche, Indianapolis, Indiana, USA) using the reported optimized conditions.158, 159 PCR 
products were analyzed on an ABI 3730 sequencer with GeneMapper software version 4.0 
(Applied Biosystem, Foster City, California, USA). 
 
4.2.6 Results and Discussion 
Only one variant (c.672*+43G>T) located in the 3’UTR of the SIGMAR1 gene was 
identified in one patient. The substituted guanine is well conserved through different 
species. Other affected family members were not available for testing, but the variant was 
not present in six other unaffected family members. However, after testing 190 matched 
controls, the variant was identified in one control, suggesting that the substitution is not 
causative of ALS in the family. No other unknown variants were identified in the 25 
patients tested. Interestingly, after performing the repeat-primed method, we found that 13 
patients actually carried a hexanucleotide repeat expansion in C9ORF72. This represents 
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52% of the total tested. The cause of the disease for the remaining 12 patients is still 
unexplained genetically. 
 
The SIGMAR1 gene was a positional candidate based on linkage in an Australian 
MND-FTLD family.149 The c.672*51G>T 3’UTR substitution in the SIGMAR1 gene was 
identified in the linked family after the sequencing of about 200 candidate genes in the 
chromosome 9p candidate region. The nonpolymorphic nucleotide change segregated with 
the disease haplotype of this Australian pedigree. The variant was not identified in 1,269 
controls. In addition, c.672*26C>T and c.672*47G>A substitutions also located in the 3’-
UTR of SIGMAR1 were identified in different FTLD pedigrees of Australian and Polish 
origins respectively. These variants were also absent in matched controls. A modification in 
SIGMAR1 gene expression was found in the Australian, while a small expression difference 
was observed for the other two families, each with only one patient actually carrying the 
variant. It was also shown that modulating the expression of SIGMAR1 influences the 
cellular localization of TDP-43 and FUS, and it was suggested that the 3’UTR of SIGMAR1 
variant causes a pathogenic alteration of TARDBP and FUS expression levels.317 
Considering that the C9ORF72 hexanucleotide repeat expansion was not reported when the 
SIGMAR1 mutations were identified and that the genes are close to each other on 
chromosome 9p, it is possible that the SIGMAR1 variants identified in the first report 
actually segregated with C9ORF72 expansions. The finding of a 3’UTR variant in our 
specifically targeted cohort permitted to test and confirm this hypothesis.  
 
Further studies in different populations will help to evaluate the contribution of the 
sigma nonopioid intracellular receptor 1 protein in MND and/or FTLD, and future studies 
need to address the reported effects on expression levels of the different proteins involved. 
However, based on our study, it can be concluded that coding mutations or UTR variants in 
SIGMAR1 are not a cause of ALS in our cohort of Caucasian ALS families with a history of 
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cognitive impairments, but that repeat expansions in C9ORF72 genetically explain a 
significant proportion of the same cohort. 
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4.3 Analysis of the SORT1 gene in familial amyotrophic lateral 
sclerosis 
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4.3.1 Rationale 
It is becoming more and more apparent that defective RNA metabolism contributes 
to the pathogenesis of several neurodegenerative diseases, including ALS.106, 322, 323 Indeed, 
TDP-43, mutated in about 5% of familial ALS, regulates various aspects of RNA 
metabolism such as transcriptional repression, exon skipping and RNA splicing.324 Also, it 
was demonstrated that the cytoplasmic redistribution of TDP-43, primarily a nuclear 
protein, seems to appear early in ALS.325 Thus, the mislocalization of TDP-43 to the 
cytoplasm, its abnormal post-translational modifications and its aggregation are believed to 
adversely affect TDP-43 function and the regulation of its RNA targets. Since TDP-43 
RNA targets are likely altered in FTD and ALS, an important aim in the field today is to 
identify those targets and determine whether these are altered in ALS and FTD. This could 
provide valuable insight into the mechanisms of TDP-43 toxicity and eventually help 
develop therapeutics for the two disorders. 
 
On the other hand, mutations in GRN, the gene encoding progranulin (PGRN), are 
the second most common cause of inherited FTD after C9ORF72 expansions.326 GRN 
mutations lead to the degradation of mutant RNA and cause PGRN happloinsufficiency.327 
The neuropathological hallmarks in common between ALS and FTD suggest that TDP-43 
and PGRN are mechanistically linked in the disease pathogenesis. However, the normal 
functions of TDP-43 and PGRN and how they contribute to neurodegeneration remain 
unclear. Nonetheless, it was recently discovered that depletion of TDP-43 in the mouse 
adult brain using antisense oligonucleotides modifies the expression levels of FUS and 
GRN, while altering the splicing of SORT1.328 Precisely, it has been shown that the 
presence of TDP-43 is associated with the exclusion of exon 18 in SORT1.328 Also, it was 
demonstrated that sortilin (SORT1) is a neuronal PGRN receptor that mediates PGRN 
uptake,329 where sortilin is the principal neuronal binding site for PGRN.329 Binding occurs 
via the c-terminus of PGRN, and this results in a rapid endocytosis of PGRN by sortilin. In 
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vivo, the absence of sortilin raises PGRN levels by 2.5- to 5-fold. Given that FTLD is 
caused by a 50% reduction of PGRN levels,330 this change has clear pathophysiological 
consequences. All of these make SORT1 an excellent candidate gene for ALS and a 
possible RNA target for TDP-43. 
 
We attempted to demonstrate in the next study that SORT1 splicing could be 
modified by mutated TARDBP. We also screened the SORT1 gene for possible mutations in 
FALS cases. While our results are negative, they explored a critical hypothesis and helped 
further refine our understanding of the pathogenesis of ALS and FTD. 
 
4.3.2 Contribution of authors 
Belzil : Study design, data generation and analysis, manuscript writing. 
André-Guimont: Technical support, data generation and analysis. 
Atallah: Technical support 
Daoud: Manuscript revision. 
Dupré, Bouchard, Camu: Clinical evaluation, sample collection, manuscript revision. 
Dion & Rouleau : Sample collection, experiment supervision, manuscript revision. 
 
4.3.3 Abstract 
Background: Substantial efforts have been deployed in the last decade to identify the 
genetic causes of amyotrophic lateral sclerosis (ALS), and we hypothesized here that 
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mutations in SORT1 or aberrant SORT1 splicing reduce progranulin level and promotes 
neurodegeneration. Methods: We sequenced the coding exons of SORT1 in a cohort of 112 
unrelated individuals with familial ALS. We also tested for aberrant SORT1 splicing by 
RT-PCR using RNA samples from cell lines expressing six different ALS-associated 
TARDBP mutations. Results: We identified one unique missense and two unique silent 
mutations in our cohort. None are predicted to have functional effects. No aberrant SORT1 
splicing event was observed. Conclusions: SORT1 mutations are not a common cause of 
familial ALS and the influence of TARDBP mutations on SORT1 splicing still needs to be 
clarified. 
 
4.3.4 Introduction 
Recently, causative mutations were reported in TARDBP, 101, 102 encoding TDP-43, 
and FUS 6, 103 in both amyotrophic lateral sclerosis (ALS) and frontotemporal lobar 
degeneration (FTLD) cases; 303, 331 the latter is a condition commonly seen in comorbidity 
with ALS. Mutations in GRN, which encodes progranulin, lead to FTLD with TDP-43 
inclusions (FTLD-TDP) as a result of progranulin haploinsufficiency. 332 It has also been 
recently found that depletion of TDP-43 in the mouse adult brain modifies the expression 
levels of FUS and GRN, and alters the splicing of SORT1, which encodes sortilin. 328 
Specifically, it has been shown that the expression of TDP-43 leads to altered splicing of 
SORT1 with exclusion of exon 18. 328 Sortilin has also recently been identified as a receptor 
that mediates progranulin uptake. 329 Thus, one can speculate that TARDBP, GRN and 
SORT1 act in a common pathological pathway. To test this notion, we screened the SORT1 
coding sequence for mutations and assessed if TARDBP ALS predisposing mutations led to 
aberrant SORT1 RNA splicing, which would confirm that SORT1 pre-mRNA is a target of 
TDP-43. 
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4.3.5 Methods 
A total of 112 unrelated FALS cases, all of European descent and negative for 
mutations in SOD1, TARDBP or FUS and without a C9ORF72 repeat expansion, were 
screened for the 20 coding exons of the SORT1 gene and its alternative exon 1. We also 
studied total RNA prepared from immortalized lymphoblastoid cells of six different 
TARDBP mutated samples (p.D169G, p.G287S, p.G348C, p.Y374X, p.A382T, p.N390D) 
as well as two healthy control individuals. The amplifications were performed using one set 
of primer pairs that covered exons 17, 18 and 19 of SORT1 mRNA, encompassing the 
splice region reported to be altered after TDP-43 depletion.  
 
4.3.6 Results 
Sequence analysis identified six novel variants in six unrelated FALS cases. One 
p.A773T (c.2317G>A) missense mutation was found in one patient, but no additional 
family members were available for testing to confirm segregation. The variant was also 
predicted to be benign or tolerated by Polyphen and SIFT bioinformatics programs. 247, 248 
A p.V104V silent mutation was found in one patient but no other familial DNA was 
available for testing. An intronic substitution of an adenine to a guanine was identified at 
position c.832+46, possibly creating a new donor splice site. However, no alternative 
isoform or aberrant splice site event were predicted by the Alternative Splice Site Predictor 
(ASSP) or Berkeley Drosophila Genome Project softwares. 333, 334 These three variants were 
nevertheless absent from 380 control chromosomes. Also, a p.K302E missense mutation 
was identified in one patient, but was also found in five control participants. Two additional 
variants were identified in two individual FALS cases, a p.I544V missense mutation and a 
p.Y600Y silent mutation, but both were not cosegregating with the disease. We then 
amplified the cDNA of six different TARDBP mutated samples and two controls to test for 
inclusion or exclusion of exon 18 in the SORT1 RNA sequence. We were expecting to 
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amplify two products: one of 181 bp for control cDNA (excluding exon 18) and one of 287 
bp for TARDBP mutated samples (including exon 18). Only one product of 287 bp was 
amplified in all samples, and exon 18 was confirmed to be included in all products by 
sequencing cDNAs of patients and controls. 
 
4.3.7 Discussion 
While the role of SORT1 in the TDP-43 pathogenic pathway has been proposed, 328 
our findings suggest that mutations in the gene do not directly predispose to ALS. One 
limitation of our study was that it was restricted to the screening of FALS samples and that 
only a few of these had a positive family history of dementia. Other mutation screens will 
be necessary to further evaluate the possible contribution of SORT1 mutations to ALS and 
FTLD. A single SORT1 isoform was amplified from cells bearing ALS-predisposing 
TARDBP mutations and from control cells. Interestingly, in all cases, the SORT1 mRNA 
contained exon 18, despite the fact that these cells are known to express TDP-43.101 
Therefore, we were unable to confirm that SORT1 is a pre-RNA target of TDP-43, both in 
normal cells and in cells from patients with ALS predisposing TARDBP mutations. Nor did 
we find any effects of mutant TDP-43 on exon 18 splicing in SORT1. However, because we 
extracted cDNA from lymphoblastoid cells, it is possible that there are cell specific 
differences in SORT1 splicing.  Possibly TDP-43 expression is necessary for the exclusion 
of SORT1 exon 18 only in neuronal cells; brain tissues were unfortunately unavailable from 
TARDBP mutated samples. Other methods will need to be used to confirm if SORT1 is an 
RNA target of TDP-43. 
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4.3.8 Supplementary Material 
Complete manuscript: long version submitted as supplementary material. 
 
Abstract 
Background: Amyotrophic lateral sclerosis (ALS) is an adult onset neurodegenerative 
disease, which affects upper and lower motor neurons. Substantial efforts have been 
deployed in the last decade to identify the genetic causes of ALS, and significant progress 
has been made, such as the identification of mutations in the TARDBP gene. Interestingly, 
depletion of TDP-43, the protein encoded by TARDBP, in mouse adult brain modifies the 
expression of FUS and GRN which encodes progranulin, and alters the splicing of SORT1, 
which encodes sortilin, a progranulin receptor. Specifically, the presence of TDP-43 is 
associated with the exclusion of exon 18 in SORT1. We hypothesized that mutations in 
SORT1 or aberrant SORT1 splicing reduces progranulin level and promotes 
neurodegeneration. In addition, we assessed if TARDBP ALS predisposing mutations lead 
to aberrant SORT1 RNA splicing, which might provide insights into disease pathogenesis. 
Methods: We sequenced the coding exons of SORT1 in a cohort of 112 unrelated 
individuals with familial ALS; among these, 23 had a positive family history of dementia. 
We also tested for aberrant SORT1 splicing by RT-PCR using RNA samples from cell lines 
expressing six different ALS-associated TARDBP mutations. Results: We identified one 
unique missense and two unique silent mutations in our cohort. None are predicted to have 
functional effects. No aberrant SORT1 splicing event was observed and exon 18 was 
retained despite the presence of TDP-43. Conclusions: SORT1 mutations are not a 
common cause of familial ALS and the influence of TARDBP mutations on SORT1 splicing 
still needs to be clarified. 
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Introduction 
Amyotrophic lateral sclerosis (ALS) is a disease that affects approximately two new 
individuals per 100,000 each year.257 Because motor neurons located in their cortex, brain 
stem and spinal cord degenerate, ALS patients generally experience progressive muscle 
weakness and spasticity of upper and lower limbs, as well as in the bulbar region. This 
progressive degeneration typically evolves over a three to five year period resulting in 
death from respiratory failure. The first symptoms are generally reported in the mid 50’s 
and 90% of cases do not have a prior family history of motor neuron diseases.309 The 
identification of ALS causative genes began with the identification of SOD1 mutations in 
~15-20% of familial ALS (FALS) and ~2% of all cases. More recently, causative mutations 
were reported in TARDBP, 101, 102 encoding TDP-43, and FUS; 6, 103 these genes together 
explain ~5% of all cases. The role of the proteins encoded by those three genes is only 
partially understood and their pathological pathways are the subject of much research. 
Interestingly mutations were identified in TARDBP and FUS both in ALS and 
frontotemporal lobar degeneration (FTLD) cases; 303, 331 the latter is a condition commonly 
seen in comorbidity with ALS. In fact, it is estimated that up to 50% of ALS patients may 
develop some sort of cognitive impairments, 19 reinforcing the belief that a common 
pathological pathway is involved in the development of the two phenotypes. Furthermore, 
two groups recently reported hexanucleotide repeat expansions in the C9ORF72 gene 158, 159 
in chromosome 9p association in ALS-FTLD families. This repeat explained ~11% of 
familial FTLD, ~24% of familial ALS, and 1/3 of European descents familial ALS cases.  
 
Mutations in GRN are a major cause of FTLD, explaining the disease in 10% of the 
overall FTLD population and more than 20% of patients with a family history of 
dementia.326 Mutations in GRN, which encodes progranulin, lead to FTLD with TDP-43 
inclusions (FTLD-TDP) as a result of progranulin haploinsufficiency. 332 It has also been 
recently found that depletion of TDP-43 in the mouse adult brain using antisense 
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oligonucleotides modifies the expression levels of FUS and GRN, and alters the splicing of 
SORT1, which encodes sortilin. 328 Specifically, it has been shown that the expression of 
TDP-43 leads to altered splicing of SORT1 with exclusion of exon 18. 328 Sortilin has also 
recently been identified as a receptor that mediates progranulin uptake. 329 Thus, one can 
speculate that TARDBP, GRN and SORT1 act in a common pathological pathway. To test 
this notion we screened the SORT1 coding sequence for mutations. We also assessed if 
TARDBP ALS predisposing mutations led to aberrant SORT1 RNA splicing, which would 
confirm that SORT1 pre-mRNA is a target of TDP-43. 
 
Methods 
Standard Protocol Approvals, Registrations, and Patient Consents 
Protocols were approved by the ethics committee on human experimentation of the 
Centre Hospitalier de l’Université de Montréal. All patients gave written informed consent 
after which patient information and blood were collected.  
 
Subjects 
All ALS patients participating in this study were recruited through clinics in France 
and Canada and independently ascertained by trained neurologists. DNA was extracted 
from peripheral blood using standard protocols. A total of 112 unrelated FALS cases, all of 
European descent and negative for mutations in SOD1, TARDBP or FUS and without a 
C9ORF72 repeat expansion, were screened for the 20 coding exons of the SORT1 gene. In 
addition, the alternative exon 1 included in alternative isoforms was screened. 
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Gene Screening 
Using 19 sets of primers, the open reading frame of the SORT1 gene was amplified 
in each sample. The PCR products contained a minimum of 50 bp from each of the flanking 
introns. Primers were designed using the ExonPrimer software from the UCSC human 
genome browser website (http://genome.ucsc.edu/cgi-bin/hgGateway). Primer sequence 
and amplification conditions are available upon request. Amplification was conducted by 
polymerase chain reactions (PCRs) using the AmpliTaq Gold DNA Polymerase (Applied 
Biosystems, Foster City, California, USA) as per manufacturer’s instructions. PCR 
products were amplified with a procedure of direct sequencing in patients, and were 
sequenced at the Genome Quebec Innovation Center (Montréal, Québec, Canada) using a 
3730XL DNA analyzer. Mutation surveyor software (version 3.10) was used for mutation 
detection analyses (SoftGenetics, Pennsylvania, USA). 
 
Bioinformatics prediction programs 
Scores predicting the functional effects for nonsynonymous SNPs were obtained 
using Polyphen prediction335 and SIFT248 bioinformatics programs. Splice site score 
predictions were obtained using the Alternative Splice Site Predictor (ASSP)334 and 
Berkeley Drosophila Genome Project bioinformatics programs.333 
 
Splicing study 
We studied total RNA prepared from immortalized lymphoblastoid cells of six 
different TARDBP mutated samples (p.D169G, p.G287S, p.G348C, p.Y374X, p.A382T, 
p.N390D) as well as two healthy control individuals. RNA was extracted using standard 
conditions. Reverse transcription polymerase chain reactions (RT-PCRs) were conducted to 
prepared cDNA using the M-MLV RT enzyme (Invitrogen, Carlsbad, California, USA) as 
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per manufacturer’s instructions. The amplifications were performed using one set of primer 
pairs that covered exons 17, 18 and 19 of SORT1 mRNA, encompassing the splice region 
reported to be altered after TDP-43 depletion. The primers were predicted to amplify a 
region of 287 bp if exon 18 is included or a product of 179 bp if the same exon is excluded.  
 
Results 
Sequence analysis identified six novel variants in six unrelated FALS cases. One 
p.A773T (c.2317G>A) missense mutation was found in one patient, but no additional 
family members were available for testing to confirm segregation. The variant was also 
predicted to be benign or tolerated by Polyphen and SIFT bioinformatics programs. 247, 248 
A p.V104V silent mutation was found in one patient but no other familial DNA was 
available for testing. An intronic substitution of an adenine to a guanine was identified at 
position c.832+46, possibly creating a new donor splice site. However, no alternative 
isoform or aberrant splice site event were predicted by the Alternative Splice Site Predictor 
(ASSP) or Berkeley Drosophila Genome Project softwares. 333, 334 These three variants were 
nevertheless absent from 380 control chromosomes. Also, a p.K302E missense mutation 
was identified in one patient, but was also found in five control participants. Two additional 
variants were identified in two individual FALS cases, a p.I544V missense mutation and a 
p.Y600Y silent mutation, but both were not cosegregating with the disease. All the variants 
identified are listed in table 1. 
 
We then amplified the cDNA of six different TARDBP mutated samples and two 
controls to test for inclusion or exclusion of exon 18 in the SORT1 RNA sequence. We 
were expecting to amplify two products: one of 181 bp for control cDNA (excluding exon 
18) and one of 287 bp for TARDBP mutated samples (including exon 18). Only one product 
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of 287 bp was amplified in all samples (figure 1A), and exon 18 was confirmed to be 
included in all products by sequencing cDNAs of patients and controls (figure 1B). 
 
Discussion 
Three unique SORT1 variants were identified in three of 112 individual with FALS. 
However, these variants are unlikely to be causative of ALS or ALS with dementia as they 
are predicted to have only a minor or no effect on the protein. While the role of SORT1 in 
the TDP-43 pathogenic pathway has been proposed, 328 our findings suggest that mutations 
in the gene do not directly predispose to ALS. One limitation of our study was that it was 
restricted to the screening of FALS samples and that only a few of these had a positive 
family history of dementia. Other mutation screens will be necessary to further evaluate the 
possible contribution of SORT1 mutations to ALS and FTLD. 
 
A single SORT1 isoform was amplified from cells bearing ALS-predisposing 
TARDBP mutations and from control cells. Interestingly, in all cases, the SORT1 mRNA 
contained exon 18, despite the fact that these cells are known to express TDP-43.101 
Therefore, we were unable to confirm that SORT1 is a pre-RNA target of TDP-43, both in 
normal cells and in cells from patients with ALS predisposing TARDBP mutations. Nor did 
we find any effects of mutant TDP-43 on exon 18 splicing in SORT1. However, because we 
extracted cDNA from lymphoblastoid cells, it is possible that there are cell specific 
differences in SORT1 splicing.  Possibly TDP-43 expression is necessary for the exclusion 
of SORT1 exon 18 only in neuronal cells; brain tissues were unfortunately unavailable from 
TARDBP mutated samples. Other methods will need to be used to confirm if SORT1 is an 
RNA target of TDP-43. 
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4.3.9 Tables and Figures 
Table XI Variants identified in the SORT1gene for FALS samples 
Variant 
SORT1 
Localization Coding DNA 
Variant 
(nucleotide) 
Coding 
DNA 
Variant 
(protein) 
FALS 
(n=112)
Controls     
(n=190) 
dbSNP 
1 x1 c.12 C>G p.P4P 62 n/a 
rs726465
53 
2 
5'UTR & x1 
alt n/a n/a 147 n/a 
rs214092
4 
3 
5'UTR & x1 
alt n/a n/a 2 n/a 
rs116767
369 
4 x2 c.312 G>A p.V104V 1 0 n/a 
5 x5 c.594 T>C p.F198F 163 n/a rs11142 
6 x5 c.597 A>G p.R199R 13 n/a 
rs726465
60 
7 x7 c.832+46A>G n/a 1 0 n/a 
8 x8 c.904 A>G p.K302E 1 5 n/a 
9 x9  c.969 A>C p.T323T 75 n/a 
rs222860
4 
10 x11 c.1330 G>C p.E444Q  5 n/a 
rs726465
68 
11 x13 c.1630 A>G p.I544V 1 
in family 
controls n/a 
12 x14 c.1800C>T p.Y600Y 1 
in family 
controls n/a 
13 x18 c.2317G>A p.A773T 1 0 n/a 
14 3'UTR n/a n/a 68 n/a 
rs577697
4 
15 3'UTR n/a n/a 36 n/a rs464218 
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Figure 11 Agarose gel electrophoresis of SORT1 mRNA and chromatograms 
 
(A) SORT1 RNA was amplified in six TARDBP mutated samples and two controls using 
5’- CAAATGCCAGGGTGGGGTAAATCCAGTTCG-3’ forward primer and 5’-at the end 
of exon 17 and the beginning of exon 19. Only one product of 287 bp was amplified in all 
samples, which includes exon 18. (B) The amplified RNA product sequence trace of one 
control participant is shown on top, followed by the sequence trace of one mutated 
TARDBP sample. All sequences were the same. This shows the exon 17-18 boundary, 
confirming that exon 18 was included in all amplified products. 
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Chapter 5 : Discussion and conclusions 
5.1 Discussion 
Substantial efforts have been deployed during the last decade to better understand 
the defective biological pathway in ALS. These efforts were guided by the sudden 
emergence in the last four years of new mutated genes in affected patients, ALS researchers 
now considering new possible avenues to the disease. 
 
Genomic mutations can definitely modify the tertiary structure of the encoded 
protein and consequently alter its ability to interact with still uncharacterized targets. It is 
also possible that a change in the protein structure results either in a gain of a new function 
or a complete loss of its initial function. For instance, evidence supports that mutated SOD1 
is not characterized by a loss of its dismutase activity, but rather by one or several toxic 
gain-of-functions.309 On the other hand, mutations in certain genes might alter their own 
expression and/or modify directly or indirectly the expression of their RNA targets. 
Precisely, mutations in TARDBP or FUS, two DNA/RNA binding proteins, are believed to 
influence the expression of their still unidentified main targets. Considering this, it can be 
suggested that the same ALS phenotype might result from two different pathological 
pathways: one caused by oxidative stress to neuronal cells involving SOD1, a pathway that 
has been extensively studied, and another caused by an RNA pathology involving TARDBP 
and/or FUS, a pathway that still need to be understood. Precisely, it was demonstrated that 
patients with SOD1 mutations display a distinct metabolic profile in the cerebrospinal fluid 
(CSF) when compared with patients without SOD1 mutations, reinforcing the idea that two 
different pathways are involved.336 In addition, cases with SOD1 mutations did not show 
any TDP-43 pathology, also suggesting that degeneration may result from a different 
mechanism.337 Conversely, it is possible that mutant SOD1 contributes to the RNA 
  
 
142
pathology through an adjacent pathway implicated in RNA processing. Specifically, G93A-
SOD1 mice have been reported to compete with the RNA stabilizer HuR for binding to the 
3’UTR of VEGF.109 Mutant SOD1 was actually found to impair the post-transcriptional 
processing of VEGF mRNA and decrease its expression. 81 VEGF encodes for a protein 
having an important neuroprotective role in the nervous system. Geneticists were prompted 
to screen for VEGF mutations in ALS patients after the report that VEGF depletion in mice 
produces a motor neuron phenotype338 and that VEGF influences motor neuron 
degeneration in ALS mice and humans.339 While the first report found an at-risk associated 
allele including VEGF, following studies were unable to replicate the results.340-343 Some 
reports however suggested a possible gender-dependant association.344, 345 Deletion of the 
hypoxia-response element (HRE) in the promoter region of VEGF in G93A-SOD1 mice 
demonstrated a susceptibility to persistent paralysis after spinal cord ischemia. Treating the 
mice with VEGF isoform A actually protected them against ischemic motor neuron death. 
339 This, combined with VEGF association with SOD1, suggests that long-term treatment 
with VEGF might delay the onset of ALS symptoms or slow down its progression.  
 
Moreover, one of the main interests in the field is intracellular aggregates resulting 
from abnormal protein misfolding after genomic mutations. SOD1, TDP-43 or FUS 
dysfunctional aggregates have been repeatedly observed in ALS patients and are used to 
categorize distinct proteinopathies of the disease. It is possible that these protein aggregates 
do not directly cause ALS but do so indirectly by preventing other proteins trapped in these 
aggregates to perform their function. These aggregations are known to cause endoplasmic 
reticulum (ER) stress then consequently mitochondrial dysfunction and excessive reactive 
oxygen species (ROS) production. In turn, oxidative stress and increased ROS induce ER 
stress, protein misfolding and a cell stress response named the unfolded protein response,346 
this way leading to a neurotoxic cycle. The cell’s pro-survival pathway and vitagene system 
are responsible for the anti-oxidant and anti-apoptotic activities contributing to reduce 
oxidative stress. The inability of these systems to effectively perform their role is believed 
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to accelerate the aging process and eventually lead to neurodegeneration. The failure to 
rescue neurons can be explained by the antioxidants being overwhelmed by the cell toxicity 
and/or by a reduced expression or action of these vitagenes.347 It can be speculated that a 
therapeutic approach targeting the vitagene system and increasing its antioxidant action 
might decelerate neurodegeneration in ALS patients. 
 
Another interest in ALS research is the role of environmental influences in the 
emergence of sporadic ALS. Precisely, oxidative stress can be induced by epigenetic 
factors as a result of environmental toxicity.174 Oxidative damage to lipids, proteins and 
nucleic acids has been extensively observed in spinal cords and other tissues of ALS 
patients348 along with impairment of the DNA repair activity.349 It is now firmly believed 
that oxidative stress play a central role in the ALS etiology, but its place in the disease 
biological cascade needs to be clearly defined. What precisely provokes oxidative stress 
and how it specifically contributes to neuronal death in ALS is still unclear. Several 
experiments gave rise to conflicting results concerning the association of several 
environmental factors with the increased risk to develop ALS. It is possible that certain 
genomic predispositions present in targeted individuals are activated by being exposed to 
an associated environmental factor. It is also probable that some exposed individuals do not 
develop the disease because they are genetically unsusceptible or are actually exposed after 
an undetermined critical age. Future studies will definitely help to better understand the 
implications and contributions of these factors in the pathogenesis of ALS as well as their 
role in other neurodegenerative diseases. 
 
No gene is known to be uniquely mutated in ALS patients (Table I). The fact that 
patients affected with different phenotypes are mutated in the same gene suggests a 
common pathway to the pathogenesis of several neurodegenerative diseases. The most 
obvious example is the comorbidity of ALS with FTD. Up to 50% of ALS patients 
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experience some impairments of frontotemporal functions,350 and about half of FTD 
patients eventually develop motor neuron symptoms.351 In turn, family members of ALS 
patients have an increased risk to develop either FTD or Parkinson’s disease (PD).23 Of 
interest, TDP-43 aggregates have been identified in both ALS and FTD patients.112 
Noteworthy, 60% of genes known to be mutated in ALS patients have also been found 
mutated in patients affected with FTD or other types of cognitive impairment. Interestingly, 
the biological changes caused by oxidative stress and observed in neuronal cells of ALS 
patients are also present in brain and peripheral tissues of individuals affected with other 
degenerative diseases, including Alzheimer's disease (AD), PD, and Huntington's disease 
(HD).348 In addition, neurological disorders such as AD, PD, ALS, HD, and Friedreich 
ataxia (FRDA) have all been associated with the production of unusual aggregated proteins, 
these diseases commonly belonging to the “protein conformational diseases” class.352 
Moreover, repeat expansions in C9ORF72 were not only present in ALS and/or FTD 
patients, but also in AD cases.353 Since the finding of those expansions is relatively new, it 
is possible that additional C9ORF72 variations will eventually be identified in patients with 
other neurodegenerative phenotypes. Also, the finding of C9ORF72 expansions in ALS and 
FTD cases put these diseases in the same growing class of noncoding repeat expansion 
disorders, which might also guide research on treatment. Expansions in this class of 
diseases are thought to cause either a perturbation of the target gene expression or splicing, 
or the release of abnormal amounts of toxic RNA, which disrupts normal cellular 
pathways.159 Specifically, RNA generated from pathogenic repeat expansions have been 
demonstrated to disrupt transcription after sequestering wildtype RNA and proteins 
involved in transcription regulation.354 Indeed, the role of RNA metabolism has been 
shown to clearly play a role in ALS after being associated to mutations in TARDBP and 
FUS.106  
 
Of interest, several observations were reported concerning both ALS and PD 
patients, suggesting that the two phenotypes formally believed to be independent actually 
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have a lot in common biologically. First, the incidence of ALS/PD was communally 
reported to be 100 times higher in Chamorro people of the Guam Island after being 
extensively exposed to BMAA produced across the cyanobacterial order.355, 356 
Interestingly, this important syndrome has now disappeared on the Guam Island, probably 
because of a drastic change in the Chamorro people’s diet.357 Similarly, an 
ALS/parkinsonism-dementia complex (PDC) was identified in the region of Kii, where the 
clinical and neuropathological manifestations of patients were similar to the syndrome 
reported in Guam.358 Another common finding is an increased level of iron and selenium 
observed in the brains of both ALS and PD patients.173 In addition, OPTN aggregates have 
been identified in both ALS and PD patients, and mutations in FUS, ANG and TARDBP 
known to cause ALS were also identified in patients affected with either PD or 
Parkinsonism (Table I). It was also recently demonstrated that an excess of rare variants in 
ANG are significantly associated with ALS and PD,359 a gene previously reported to be 
mutated not only in ALS but also in FTD and Parkinsonism patients. It is also interesting to 
mention that family members of ALS patients have an increased risk to develop PD,23 and 
that they are some reports of family members of FALS patients with both ALS and/or 
Parkinson’s disease360 or patients with ALS and Parkinsonism.361 ALS, PD and FTD are 
consistently found in comorbidity, and must share a common biological pathway. Research 
on treatment must indeed combined results obtained from the three different fields to 
succeed and eventually treat the patients effectively. 
 
Another interesting observation is the phenotypic variability found in ALS families. 
Some family members of FALS patients may experience different phenotype, age of onset, 
place of symptoms onset, or disease duration, and this even if they carry the same genomic 
mutation. This fact is well illustrated by the inherited A382T TARDBP mutation identified 
in Sardinian ALS patients.68 Another example is the report of A382P TARDBP mutation 
previously reported in ALS362 but also found in a patient experiencing sensory and motor 
symptoms.363 Another case of a juvenile ALS patient experiencing a rapid progression and 
carrying a FUS mutation with the same mutation carried by his unaffected mother was 
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described in this work.186 Considering that ALS shares a lot genetically and biologically 
with other neurodegenerative phenotypes and that exposure to the same environmental 
toxin can lead to two different phenotypes just like mutations in the same gene can lead to 
different neurological diseases, we will certainly learn much from research conducted on 
other diseases and this will surely guide research on treatment discovery. In fact, research 
on ALS treatment has not been successful up to now. The only known treatment is 
Riluzole, which has a modest effect on survival and is expected to prolong life of only two 
to three months.2 
 
Furthermore, the accumulation of misfolded proteins inside and outside neurons and 
glial cells in ALS prompted the suggestion that ALS may be a prion-like pathology. 
Precisely, this comes from the fact that protein aggregates play an essential role in ALS 
initiation and progression by acquiring toxic properties through increased hydrophobicity 
and sequestration of vital cellular constituents within the aggregates. This degenerates into 
ROS production, proteasome inhibition, and dysfunction of other pathways.12 On the other 
hand, prion diseases have been demonstrated to also consist of a misfolded form of the 
normal prion protein that accumulates into aggregates, recruiting the wildtype form of the 
protein and inducing its conformation change.364 This misfolded protein is then released out 
of the cell, which eventually induces conformation changes of normal prion proteins in the 
neighboring cells. This type of spreading and propagation has been previously reported in 
other neurodegenerative diseases.12 It was demonstrated that aggregated forms of either 
SOD1 or TDP-43 proteins can seed misfolding into a more important amount of the 
corresponding wild-type protein in vivo.365, 366 Misfolded forms of both SOD1 and TDP-43 
in culture cells prompted the misfolding and successive aggregation of the normal 
proteins.366-369 Significantly, induced aggregation of endogenous SOD1 was demonstrated 
to continue after removing the misfolded seeds.367, 368 These results suggest that the new 
aggregates can act as templates for the subsequent misfolding of wildtype SOD1. This type 
of spreading is consistent with a self-perpetuating cyclic reaction similar to the one induced 
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by infectious prion aggregates, which explains why some groups proposed that a prion-like 
pathology defines ALS. Considering this, current research on prion treatment should not be 
disregard to elaborate therapeutics for ALS. 
 
One last field of research that is promising is the contribution of hormones to the 
initiation and /or progression of ALS. Precisely, the hypothalamic-pituitary-adrenal (HPA) 
axis regulates itself by biofeedback and plays a major role in homeostasis by regulating the 
body’s reaction to stress and other vital processes including the activation of sympathetic 
nervous system and immune response as well as the regulation of many inflammatory 
genes.370 The latter is specifically of interest, considering the role of inflammation in 
ALS.371 Overproduction of glucocorticoid such as cortisol, one of the end products of the 
HPA axis, is associated with a significant disruption of cellular functioning leading to 
widespread physiological dysfunction and aging.372 Considering that the majority of 
patients experience the first ALS symptoms at a time when most individuals retire from 
work, it is tempting to suggest that an increase in cortisol level following such stressful life 
event may influence other biological systems and initiate the disease. Precisely, just like 
depressed individuals who are found with a persistent increased cortisol level,373 ALS 
patients experience a dysregulation of adrenal activity characterized by a loss of the cortisol 
circadian rhythm.374 Consequently, ALS patients have an increased cortisol level in the 
evening compared to controls whose cortisol level is at its lowest. This dysregulation of 
cortisol rhythm is also revealed by the lack of cortisol variation following a stress reaction. 
ALS patients do not show any physiological increase of cortisol after a mild stressor.374 
Considering that depression is more prevalent in war veterans, the association between high 
cortisol level in veterans and the development of ALS should be explored in the future. 
Opposing results were reported by other groups. One example is the transgenic 
overexpression in mice of the corticotropin releasing hormone (CRH), a modulator of the 
HPA axis and a precursor of cortisol. The resulting increased in cortisol expression has 
been demonstrated to provide a protective effect on neuronal cells.375 In the same way, 
elevated cortisol level induces the release of glucose, which is known to increase neuronal 
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cells survival and branching through exogenous galanin when released in sufficient 
amounts.376 In addition, estrogen administration has been shown to elevate cortisol level.377 
Estrogen is known to interact with VEGF,378 has been proven to be an effective 
neuroprotective agent and its use has been suggested to attenuate motoneuron death in 
ALS.379 Precisely, considering that the incidence of sporadic ALS is higher in men than 
women, it was demonstrated that the female advantage results from the protective attribute 
of estrogen. The female advantage actually disappears with increased age because of a drop 
in estrogen level during menopause.380 Another opposing proposition about gender 
disparity in terms of incidence is the possible role played by free testosterone which is 
known to be significantly reduced in ALS.381 These controversial results about cortisol 
along with the influence of other hormones in ALS still need to be clarified, but they might 
underline new therapeutic avenues to consider.  
 
 Combined efforts from different fields to understand ALS are crucial. Among those, 
mutation reports are clearly essential to define the pathological pathway involved in ALS, 
and each mutation finding along with all mutated gene identifications add crucial pieces to 
the puzzle, bringing us closer to a complete understanding of the disease. Considering what 
we know today, it can be speculated that SOD1, VEGF and ALSIN are part of the same 
pathway, which could be influenced by the endocrine system. This is based on the fact that 
SOD1 binds to VEGF,109 that estrogen interacts with VEGF,378 and that ALSIN binds 
uniquely to mutant SOD1.382 On the other hand, TARDBP, FUS and SETX all have a 
DNA/RNA recognition domain in their c-terminal region and are thus all involved in RNA 
processing. Like suggested earlier, these two different pathways involving different genes 
can be closely interrelated (Figure 12A). 
 
The genetic results obtained from this Ph.D project definitely permitted a better 
understanding of the role of certain mutated genes in ALS and ruled out the direct 
implication of others. New mutations were identified, and the proportion of patients of 
European descents that could be genetically explained by variations in the identified 
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causative genes have also been assessed, which permitted all together a better evaluation 
and understanding of these genes contribution to the ALS pathology. Precisely, it was 
demonstrated in chapter 2 that mutations in FUS are found in about 1.3% of the FALS and 
1.3% of the SALS tested cohorts of European origin (FALS: 3/235; SALS: 8/595) 
representing the same percentage of the total tested cohort. This is slightly more than what 
is reported to date for sporadic cases, but definitely less than what was expected for familial 
cases. The fact that the tested cohort is part of a heterogeneous population can explain why 
so few genetic variations were identified. It is predicted that the screening for expansions in 
the C9ORF72 gene will genetically explain a major proportion of this previously tested 
cohort. Genetic screening for FUS mutations also permitted the identification of a new 
causative variant in a juvenile ALS patient and his still unaffected mother, discovery that 
contributed to reinforce the idea that environmental factors may play an important role in 
disease onset. Chapter 3 permitted to demonstrate that the percentage of mutation in SOD1 
is probably underestimated, and that patients pretended to be SOD1negative can possibly 
carry an intronic variation influencing the splicing of the gene. Also, it was demonstrated 
that SOD1 is not an RNA target of TARDPB or FUS, as mutations in these two genes do 
not influence SOD1 splicing. This discovery reinforces the idea that SOD1 is part of an 
independent pathway. Finally, chapter 4 demonstrated that mutations in OPTN, SIGMAR1 
and SORT1 all considered by the field as candidate genes for ALS, are not a direct cause of 
the disease in patients of European origin. It can however be speculated that these genes 
play an indirect role in the pathology. 
 
The aim of genetic screening in ALS is first to identify the genes implicated in the 
pathological pathway or pathways involved in order to understand the role of each player in 
the disease, and second to offer genetic diagnosis for patients. What has been described 
throughout this work and what is known so far in the genetics of ALS is summarized in 
Figure 12B. The final outcome of this work is to target the most upstream players of the 
pathway in therapeutics to eventually obtain more efficient treatments. Identifying all 
mutated genes in ALS will also permit the implementation of personalized genetic 
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treatments. While being able to decelerate disease progression would be a major 
breakthrough in the ALS field, the ultimate goal would be to stop and even prevent the 
degeneration of motor neurons. Precisely, a complete understanding of the pathological 
pathway or pathways will lead to the development of appropriate treatments for ALS 
patients mutated in different genes. Genetic diagnosis will be essential to provide 
appropriate targeted preventive treatments to patients. Considering that so many 
neurodegenerative diseases possibly share some attributes in the pathological pathway 
involved, such findings would be beneficial for different research fields and ultimately for a 
wider spectrum of patients. 
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Figure 12 Genes and factors contributing to ALS and other associated phenotypes 
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5.2 Conclusions and future perspectives 
After reviewing the literature and describing the results obtained, it was 
demonstrated in this work that mutations in genes such as SOD1, TARDBP, and FUS 
definitely cause ALS. The implication of OPTN, SIGMAR1 and SORT1 is not as 
conclusive. Consequently, the production of truncated or dysfunctional SOD1, TDP-43 and 
FUS proteins is believed to cause oxidative stress to neuronal cells, the phenomenon being 
so widespread in the nervous system that the anti-oxidant mechanisms of neurons are 
unable to act efficiently and rescue the cells. The biological consequences of the C9ORF72 
expansions still need to be determined, but when better understood it will definitely fill an 
important portion of the puzzle. While the genetic implication of the four causative genes 
has definitely been demonstrated, the role of others is still questionable. The contribution of 
the other eleven genes in the ALS pathology cannot be dismissed, since a few patients do 
carry mutations and changes at the protein level have been biologically demonstrated. 
However, since mutations in those genes are so rare, it is possible that they actually act as a 
disease modifier instead of playing a direct causative role in ALS. It is also possible that the 
genes identified are part of different interacting pathways, and not part of a single 
biological cascade. 
 
The identification of ALS loci using large families marked an era of ALS genetic 
research. Three ALS/FTD and fifteen ALS loci for a total of eighteen regions have been 
identified, and mutations have been found in fifteen different genes. It can be speculated 
that the three remaining loci are actually associated to mutations in genes already identified. 
Specifically, the associated locus on chromosome 20p13 might actually be linked to 
mutations in VAPB on chromosome 20q13.32, and the published locus on chromosome 
9q21-22 might actually be linked to C9ORF72 expansions on chromosome 9p21-22 or 
VCP mutations on chromosome 9p13.3. Concerning the ALS3 locus on chromosome 
18q21, conflicting results might have arisen due to variations in linkage results, probably 
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explained by inconsistence in clinical assessments. Still, this hypothesis needs to be 
demonstrated. Now that most if not all ALS loci are elucidated, ALS geneticists turn to 
exome and genome sequencing to identify the remaining players of the pathological 
pathway or pathways involved. The finding of additional genes will definitely help to 
clearly define and understand the role of each contributor in the pathology, and to 
adequately target the best therapeutic approach. While a major portion of familial ALS 
have been elucidated, sporadic patients who are principally affected by the disease still 
need to be interpreted and the role of environmental or hormonal influences should not be 
underestimated. Precisely, 25-35% of familial cases and less than 75% of sporadic patients 
still need to be genetically explained.383 The eventual development of biomarkers will play 
an important role in eliminating other diagnostic possibilities and detecting ALS earlier.14, 
Knowing that the penetrance is extremely high in autosomal dominant families, the 
identification of biomarkers will permit to treat mutation carrier before they experience the 
first symptoms, when effective therapeutics will be available.384 
 
The sudden explosion of genetic results during the last ten years in the field 
permitted the emergence of more precise and better directed hypotheses about the disease 
etiology. This is an exciting time for ALS researchers, and I strongly believe that an 
effective treatment to slow down the disease progression will be soon described. I sincerely 
hope for all the patients and family members affected directly or indirectly by the disease 
that ALS will be, one day in a near future, effectively cured and prevented. 
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